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SUMMARY
Maternal antibodies to placental-specific antigens were 
not detected in third trimester maternal sera or in concentrated material 
adsorbed from maternal sera on a placental affinity column using immuno­
fluorescence and gel precipitation techniques, A method was described 
for the dissociation of antigens of less than 100,000 daltons from 
soluble antibody-antigen complexes. This method was applied successfully 
to the dissociation of albumin-anti-albumin complexes formed in antigen 
excess. Application of this method to pregnancy serum followed by 
immunisation of rabbits with the dissociated material resulted in anti- 
SP1 response detectable on AACE, The molecular weight of SP1 is approx, 
100,000 daltons and the bulk of SP1 was detectable in the retentate at 
the end of the dissociation. This argued against a conclusion that SP1 
had been dissociated from immune complexes.
Immunisation of rabbits with soluble extract of a placenta 
which had been adsorbed over anti-human serum column induced AACE- 
detectable responses to very few serum proteins, PAPP-A, HPL, SP1 and 
several unidentified antigens found in placental tissue. Placental 
soluble extract which had in addition been adsorbed over anti-human lung 
column and anti-human amniotic fluid column induced responses to very 
few serum proteins, PAPP-A and HPL, Using these latter antisera two 
other antigens were identified in placental soluble extract (antigens 
_a and _b) which were not detectable in lung soluble extract or in non­
pregnant serum. Antigen b was also detected in pregnancy serum. By 
contrast, immunisation with unfractionated placental soluble extract 
induced extensive anti-serum response, anti-HPL and anti-SPI but no 
detectable anti-PAPP-A response.
The extent to which several serum proteins were denatured
by a variety of commonly used dissociants of antibody-antigen complexes
was assessed by changes in the protein's precipitating behaviour on
one-dimensional AACE. AACE was found to be superior for this to double
immunodiffusion. The smaller proteins studied were more resistant to
irreversible dénaturation, but the sample size was too small to seek a
general relationship between molecular weight and dénaturation. All
proteins examined proved resistant to one hour exposure to 1*5 M KI-PBS
and to pH 11 buffer,
1*5 n KI-PBS was used in the purification of PAPP-A by
antibody affinity chromatography followed by DEAE-cellulose ion exchange
and Sepharose 68 gel filtration. Double AACE arcs formed by PAPP-A in
term maternal serum were also formed by partially-purified PAPP-A
indicating that the antigenic variants had not been separated. The
purification product contained PAPP-A which was 427-fold purified in
terms of immunological reactivity on AACE, The high degree of purity was
also suggested by studies with the radiolabelled purification product, 
125
I-PAPP-A was shown to have similar molecular weight and electro-
125phoretic mobility to maternal serum PAPP-A, Immune-precipitated I- 
PAPP-A was analysed by 5^ and 3% SDS-PAGE and found to contain a major 
radioactive component of approx, 180,000 daltons and a minor component 
of between 74,-93,000 daltons. The nature of the minor component has not 
been determined. It may be tentatively concluded that PAPP-A (mol, wt, 
750,000) contains polypeptide subunits of approx, 180,000 daltons and 
may therefore be composed of up to four such subunits,
A collaborative clinical study in which PAPP-A was assayed 
in the blood of women during the third trimester of pregnancy by AACE 
suggested that fetal sex may affect PAPP-A levels with males giving rise
* ■1 1 *
to higher levels than females. No significant difference in the levels 
of PAPP-A was detected when patients with babies affected with intra­
uterine growth retardation were compared with controls. No significant 
change in the mean concentration of PAPP-A was detected in the group of 
patients with gestational diabetes, but some very high values were 
found in this group. In the group of patients with insulin-controlled 
diabetes the mean concentration of PAPP-A was significantly reduced.
■111-
A BBREVIATIONS
AACE Antibody-antigen crossed electrophoresis
HPL Human placental lactogen
PAPP-A Pregnancy-associated plasma protein
PBS Phosphate-buffered saline solution: 0*16 M NaCl 5 mM
potassium phoshate, pH 7*5 
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
SP1 Pregnancy specific beta-1-glycoprotein
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c h a p t e r  1 INTRODUCTION
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1 . GENERAL INTRODUCTION
This chapter examines the current state of knowledge of 
the pregnancy-associated proteins, including placental-specific 
proteins found in sera of pregnant women. As background it is first 
necessary to describe briefly human placental structure and function. 
Individual pregnancy-associated proteins are then discussed in turn, 
together with a review of the areas of current and potential application 
of pregnancy-associated proteins: obstetric diagnosis, cancer diagnosis 
and the diagnosis and treatment of conditions of pregnancy with 
immunological aetiologies. The final discussive part of this chapter 
considers the use of affinity chromatography in the search for and in 
the purification of new proteins. The information presented in this 
chapter is then used to formulate lines of further investigation,^
2, HUMAN PLACENTAL DEVELOPMENT, STRUCTURE AND FUNCTION
2,1 Human Placental Development and Structure
The morphological features typical of the human placenta 
have been discussed in detail in reviews by Boyd and Hamilton (1975), 
Llewellyn-Jones (1975), Wynn (1975) and Walker and James (1976) which 
have acted as the sources of information used to construct the follow­
ing brief account.
Human Placental Development
The human blastocyst implants on the 6th day of gestation* 
Prior to implantation progesterone and estrogen secreted by the corpus 
luteum (a body formed in the ovary after ovulation) modify the uterine 
endometrium to form the decidua which is more suitable for implantation
of the blastocyst and the nourishment of the embryo. Around the time of
implantation the trophectoderm of the blastocyst gives rise to two
basic forms of trophoblast, an inner cellular cytotrophoblast and an 
outer syncytiotrophoblast. The syncytial form is derived by differential 
tion and the breakdown of the cell membranes of the cellular layer. The 
inner cell mass in the blastocyst which will ultimately form the fetus 
has sparated from the cells of the trophoblast and has differentiated 
by the time of implantation.
At the time of implantation the syncytial cells erode the 
superficial cells of the decidua. During the subsequent few days 
proliferation of the cytotrophoblast pushes the knobs of the tropho­
blast deeply into the decidua and by the 10th day of gestation there is
much intermingling of trophoblast and maternal tissues* Within the
projecting knobs of trophoblast, a third layer of connective tissue, 
or stroma, the mesoblast is differentiated from the inner surface of the 
cytotrophoblast. The mesoblast proliferates rapidly and not only forms 
the core of the projecting knobs of trophoblast but also lines the 
cavity of the blastocyst which is now termed a chorionic sac. With 
further proliferation the trophoblastic knobs assume a finger-like 
shape and are termed chorionic villi. Spaces appear between the closely 
packed trophoblastic projections so that they are split into separate 
villi and by coalescence the spaces (lacunae) increase in size. By this 
time the tips of the villi have reached the decidual capillaries and 
the spiral arterioles and have surrounded and eroded their walls so that 
maternal blood sweeps into the lacunae. Maternal blood then fills and 
expands the lacunae which coalesce further creating large blood-filled 
spaces segregated by chorionic villi. Once the spiral arterioles have 
been surrounded fibrin deposits begin to appear between the decidua and
trophoblast, Trophoblast invasion is not uniform - ridges of maternal 
decidua persist amongst the trophoblast which gives rise to the placent­
al septa seen on the mature placenta. Recent work by Robertson and his 
colleagues (Robertson et al,, 1976 ) has shown that waves of non-villous 
trophoblast also penetrate the basal decidua and progress up the spiral 
arteries in a retrograde direction. Unlike the syncytiotrophoblast of 
the chorionic villi these interstitial trophoblast cells in the basal 
decidua are not in direct contact with the intervillous blood.
In the richly nutritive conditions created by maternal 
blood in the intervillous space syncytial sprouts appear on the primary 
villi. These develop, subdivide and branch so forming villous trees.
Some of the primary villi retain their attachment to the decidua 
(anchoring villi). By the 18th day of gestation primitive blood vessels 
have formed in the mesoblastic core of the primary and secondary 
villous trunks. Around the21st day the intravillous vascular network 
meets the umbilical vessels to establish the fetal circulation.
Towards the end of the 8th week the villi begin to group together at 
the implantation site. During the third month of pregnancy the conceptus 
begins to grow to occupy the entire uterine cavity. At this stage the 
trophoblastic villi which are adjacent to the implantation site develop 
into placental tissue, whilst the others atrophy. Thus at twelve weeks 
the placenta is clearly defined. After twelve weeks the number of 
primary villi does not increase but growth occurs by continuing 
proliferation of peripheral villi right up to term. Once the establish­
ment of the main placental region is complete, the chorionic membrane, 
composed of a layer of cytotrophoblast, surrounds the remainder of the 
fetus.
At all periods of pregnancy a syncytiotrophoblastic
barrier separates the maternal and fetal circulations. However, with 
increasing placental age the structure of the villi changes. Early (10- 
18 weeks) villi are large (up to 0*3 mm diameter) and have an outer 
layer of syncytiotrophoblast and an inner layer of cellular cytotropho­
blast, which is initially two cells thick, and a relatively acellular 
mesoblastic core containing small fetal vessels. By the 24th week cyto- 
trophoblastic cells are few, the stroma is more cellular and compact 
containing phagocytic cells and the fetal vessels larger and closer to 
the trophoblastic covering. By the 36th week, the villi are much smaller 
(Of05-0*1 mm in diameter), the cytoblastic cells have largely disappear­
ed, the syncytium has become attenuated and aggregations of nuclei 
within it. Fibrin deposits on the surface of the mature villi are 
commonly seen. Throughout pregnancy the maternal side of the syncytium 
is in direct contact with the maternal blood in the intervillous space. 
The fetal side of the syncytium is covered by a basement membrane which 
abuts onto the cells of the cytotrophoblast, and where these have dis­
appeared, onto the fatal mesoblast and the fetal capillary endothelium 
(Figure 1,1).
Human Placental Structure at Term
The mature placenta is basically a chorioallantoic 
structure (also found in all true mammals and a few marsupials) in 
which the fetal blood supply is received through allantoic, or umbilic­
al, vessels. Mainly on the basis of the degree of invasiveness of its 
trophoblast cells into the maternal tissues it is further classified 
as a haemochorial placenta. The degree of trophoblast invasiveness is 
most extreme in this type of placenta - the uterine capillaries are 
breached and the trophoblast bathed directly in maternal blood. The 
placenta at term is disc-shaped,about 15-20 cm in diameter, 2*5-3*0 cm
thick in the middle and tapering towards the edges. It weighs around 
650 g (mean figure with considerable variation). It is bounded on its 
upper (fetal) surface by the amnion beneath which lies the chorion (the 
chorionic plate). Within the chorionic plate run the fetal vessels. On 
the lower (maternal) surface the placenta is bound by the decidua (the 
decidual or basal plats). Between the two surfaces is adense mass of 
fetal villi bathed by maternal blood in the intervillous space (Figure 
1,2), Fetal blood reaches the placenta via the umbilical arteries; from 
the placenta it reaches the fetus by the umbilical vein. Two umbilical 
arteries and one umbilical vein are normally contained within the 
umbilical cord. The fetal placenta is divided into 50-60 lobes or 
cotyledons. Each fetal cotyledon is a separate vascular system 
consisting of a single villous tree supplied by one artery and drained 
by one or more veins. The maternal surface is incompletely divided into 
about 15-20 cotyledons by septa of various heights and shapes which 
project from the decidual plate into the intervillous space. These 
maternal cotyledons correspond to one or more usually several fetal 
cotyledons. The maternal blood enters and leaves the intervillous space 
through vessels opening in the decidual plate. During systole the 
arterial blood spurts into the intervillous space at a pressure of 
about 80 mm Hg and pushing the villi aside to reach the chorionic plate 
flows laterally and cascades down bathing the branched villi. It then 
escapes slowly through the veins which tend to form venous lakes in the 
decidua (Figure 1,3),
2,2 Human Placental Function
The placenta's functional characteristics include full 
growth and development within a limited lifespan, anatomic adaptations
to diverse tasks such as transport of gases and metabolites to and from 
the fetus and elimination of waste products and, of main interest in the 
context of this investigation, the synthesis of a wide range of hormones, 
enzymes and other proteins* The placenta can secrete proteins in the 
absence of a fetus in an anembryonic pregnancy (Bennett et al., 1970).
The synthesis of all types of proteins is generally attributed to 
syncytiotrophoblasts, which have been shown to contain the cell 
organelles (endoplasmic reticulum) necessary for protein synthesis; 
cytotrophoblasts, on the other hand, have been shown to.contain feu 
such organelles (Pierce and Midgly, 1963; Lister, 1963; Yoshida, 1964), 
Electron microscope studies (Burgos and Rodrigues, 1966) have pointed to 
the existence of "thick" and "thin" areas in the syncytiotrophoblast; 
the former rich in endoplasmic reticulum and microvilli, thought to be 
specialized in protein synthesis and the latter (known as vasculo- 
syncytiai membranes - Getzowa and Sadowsky, 1950) without microvilli 
and thought to be specialized in the transport of metabolites and 
waste products to and from the fetal capillaries which they overlie 
(F igure 1.1).
Evidence supporting the assumption that specific placental 
proteins are produced by syncytiotrophoblasts is indirect and comes 
mainly from immunohistochemical studies (Currie et al,, 1966; Horne et 
al,, 1976; Lin and Halbert, 1976 ). The validity of these studies has 
however been questioned because of the lack of appropriate controls and 
because a theoretical analysis suggests that the actual concentrations 
in the trophoblast cytoplasm could not be detected by the techniques 
used (Gau and Chard, 1976), The placental proteins appear to be secreted 
into the intervillous space from which they are carried into the 
maternal ciculation, rather than through the basement membrane and the
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villous stroma and thence into the umbilical cord and the fetal 
circulation (Diczfalusy, 1974). This has been suggested to be due to 
the architecture of the chorionic villus described in Section 2.1 of 
this chapter: the syncytiotrophoblasts are in direct contact with the 
maternal blood in the intervillous space but are separated from the 
fetal blood by the basement membrane and the capillary endothelium 
(Gordon and Chard, 1979).
3. PREGNANCY-ASSOCIATED PROTEINS IN THE MATERNAL CIRCULATION
3.1 Placental-specific Proteins
Currently known placental-specific proteins can be divided 
into three groups:
(1) The hormones - human chorionic gonadotrophin (HCG), 
human placental lactogen (HPL) and human chorionic thyrotrophin (HCT).
(2) The enzymes - histaminase, placental alkaline 
phosphatase and oxytocinase.
(3) Proteins which have been detected immunologically by 
gel diffusion methods and whose biological functions remain to be 
elucidated - pregnancy specific 13,glycoprotein (SP1), pregnancy 
protein 5 (PPS) and pregnancy-associated plasma proteins A and B 
(PAPP-A and PAPP-B).
Although development of more sensitive techniques may yet reveal the 
presence of very low levels of some of the above placental-specific 
proteins in non-pregnant serum or extracts of adult tissues, for the 
purpose of this discussion they will be considered specific for 
pregnancy.
Unlike the steroid proteins produced by the placenta
whose role in the maintenance of pregnancy is well-documented the 
precise roles of specific protein hormones produced by the placenta are 
incompletely understood* The two major hormones produced by the 
placenta, HCG and HPL, have both been purified to high degree and have 
been demonstrated to have analogues in the pituitary with which they 
show chemical, biological and immunological similarities.
HCG was the first placental protein hormone to be 
described. It was discovered as a substance which induced ovarian 
hyperaemia, oestrus and the formation of corpora lutea in guinea pigs 
(Aschner, 1912) and mice (Aschheim and Zondek, 1927). Its production by 
placental tissue grown in culture was first demonstrated by Gey et al. 
(1938). Immunocytochemical studies point to its synthesis by syncytio­
trophoblast cells of placental villi (Midgley and Pierce, 1962; Leznoff 
and Davis, 1963; Thiede and Choate, 1963). HCG is similar to pituitary 
luteinizing hormone (LH) in physicochemical and immunological properties 
but has a higher carbohydrate content and a high content of sialic acid. 
Its molecular weight is 45,000-50,000 (Bahl et al.. 1973; Vaitukaitis, 
1977). Like all glycoprotein hormones (luteinizing hormone, follicle- 
stimulating hormone and thyroid hormone) it is composed of two subunits, 
an alpha subunit and a beta subunit. With very minor modifications the 
alpha subunit is common to all the glycoprotein hormones (Pierce et al.,
1971) and the beta subunit confers unique specificity to the HCG 
molecule. Beta-HCG has 147 amino acids: 30 of these residues at its 
-COOH terminus are not present in the subunits of the other glyco­
protein hormones (Carlsen et al.. 1973). Information is still 
accumulating concerning the biological function of HCG and it is not 
known whether it is essential to normal pregnancy. It is believed to 
maintain the corpus luteum of the menstrual cycle, permitting its
conversion to the corpus luteum of pregnancy (Johansson and Bosu, 1974) 
thus allowing the continued production of progesterone necessary for 
decidual development. The corpus luteum functions maximally during the 
first four weeks of pregnancy and its functional lifespan may be ten 
weeks; the placenta gradually takes over progesterone production 
between the 6th and 10th week of pregnancy. However, a study by Yoshimi 
and his colleagues has revealed that plasma HCG levels increase through­
out the period that plasma levels of progesterone are falling, that is 
between the 4th and 6th week of pregnancy (Yoshimi et al., 1969). This 
finding has raised questions about the control of corpus luteum 
function by HCG* Nevertheless, HCG has been demonstrated to cause an 
increase in plasma progesterone in non-pregnant women when administered 
during the luteal phase of the menstrual cycle (Strott et al,. 1969).
HCG may regulate steroid production in the fetus - dehydroepiandrosterone 
sulphate (DHAS) by the fetal zone of the adrenal gland and testosterone 
by the testis (Jaffa et al.. 1977; Seron-Ferre et al,. 1978), A role for 
HCG as a thyroid stimulator in pregnancy has also been suggested 
(Nisula and Ketelslegers, 1974). Pregnancy is known to have a variety 
of effects on maternal thyroid function some of which may be responsible 
for the enlargement of the thyroid which occurs frequently (see the 
review by Turnbridge and Hall, 1975), Although the postulated thyroid- 
stimulatory role of HCG in pregnancy has yet to be proven, it has been 
demonstrated that the thyrotrophic activity in pregnancy urine and in 
the serum of patients with hydatidiform moles is due to HCG (Nisula and 
Ketelslegers, 1974; Kenimer et al,. 1975), HCG has so far been detected 
in maternal blood and urine; trace amounts have also been detected in 
amniotic fluid, fetal blood and fetal tissues - ovary, testis, kidney 
and thymus (Huhtaniemi et al., 1977). In maternal blood and urine it 
may be detected/
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may be detected as early as the tenth day after ovulation, very soon 
after the implantation of the early developing blastocyst (Mishell et 
al.. 1963). The mean concentration rises rapidly to reach a peak of 
60-130 i.u. per ml. (5,000 i.u. = 1 mg. pure HCG: see Uaitukaitisetal,
1972) in the serum between the 60th and 80th day of gestation then 
declines rapidly before reaching a plateau around the 120th day of 
pregnancy (Borth, 1971; Varma et al». 1971) and afterwards remains 
fairly constant until term with a mean concentration in the range 
10-25 i.u. per ml. serum. It disappears rapidly from the maternal serum 
after delivery (Hertz et al., 1959). In placental tissue a mean maximum 
concentration of 100-500 i.u. per gram placental tissue is reached 
around the 60th day of gestation. Therafter the mean concentration 
declines to 10-20 i.u. per gram tissue at term (Diczfalusy, 1953;
Hobson, 1971).
HPL, discovered independently by Ito and Higashi (1961) 
and Oosimovich and Maclareh (1962), is also believed to be synthesised 
by the syncytiotrophoblast cells of the placental villi (Beck and Currie, 
1967; Ikonicoff and Cedard, 1973; Lin and Halbert, 1976), HPL is similar 
to human growth hormone (HGH) in physicochemical and immunological 
properties. The molecular weight of HPL is 21,000-23,000 daltons and it 
is a single chain polypeptide with two intra-chain disulphide bonds, 
composed of 191 amino acids and showing a 96^ homology with HGH (Ito and 
Higashi, 1961; Friesan, 1965; Li et al..1971 ; Niall et al.. 1971; 
Josimovich, 1977). Although there is no solid evidence that HPL is 
essential for pregnancy it is believed to exert important metabolic 
effects on the mother. The major of these is HGH-like diabetogenic 
influence on carbohydrate and lipid metabolism which ensures an 
adequate supply of glucose for the fetus (Grumbach et al., 1973),
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As pregnancy progresses the fetus increases its substrate requirement 
which is thought to lead to an increased functional role for HPL in the 
second and third trimesters (Kaplan, 1974)* HPL has also been demonstrated 
to have lactogenic properties in the pseudopregnant rabbit and luteo- 
trophic properties in the pseudopregnant rat (Josimovich and MacLaren, 
1962); whether or not it has lactogenic and luteotrophic properties in 
women remains to be established* HPL has so far been detected in 
maternal blood and urine: trace amounts have also been detected in 
fetal serum and in amniotic fluid (Kaplan, 1965). In maternal serum it 
first becomes detectable by radioimmunoassay around the eighth week of 
gestation. Levels rise steadily to a peak of 6-20 ug. per ml. maternal 
serum at 32-36 weeks; thereafter concentrations remain steady, or fall 
slightly, to term (Josimovich and Atwood, 1964; Kaplan and Grumbach,
1965). Postpartum it disappears from maternal serum within 1-2 days 
(Lin and Halbert, 1976b). The concentration of HPL in placental tissue 
remains approximately the same throughout gestation (Jasimovich and 
Atwood, 1964) and rising serum levels reflect the increasing mass of 
the placenta (Jasimovich et al.. 1969). The placenta produces and 
secretes into the maternal circulation in excess of 1 gram HPL per day 
during the third trimester of pregnancy.
HCG and HPL have both been attributed with immunosuppressive 
properties* It has been claimed that they reduce the transformation 
(proliferation) of lymphocytes that occurs when the lymphocytes are 
confronted with the T cell mitogen, phytohaemagglutinin (PHA)
(Contractor and Davies, 1973). In the case of HCG the effect was thought 
to be reversible and without cytotoxicity (Adcock et al*. 1973; Marz et 
al.. 1973). HCG has also been claimed to inhibit mixed lymphocyte 
culture (MLC) which involves the stimulation of lymphocytes by foreign
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lymphocytes rather than by PHA (Kaye and Jones, 1971; Jenkins and 
Acres, 1972). HCG and HPL were postulated to exert their effects by 
blocking the antigen receptor sites of the lymphocytes (Contractor and 
Davies, 1973). However, the evidence for the immunosupressive role of 
HCG has proved controversial (Caldwell et al.. 1975). The specificity 
of the inhibition of the lymphocytes (both PHA-induced and in MLC) has 
been questioned because highly purified preparations of HLC have been 
demonstrated to be without effect (Carr et al.. 1973; Caldwell et al.. 
1975; Muchmore and Blaese, 1977).
Several investigators have suggested that a third protein 
hormone, human chorionic thyrotrophin (HCT) is also synthesised and 
secreted by the placenta (Hennen et al.. 1969). HCT shows physico­
chemical and immunological similarities to pituitary thyroid 
stimulating hormone (TSH). The molecular weight of HCT has been deter­
mined as 45,000 daltons and it has been shown to be composed of two 
subunits (Hershman and Starnes, 1971). The physiological role of HCT 
has not been elucidated clearly. Hennen and his colleagues (Hennen et 
al.. 1969) suggested a role for it in the regulation of thyroid function 
during pregnancy. However, although has been demonstrated to have 
thyrotrophic properties (Hershman et al.. 1973) its action on the human 
thyroid is unknown. Thyrotrophic activity in pregnancy urine and in the 
serum of patients bearing trophoblastic tissue has been demonstrated to 
be due to HCG, and the thyrotrophic activity of placental tissue in 
pregnancy postulated to be a function predominately of HCG ( Nisula and 
Ketislegers, 1974; Kenimer et al.. 1975). In addition the placental 
content of HCT is known to be very low and variable (Hershman and 
Starnes, 1971). Similarly, in normal pregnancy serum it is difficult to 
detect and several investigators have been unable to do so.
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The enzymes presently known to be produced specifically by 
the fetal placenta are heat-stable alkaline phosphatase and oxytocinase*
In addition, a third enzyme, histaminase is thought to be produced 
specifically by the maternal portion of the placenta.
The first of these enzymes, heat-stable alkaline 
phosphatase, has been localised on the microvilli of the syncytiotropho- 
blasts by immunohistochemical studies (Kameya et al.. 1973). It has been 
demonstrated to be an isoenzyme of the heat-labile alkaline phosphatase 
found in the non-pregnant adult (Fishman et al.. 1968a and b; Sussman 
et al.« 1968; Neale et al.. 1965). The molecular weight of placental 
heat-stable alkaline phosphatase has been determined as 128,000 daltons 
and it was found to be composed of two identical subunits of molecular 
weight 64,000 daltons each&(Luduena and Sussman, 1976). The serum levels 
of this enzyme have been determined in maternal serum by radioimmunoassay. 
A 25-fold increase from low levels during the first trimester to 250 ng. 
per ml. in the 40th week of gestation has been reported (Holmgren ^  
ai'» 1978).
The second placental enzyme, oxytocinase, has also been 
localised in the syncytiotrophoblasts by immunohistochemical studies 
(Small and Watkins, 1971). This enzyme has been demonstrated to be an 
isoenzyme of the oxytocinase found in the non-pregnant adult (Watkins 
and Small, 1972; Buul and Van Oudheusden, 1978). The molecular weight 
of placental oxytocinase has been determined as 300,000 daltons (Yman, 
1970). The presence of both the placental and the non-pregnant adult 
forms of oxytocinase has been demonstrated in maternal serum (Buul and 
Van Oudheusden, 1978).
Relatively less is at present known about the third 
placental enzyme, histaminase. Recent immunohistochemical studies have
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localised it in the cytoplasm of the decidual cells of the placenta 
(Weisburqer et al,, 1970). The molecular weight of histaminase purified 
from the placenta has been calculated to be 180,000 daltons and it was 
found to be a dimer composed of identical subunits of molecular weight
90,000 daltons each (Bardsley et al.. 1974): similar results were 
obtained for histaminase purified from pregnancy plasma (Baylin and 
Margolis, 1975). However, little has been done to compare histaminase 
purified from the placenta with histaminases found in the non-pregnant 
adult.
Of the placental proteins which have been detected 
immunologically by gel diffusion methods, SP1 has been the subject of 
most studies. It was discovered independently by Tatarinov et al.. 
(1970) and Bohn (1971). Immunohistochemical evidence indicates that its 
synthesis is initiated by the cytotrophoblast cells of the immature 
placenta (Tatarinov et al.. 1976) and continues in the syncytiotropho­
blast of the chorion (Bohn and Ronneberger, 1973; Horne et al., 1976; 
Lin and Halbert, 1976; Tatarinov et al.. 1976). However,, a preliminary 
investigation by Klopper and his colleagues (Klopper et al.. 1979) who
claimed to have studied representative samples of retroplacental blood
■the hypothesis
has supported^that, unlike HPL, the bulk of SP1 does not enter the 
maternal circulation through the intervillous space. This observation 
has led them to postulate that a substantial proportion of 5P1 may be 
synthesised by the non-villous interstitial trophoblast in the basal 
decidua and then makes it way into the maternal ciculation via the 
channels of uterine drainage not involved in the intervillous space.
SP1 has been highly purified by physicochemical methods (Bohn, 1976; 
Bohn, 1979) and its molecular weight has been estimated at 90,000 
daltons in one study (Bohn, 1974) and at 110,000 daltons in another
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(Lin et al,, 1974a). It is composed of a single peptide chain and contains 
28^ carbohydrate in addition to iron and sialic acid residues (Bohn,
1972; Lin et al,. 1974b). Studies by Bohn (1973) have revealed a degree 
of chemical and antigenic heterogeneity in the protein. The biological 
function of SP1 remains unknown but it is known to have an affinity for 
and may weakly bind steroid hormones especially estriol, 17- estradiol 
and cortisol (Bohn, 1974). It is also known to exert an inhibitory 
effect on the PHA stimulation of human lymphocytes and may therefore 
have immunosuppressive properties (Horne et al.. 1976). There appears 
to be no correlation between maternal levels of SP1 and placental 
weight (Lin at al.. 1976c): this finding supports the hypothesis that 
5P1 is synthesised by the interstitial trophoblast cells in the basal 
decidua (Klopper et al., 1979) which, if correct, would suggest a local 
function for SP1 within the uterine tissue. SP1 has so far been 
detected in maternal blood and in trace amounts in cord (fetal) blood, 
amniotic fluid and colostrum (Bohn, 1974; Tatra et al.. 1976). In 
maternal serum levels around 2 mg. per 100 ml. are typical during the 
20th week of gestation. Maternal serum levels continue to rise slowly 
until around the 36th week when a plateau ranging from 5-25 mg. per 
100 ml. is retained until term. Postpartum it ceases to be detectable 
in the maternal circulation within 3-4 weeks and has a half-life of 
30-40 hours (Bohn, 1974). Levels in the term placenta average 30 mg. 
per placenta,(Bohn, 1976).
Another placental protein purified to a high degree and 
characterised by Bohn (1976) and Bohn and Uinekler (1977a), PP5, has 
been demonstrated to be localised in the syncytiotrophoblast and the 
villous stroma of the term placenta by immunohistochemical methods 
(Sedlacek et al., 1975), In the early placenta (0 weeks) it is
.16.
localised almost exclusively in the syncytiotrophoblast (Jones, 1976).
Its molecular weight is 36,600 daltons and it is a glycoprotein 
containing sialic acid residues. A possible biological function of PP5 
may be protease inhibition since studies by Bohn and Uinekler (1977a) 
have revealed that it inhibits proteolytic activity of trypsin and 
plasmin in vitro. In maternal serum PP5 is found in trace amounts; its 
concentration there has been found to average 0*1 mg. per 100 ml. In 
term placenta the average PP5 content has been estimated at 1*2 mg. per 
placenta (Bohn 1976).
The remaining two placental proteins, PAPP-A and PAPP-B, 
were first identified by Lin and his associates and have been partially 
purified by physicochemical means by them (Lin et al.. 1974a; Lin et al.,
1978), However, no physicochemical evidence of purity was provided and 
the degree of purification (115-fold in the case of PAPP-A and 800-fold 
in the case of PAPP-B) was indirectly assessed in terms of immunological 
reactivity. The 115-fold purified PAPP-A preparation contained easily 
detectable serum proteins. Immunohistochemical studies have localised 
PAPP-A in the syncytiotrophoblast of the term placenta (Lin and Halbert,
1976). The molecular weight of PAPP-A has been estimated at 750,000 
daltons (Lin et al.. 1974a; Lin et al.. 1974b) but the subunit 
composition has not been determined. It was found to be a glycoprotein 
containing sialic acid (Lin and Halbert, 1975). The biological function 
of PAPP-A has not been determined. A correlation has been found between 
high concentrations of PAPP-A in maternal serum and large placental or 
newborn weights and the levels of PAPP-A in maternal serum were found to 
be higher in primigravid women and in women with high diastolic pressure 
(Lin et al., 1976a) but the significance of these findings is at present 
unknown. SoTfar, PAPP-A has not been detected anywhere other than in
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maternal serum (Lin et al,, 1974d), A steady rate of increase is 
typical during the second trimester of pregnancy followed by a steep 
rate of increase during the third trimester. Postpartum the concentration 
of PAPP-A drops rapidly within 2-3 days and becomes undetectable within 
3-4 weeks with a half-life of 3-4 days (Lin et al,. 1974c; Lin at al.. 
1976b).
PAPP-B has so far only been reported and studied by Lin 
and his colleagues who have shown it to have a molecular weight of 
1,000,000 daltons (Lin et al.. 1970). The subunit structure of PAPP-B 
has not been determined. This protein appears to be present in very low 
concentrations in maternal serum. It was frequently not detected before 
the 28th week of pregnancy and in over 50^ of the samples from the last 
two months of pregnancy. The mean concentrations show a gradual increase 
during the second trimester and a more steep increase during the third 
trimester, reaching a plateau in late gestation. Postpartum PAPP-B 
disappears from the maternal circulation within one day.
3.2 Other Pregnancy-Associated Proteins
Two proteins found in pregnancy serum have not so far been 
detected in non-pregnant adult serum: namely pregnancy protein 6 (PP6) 
and alpha-uterine protein (AVP).
PP6 was first isolated from the placenta and studied by 
Bohn (1975), who showed it to be localised in the nuclei of the 
syncytiotrophoblasts. Its molecular weight has been estimated at 
between 800,000-1,000,000 daltons. It contains 1% carbohydrate and 
appears to be composed of at least four different subunits of molecular 
weights ranging from 20,000 to 35,000 daltons which subunits are non- 
covalently bound. Although its biological function is unknown it is
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known to have steroid-binding properties. A protein with identical 
properties to PP6 has been detected in extracts of other human adult 
tissues as well as in the erythrocytes but not in non-pregnant serum 
(Haupt and Bohn, 1975), In pregnant serum PP6 occurs in concentrations 
of around 1-3 mg. per 100 ml.
AUP was discovered, purified and studied by Sutcliffe and 
his associates (Sutcliffe et al.. 1978; Sutcliffe et al.. 1980). It 
appears to be synthesised by the pregnant uterus but has also been 
detected in some samples of non-pregnant endometrium. Its molecular 
weight is 50,000 daltons and it appears to be a dimer composed of two 
identical subunits. Its biological function is unknown. The demonstration 
of the presence of AUP in maternal serum requires the use of radioimmuno­
assay; it is however readily detectable in amniotic fluid.
A fetal-specific protein, alpha-fetoprotein (AFP), found 
in pregnancy serum is only present in trace amounts in non-pregnant adult 
serum. AFP is synthesised by the human yolk sac, the fetal liver and 
gastro-intestinal tract (Gitlin, 1971). The molecular weight of AFP 
has been calculated as 70,000 daltons; it consists of a single subunit 
and contains 4% carbohydrate (Nishi, 1970; Ruoslahti and Seppala, 1971). 
The fiding of an average homology of 45^ between the amino acid 
sequences of fragments of AFP and the corresponding regions in albumin 
(Ruoslahti and Terry, 1976) and the demonstration of an immunological 
cross-reaction between unfolded derivatives of AFP and albumin 
(Ruoslahti and Engvall, 1977) have suggested that AFP may be evolution- 
arily related to albumin. Both proteins may therefore have similar 
functions as, for example, carriers in plasma. According to Uriel and 
his colleagues (Uriel et al,, 1972) AFP, like albumin, can bind estrogens. 
It has been suggested that possession of special functions by AFP, such
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as immunosupression, may offer an advantage over albumin to the fetus 
(Ruoslehti and Engvall, 1977). Although several authors have reported 
supressive effects of AFP on MLR and PHA-induced transformation of 
lymphocytes (see review by Lau hnd Linkins, 1976) recent studies by 
Labib and Tomasi (1978) have indicated that the supression of lymphocyte 
activity may be due to contaminating proteins or to certain subfractions 
of AFP. By means of the technique of radioimmunoassay trace amounts of 
AFP (less than 10-23 ng. per ml.) have been detected in non-pregnant 
adult serum (Ruoslahti and Seppala, 1972). In pregnancy serum the 
concentrations increase to 150-550 ng. per ml. during the third 
trimester dropping shortly before term to normal (Seppala and Ruoslahti,
1972). In fetal serum maximal concentrations are reached at about the 
14th week of intra-uterine development, falling thereafter to low 
levels in cord serum (Gitlin, 1975).
The remaining pregnancy associated proteins can all be 
detected in non-pregnant serum but are present in increased concentra­
tions in pregnancy serum. Proteins found in greatly increased 
concentrations include steroid-binding beta-globulin (SP2), pregnancy 
zone protein (PZP) and a number of protein hormones.
SP2 has been isolated from human placentae and studied by 
Bohn and Kranz (1973) and Bohn (1974b,c and d). Its molecular weight is
65,000 daltons: it contains 13^ carbohydrate and is composed of four 
identical subunits of 16,000 daltons each held together by non-covalent 
bonds. Although its bidlogical function is unknown SP2 is known to have 
steroid binding properties and shows a preferential for testosterone and 
estrodiol. SP2 is found in trace amounts (less than 1 mg. per 100 ml.) 
in male and in non-pregnant female sera. It appears to be dependent on 
the presence of estrogens and is often found in greatly increased
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concentrations in the serum of patients treated with estrogens. It may 
also occur in slightly increased concentrations in the sera of patients 
suffering from a range of different diseases. During the first half of 
pregnancy the levels of SP2 rise rapidly to 2-10 mg. per 100 ml. In the 
last month the range of concentrations found is 2*4-12*6 mg. per 100 ml. 
After parturition the levels of SP2 return to normal within 5-10 weeks 
with a half-life of 6-7 days.
PZP has been known under the following names; alpha-2 
pregnoglobulin, pregnancy-associated alpha-2 glycoprotein, new serum 
pregnancy alpha-2 macroglobulin, PAG, pregnancy-associated alpha-2 
globulin, SP3, Pal, Xh and Xm (Lin and Halbert, 1975). It appears to be 
synthesised by peripheral blood leucocytes (Stimson and Blackstock,
1975). Immunohistological studies have indicated that PZP is present in 
blood vessel cells and parenchymal structures within the placental 
villous stroma as well as in the trophoblast cytoplasm (Lin and Halbert,
1976). It contains 10-12% carbohydrate and molecular weight is 360,000 
daltons; it is made up of two identical subunits of 180,000 each held 
together by non-covalent bonds (Bohn and Uinekler, 1976), The biological 
function of PZP is incompletely understood. It has been found to be 
estrogen-induced and to show preferential binding for estriol. A 
postulated function for it as a steroid-carrier (Bohn and Kranz, 1973) 
has, however, been rejected (Van Schoultz and Stigbrand, 1973; Stimson,
1973), It has also been found to inhibit the PHA-induced stimulation of 
lymphocytes (Uon Schoultz et al.. 1973; Stimson and Blackstock, 1975; 
Home et al., 1976) and may therefore have immunosupressive properties. 
The mean levels of PZP are known to increase in multigravidas and one 
possible interpretation of this finding is that antigenic stimulation 
has occurred during previous pregnancies. In primigravidas there is an
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inverse correlation of PZP concentration with placental weight (Lin at 
al.. 1976a). PZP is found in trace amounts (less than 1 mg. per 100 ml.) 
in male and in non-pregnant sera, cord sera and amniotic fluid (Beckman 
et al.. 1973; Damber et al.. 1976). Like SP2 it appears to be dependent 
on the presence of estrogens and is often found in greatly increased 
concentrations in the sera of patients treated with estrogens. A less 
pronounced increase may also accompany a range of different diseases 
(Beckman et al.. 1973; Bohn and Becker, 1976; Stimson, 1977). PZP appears 
with increasing frequency during pregnancy between weeks 9 and 25 
(Afonso and de Alvarez, 1964). The concentration of PZP increases 
rapidly at the end of the first trimester, then there is often a 
decline after reaching a maximum until the third trimester when the 
concentrations stabilise around 100 mg. per 100 ml. (the range at term 
is 50-200 mg. per 100 ml.). Postpartum there is a rapid decrease in 
concentrations which tend to return to normal within 5-10 weeks with a 
half-life of 6-7 days (Bohn, 1974b).
The protein hormones found in greatly increased concentra­
tions in pregnant serum include adrenocorticotrophic hormone (ACTH), 
melanocyte stimulating hormone (MSH), LH-releasing hormone, relaxin, 
oxytocin and vasopressin (see reviews by Diczfalusy and Troen, 1961 and 
Brody, 1969). Recent evidence indicates that the precursor polypeptide 
for ACTH and MSH is made in the placenta (Liotta et al.. I960). In 
vitro biosynthesis of LH-releasing hormone has also been demonstrated 
(Gibbons et al.. 1975). Relaxin, oxytocin and vasopressin have been 
identified in placental tissue (Zarrow et al.. 1955; Caldeyro-Barcia, 
1960) and may therefore also be synthesised by the placenta.
In addition the concentrations of several other normal 
serum proteins increase slightly during pregnancy; for example
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ceruloplasm, alpha-1-antitrypsin, transferrin, beta-lipoprotein, 
lactoferrin and the complement fractions beta-1-A-C (Mendenhall, 1970; 
Studd, 1971; Stimson, 1972).
4. AREAS OF CURRENT AND POTENTIAL PRACTICAL APPLICATION OF THE STUDY
OF PREGNANCY-ASSOCIATED PROTEINS
4.1 Obstetric Diagnosis
Monitoring of placental function may be necessary during 
pregnancies complicated by any one of the following conditions: uterine 
bleeding, threatened abortion, hypertension, oedema, proteinuria, 
preeclàmpsia, placental insufficiency, post-maturity, diabetes meéitus 
and erythroblastosis: or for predicting fetal growth retardation, death 
in utero and fetal distress in labour. Several of the biochemical tests 
presently used to monitor placental function are based upon the
measurement of substances synthesised in the feto-placental unit; for
example steroid hormones and enzymes. The most common test hitherto 
used, the estimation of estriol or total estrogens in a 24 hour 
specimen of urine, is a measure of the function of the placenta and 
fetus together (Katagiri et al». 1976). Reduced estriol output is 
associated with an increased incidence of fetal growth retardation, 
fetal distress in labour and fetal death in utero (Beischer et al», 
1968). However, about 10% of mothers in whom the fetus is seriously 
compromised can have urinary values within the normal range (Yousem, 
1966). On the other hand, low urinary values may occur without the
fetus being metabolically compromised and may be due to a deficiency at
a single point in the complex series of steps between the fetal adrenal 
which initiates synthesis of estriol and the maternal urine used for
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analysis (Fliegner et al.. 1972; France et al.. 1973). Furthermore, the 
interpretation of the estriol levels can be confused by other factors 
such as the volume of urine, errors in urine collection and interference 
from drugs used in the treatment of patients. Wide fluctuations in 
urinary output make this method unsuitable for use in diabetic mothers 
(Klopper, 1969). Plasma estriol shows large day-to-day fluctuations and 
subject-to-subject variability (Klopper et al.. 1979), In a controlled 
study in which plasma estriol levels were used as a marker of fetal well­
being in late pregnancy a significant number of false positive results 
occurred and the conclusion reached was that the test was not valuable 
in timing delivery of the baby (Puenhoelter et al.. 1976). Even assays 
of plasma estradiol 17-beta, shown to have less diurnal variability 
than plasma estriol, have not been demonstrated to be superior to that 
of urinary estrogens (Uindberg et al., 1974).
Placental proteins such as HPL,SP1 and PAPP-A show much 
smaller day-to-day and subject-to-subject variability than plasma 
estrogens (Masson et al». 1977b; Klopper et al.. 1977). A number of 
placental proteins have already been used in obstetric diagnosis. The 
clinical usefulness of these proteins, with the possible exception of 
HPL, has not been subjected to any critical analysis. The literature 
abounds with claims and counter-claims as to the usefulness of 
individual placental proteins: however, most studies lack adequate 
controls and do not attempt to compare the value of the particular 
placental protein assay with that of other biochemical, physical or 
clinical tests available. The uncertainty currently surrounding the 
physiological role, and the control of production, release and 
elimination of placental proteins means that nothing definite can be 
said about the likely clinical significance of individual circulating
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placental proteins: it is not known to what extent their concentration 
reflects placental function* Any variations in the clinical usefulness 
reported may simply be due to differences in the precision and 
practicality of the measurement of individual proteins.
The HPL test has been the subject of most studies (see 
reviews by Loraine and Bell, 1966; Singer et al,. 1970; Genazzani et al,* 
1971; Spellacy et al,, 1971; Spona and Janisch, 1971; Karjalainen et al.. 
1975), Serial determinations are usually required: consistently low 
values of HPL concentrations in third trimester maternal plasma have 
been claimed to indicate the risk of fetal distress in labour or neonatal 
asphxia (Letchworth and Chard, 1972) and have been used to predict the 
outcome of threatened abortion (Niven et al.. 1972; Garoff and Seppala, 
1975), In pregnancies comlicated by hypertension low values of HPL 
have been claimed to indicate the risk of fetal death in utero 
(Spelacy et al.. 1971). However the HPL assay could not be used to 
predict intrauterine death in the absence of severe hypertensive 
disease (Spellacy et al.. 1975). HPL levels were found to be lower in 
mild than in severe toxemia (Letchworth and Chard, 1972). Normal or 
increased values of HPL have been found in pregnancies complicated by 
rhesus immunisation, maternal diabetes, toxemias and chronic nephritis 
(Josimovich et al..1970; Soler, 1974; Lin et al.. 1977). Preliminary 
experiments have recently been carried out aimed at assessing whether 
the value of the HPL test as a predictor of neonatal morbidity is 
better than that of some of the other parameters currently used (for 
example, maternal weight and smoking) and whether the HPL test can be 
used to predict the optimal time for the delivery of the baby, A 
prospective study of 1029 women delivered at a London hospital showed 
that depressed circulating levels of HPL were associated with a higher
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risk of neonatal morbidity in late pregnancy than any other antenatal 
parameter tested,.except in severe preeclampsia (Gordon et al.. 1978). 
However, the HPL test was not compared with other biochemical tests 
(except with the measurement of AFP levels between 16-20 weeks), with 
ultrasonic measurements of the fetus nor with antenatal fetal heart 
monitoring in late pregnancy. It is possible that the prediction of 
fetal risk using ultrasonography will be superior because the fetus is 
assessed directly whereas HPL is an indirect index (Gordon and 
Grudzinskas, 1978). A controlled study by Spellacy and his colleagues 
(Spellacy et al.. 1975) indicated that the measurement of HPL was a 
useful adjunct in decreasing perinatal deaths. However, according to 
Gordon and Chard (1979) subjects with low levels of HPL do not show a 
fall: this is consistent with the exponential nature of the rate of 
increase in circulating concentrations of HPL in late pregnancy.
Information concerning the value of the SP1 test in 
obstetric diagnosis is slowly accumulating. Low levels of SP1 in the 
third trimester of pregnancy have been reported to be associated with 
intrauterine growth retardation and fetal death in utero (Tatra, 1977): 
furthermore it has been claimed to be superior to HPL in predicting 
intrauterine growth retardation (Gordon et al.. 1977; Towler et al.. 
1977; Horne et al.. 1979). Consistently low levels of SP1 have been 
reported to be associated with preeclampsia and eclampsia (Afanasjeva 
et al.. 1976; Tatra et al., 1974a). SP1 has also been used to detect 
pregnancy (Grudzinskas et al.. 1977a,b) and identify abnormalities of 
early pregnancy such anembryonic pregnancy (Bennett et al.. 1978), 
ectopic gestation (Grudinskas et al.. 1977a) and predict the outcome of 
threatened abortions (Schultz-Larsen and Hertz, 1978). In addition there 
is some evidence which suggests that measurement of SP1 concentrations
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in amniotic fluid may be useful in monitoring high-risk pregnancies 
(Tatra et al., 1976a). In pregnancies complicated with diabetes plasma 
SP1 concentrations appear to be within normal limits (Lin et al. 1977) 
even though studies by Tatra and his colleagues (Tatra et al., 1976b) 
have suggested that the plasma SP1 level in pregnancy may be related to 
the maternal blood sugar level and carbohydrate metabolism* Normal 
levels of SP1 have also been reported in pregnancies complicated with 
toxemias (Lin et al.. 1977). A recent suggestion that SP1 may be a 
protein active locally within the uterine tissue and that the material 
found in the maternal peripheral circulation may be waste leaking away 
from the site of action (Klopper et al.. 1979; see section 2.1), if 
correct, would detract from the likely usefulness of SP1 in maternal 
blood as a means of assessing placental function.
HCG has no established clinical application other than in 
the early detection of pregnancy (Landesman and Saxena, 1976), although 
its levels have been found in one study to be above average in pre­
eclamptic toxemia and in diabetes mellitus (Loraine and Mathew, 1953); 
and concentrations below average have been reported by Brody and 
Carlstrom (1965a) to be associated with pregnancies which threaten to 
abort and which subsequently end in abortion (see also reviews by 
Loraine and Bell, 1966 and Saxena, 1971). Only preliminary studies of 
PAPP-A and PAPP-B levels in normal and abnormal pregnancies have been 
carried out: they indicate that PAPP-A concentrations may be increased 
in toxemia but is not affected in pregnancies complicated with diabetes 
(Lin et al.. 1977) while PAPP-B concentrations appear to be decreased 
in toxemia and in pregnancies complicated by diabetes (Lin et al., 
1978b). Measurements of plasma levels of the placental enzymes heat- 
stable alkaline phosphatase (see reviews by Uatney et al.. 1970; Curzen
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and Varma, 1971; Merret and Hunter, 1973), histaminase (Suamberg, 1950; 
Beav/en et al,. 1975) and oxytocinase (Hensleigh and Krantz, 1970; Carter 
et al..1974) have been advocated to be of value, but all have proved 
disappointing in clinical practice (Lind,1976).
Pregnancy-associated proteins of non-placental origin 
advocated to be of value in assessments of fetal status include PZP and 
AFP. Determinations of PZP in early pregnancy may be of some predictive 
value as studies by Beckman and his colleagues (Beckman et al.. 1974a) 
have pointed to a higher than normal incidence of early spontaneous 
abortion in women in whose serum no PZP could be detected by means of 
double immunodiffusion. Determinations of AFP in maternal serum or 
amniotic fluid can reveal neural tube defects and a variety of other 
prenatal conditions (Brock and Sutcliffe, 1972; Brock 1970a and b; Brock
1979). Persistently low levels of HPL have also been found to be 
associated with a range of fetal abnormalities (Gau and Cadle, 1974).
4.2 Cancer Diagnosis
Pregnancy-associated proteins are synthesised eutopically 
in non-pregnant patients with trophoblastic cancer (Bagshawe, 1974) and 
ectopically in a proportion of other forms of cancer (Gordon et al..
1977). Marker-sided cancer diagnosis is an area which is only beginning 
to be explored, but it is becoming increasingly clear that specific 
tumour markers may aid in early tumour detection and localisation as 
well as the detection of tumour recurrence. Specific placental proteins 
which have been shown to be associated with cancer occurrence include 
HCG, HPL, SP1 and placental alkaline phosphatase. At present the only 
well established use of a placental tumour marker is in the measurement 
of HCG in the blood of patients with choriocarcinoma and teratomas. HCG
•28-
is known to be secreted by choriocarcinoma tumour cells and a proportion 
of teratoma cells. Measurement of beta-HCG in the blood or urine of 
women suspected of having choriocarcinoma has made possible the 
detection of this type of cancer at a treatable stage (Uaitukaitis et 
al.. 1972; Karana and Bagshawe, 1976; Bagshawe 1977; Yuen et al.. 1977; 
Bagshawe, 1978). The measurement of beta-HCG in the blood of patients 
with teratomas, when combined with the measurement of AFP which is also 
produced by a proportion of teratoma cells (Abelev, 1974) has been 
found very useful in the monitoring of the course of these tumours 
(Perlin, 1976; Lange, 1978; Narayana et al.. 1978; Walker, 1978). A 
wide variety of other malignant tumours, including tumours of the bowel, 
breast, lung, gonad and melanomas,have also been found to be associated 
with ectopic HCG production (Sheth et al.. 1974; Rosen et al.. 1975; 
Vaitukaitis et al*. 1976; Stone et al*. 1977; Crowther et al.. 1978),
The incidence of ectopic HCG production ranged between ^ 9 and 62% among 
the tumours in the studies cited. However Weintraub and his colleagues 
(Ueintraub et al.. 1975) have reported differences in the physical and 
combining properties of purified ectopic and normal alpha-subunits of 
glycoprotein hormones such as HCG. They have suggested that these 
differences may reflect abnormalities of neoplastic protein synthesis 
or carbohydrate attachment or alternatively the production of as yet 
unrecognised alpha precursor forms by tumour cells. Unbalanced or 
isolated ectopic production of the alpha- or beta- subunits of HCG has 
also been demonstrated in certain ectopic tumours (Tashjian et al*,
1973; Vaitukaitis, 1973; Weintraub and Rosen, 1973; Rosen and Weintraub,
1974).
Ectopic production of HPL has been detected in a proportion 
of patients with malignant tumours of the breast, lung, bowel and
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ovarian carcinomas (Rosen et al.. 1975; Samaan et al». 1976, Sheth et 
al., 1977; Crowther et al.. 1978). Ectopic production of SP1 has been 
detected in a proportion of patients with the same types of malignant 
tumours as have been found to be associated with HPL production as well 
as in testicular carcinomas and in melanomas (Tatarinov and Sokolov, 
1977; Towler et al.. 1977; Crowther et al.. 1978; Grudzinskas et al.. 
1978; Searle et al.» 1978). Ectopic production of placental alkaline 
phosphatase has also been found to be associated with a wide variety of 
cancers (Fishman, 1973).
4.3 Diagnosis and Treatment of Conditions of Pregnancy with
Immunological Aetiologies 
In taking stock of the current understanding of the factors 
involved in the maintenance of the immunological homoeostasis during 
pregnancy (Section 4.3a) it will become apparent why a straightforward 
statement cannot yet be made about the role and relative importance of 
each of the pregnancy- associated proteins whose involvement is 
implicated. A general statement can, however, be made to the effect 
that different pregnancy-associated proteins may act to stimulate and/ 
or suppress maternal immune responses during pregnancy and may therefore 
play a part in abnormal states of pregnancy (discussed in Section 4.3b) 
which have suspected immunological aetiologies. The elucidation of the 
precise roles of these pregnancy-associated proteins is a continuing 
quest which may one day open the way to the diagnosis and treatment of 
women with immunological complications of pregnancy. Prophylactic 
immunisation against the offending antigen(s) may then also become 
possible, either by supplying the antigen prior to pregnancy or by 
supplying specific blocking factors or non-specific constituents
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normally formed during pregnancy.
4.3a The Maintenance of the Immunological Homoeostasis During Pregnancy 
There is substantial evidence to suggest that maternal 
humoral and cellular responses to placental and fetal antigens occur in 
normal pregnancy. Responses to paternal histocompatability (HL-A) alio- 
antigens have been most extensively studied. Current experiments 
indicate that developmentally mature and immature human trophoblasts 
have little or no exposed or masked HL-A determinants on their surface 
(Faulk and Temple, 1976; Faulk and Johnson, 1977; Faulk et al.. 1977). 
Studies in mice have suggested that loss of histocompatability (H-2) 
antigens occurs on the trophectoderm at the time of implantation of the 
blastocyst (Searle et al». 1976), HL-A antigens have, however, been 
detected on the stromal cells of the placenta (Faulk and Temple, 1976; 
Faulk et al.. 1977). They may also be presented to the mother on fetal 
cells which frequently enter the maternal circulation (McConnell, 1969; 
Herzenberg et al.. 1979). Cytotoxic antibodies apparently directed 
against paternal HL-A antigens are frequently found in the sera of 
multiparous pregnant women (Terasaki et al.. 1970) and in one study 
have been detected in 20% of primiparous pregnancies and in 40% of 
molar pregnancies, where the mode of antigen presentation may be 
different (Bagshawe and Lawler, 1975). Complement-fixing antibodies to 
a major composite protein from placental microsomal fraction, thought to 
contain HL-A antigens, have been detected in 40% of normal pregnancies 
(Gaugas and Curzen, 1974). In addition, antibodies to la-like allo- 
antigens expressed on beta-lymphocytes have been identified in sera 
of multigravid women (Winchester et al., 1975). Cytotoxic effects of 
maternal and allogeneic lymphocytes on both normal trophoblasts (Currie
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and Bagshawe, 1967b) and trypsinised human placental monolayers have 
been reported (Douthwaite and Urbach, 1971), Other studies of cell 
mediated immunity in pregnancy using in vitro models have revealed a 
maternal lymphocyte hypersensitivity to unidentified paternal allo- 
antigens (Rocklin et al,. 1973) in multigravida and placental antigens, 
thought to be either la-like alloantigens or placental-specific 
antigens, in primigravida (Youananukorn and Matangkasombut, 1973; 
Youananukorn et al.. 1974; Stimson et al.. 1979). As has already been 
mentioned, passage of fetal blood elements into the maternal 
circulation often occurs and antibodies to fetal antigens such as 
embryonic gut antigens have been detected in the sera of pregnant 
women (Gold, 1967).
Maternal sensitisation to specific protein products of the 
placenta has hot been unequivocally demonstrated as yet. Antibodies 
against HCG have been detected in some pregnancy sera (Ruzic et al..
1973). The presence of anti-HPL antibodies in some pregnancy and 
postpartum sera has been reported (Gusdon et al.. 1970; Gusdon et al.. 
1971; lannuzzi et al., 1976). However, these findings cannot be accepted 
as evidence of sensitisation to HCG and HPL since antibodies cross­
reacting with HCG as well as antibodies cross-reacting with HPL have 
been detected in the sera of some non-pregnant individuals (lannuzzi et 
al.. 1976; Wass et al.. 1978). It is not known what provokes the 
formation of these antibodies. One possibility is exposure to micro­
organisms which share antigenic sites with HCG or HPL: supporting this 
is the finding that some antigens are shared by microorganisms and 
certain mammalian cells (Kaplan and Suchy, 1964; Chase and Rappaport, 
1965) or cancer cells (Minden et al.. 1976) and the detection of HGG- 
producing bacteria in the tissues of patients with malignant neoplasms
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(Cohen and Srampp, 1976; Aceredo et al., 1978). Antibodies directed at 
syncytiotrophoblastic cytoplasm have been reported to occur in some 
postpartum sera (Hulka et al., 1963), although this finding was not 
confirmed by other workers (Curzen, 1970), Circulating immune complexes 
containing an unidentified placental antigen with a molecular weight of
400,000 daltons have been detected in pregnancy sera by Masson et al., 
(1977).
Tolerance to some pregnancy-associated proteins in the 
pregnant state, however, may be due to these proteins being also 
present in small but persistent levels in the non-pregnant adult state. 
This explanation has been put forward to account for the absence of 
anti-AFP antibodies in the pregnancy serum (Ruoslahti and Pihko, 1976). 
In the case of cross-reacting antigens such as HCG and HLH or HPL and 
HGH exposure to HLH and HGH in the non-pregnant adult state may result
in tolerance to HCG and HPL in the pregnant state.
Of the many mechanisms proposed to account for the success
of pregnancy in immunological terms, the following are best supported
by the available experimental evidence:
(i) The acquisition of special protective properties by 
the trophoblast cells.
(ii) The production of non-specific immunosupressive
factors by the mother and/or fetus.
(iii) The production of specific blocking factors to
balance the developing cell-mediated immunity.
The evidence for each of the above mechanisms will now be 
reviewed in turn:
(i) The acquisition of special protective properties by 
the trophoblast cells. Since the placenta is the site of contact and
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exchange in the materno-fetal relationship a mechanical barrier on its 
surface would segregate the placental antigens and any any fetal allo­
antigens presenton trophoblasts from potentially agressive maternal 
lymphocytes. In the case of HL-A and la-like alloantigens, however, 
protection may result from the partial or complete loss of these antigens 
from the trophoblasts’ surface (Faulk and Johnson, 1977; Faulk et al..
1977). As has already been mentioned, a layer of fibrin or sialomuco- 
protein is known to exist in the hemochorial placenta. In the mouse this 
contains sulphate and sialic acid residues which confer upon the surface 
a relatively large negative charge (Bradbury et al.. 1965; Kirby et al..
1964). Transplanted mouse blastocysts have been shown to develop 
normally in the uterus but not in the kidneys of hyperimmune recipient 
mice; this effect has been attributed to the immunologically protective 
role of the sialomucoprotein layer associated with the decidua (Kirby 
et al.. 1966). In man the layer contains sulphates but little sialic 
acid (Bradbury et al.. 1969), This layer may form an electrostatic 
barrier, preventing the attachment of cytotoxic lymphocytes (Currie and 
Bagshawe, 1967a) or complement-fixing antibody molecules. There is, 
however, disagreement as to continuous nature of this layer on the 
mammalian placenta (Martinek, 1970), The involvement of HCG, which has 
been postulated to be a structural antigen as well as a secretory 
product (Smith and Brush, 1973), in barrier formation has been impli­
cated by experiments in which HCG treatment was shown to prolong the 
survival of transplanted neuraminidase treated human trophoblast in the 
guinea pig (Borland et al.. 1975), It is also possible that the barrier 
consists of the so-called ’symbodies* - serum sialomucins which interact 
with conventional antibodies to provide a protective coat around the 
trophoblast cells (Apffel and Peters, 1969). Although there is
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extensive contact between the fetal chorionic membrane - known to be 
antigenic in the mouse - and the uterine tissues away from the placental 
site, the membrane is not vascularised by the uterine vessels which could 
partly account for its lack of susceptibility (Billington, 1975),
(ii) The production of non-specific immunosuppressive 
factors by the mother and/or fetus. Early studies of maternal immuno­
logical activity that the maternal immune system is normal (Medawar and 
Sparrow, 1956; Gillingham and Lampkin, 1957) or only slightly impaired 
during pregnancy (Lichtenstein, 1942; Breyere, 1961; Lajos et al.. 1964), 
Subsequent studies of maternal lymphocyte reactivity produced conflicting 
results. Although some workers could find no evidence for either 
increased or reduced non-specific proliferative responses of maternal 
lymphocytes stimulated with allogeneic lymphocytes, mitogens or soluble 
antigens (Carr and Stites, 1972; Harrison, 1972), other workers 
reported that they are reduced in the second and third trimesters of 
pregnancy (Kasakura, 1971; Finn et al., 1972; Purtilo et al.. 1972; 
Petrucco et al.. 1976) and suggested that the suppression of the 
immunological reactivity of maternal lymphocytes occurs in late 
pregnancy. However, there is general agreement that the responses of 
human lymphocytes stimulated with mytomycin-C treated allogeneic cells, 
mitogens or soluble antigens can be inhibited by plasma from pregnant 
women (Ceppellini et al.. 1971; Kasakura, 1971; Leventhal, 1971;
Buckley, 1972; Hill et al.. 1973; 3ha et al.. 1975; Pence, 1975;
Petrucco et al,. 1976; Stimson, 1976; Stimson and Blackstock, 1976). The 
serum concentrations of the immunoglobulins IgG, IgM and IgA were found 
to decrease in the second half of pregnancy (Maroulis et al., 1971;
Tatra et al., 1974b) while IgM-bearing B-lymphocytes were found to 
increase in the peripheral blood during pregnancy (Loke et al., 1975),
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suggesting the suppression of immunoglobulin synthesis during pregnancy* 
Other studies have demonstrated that the composition of the lymphoid 
tissues changes during pregnancy (Nelson and Hall, 1964; Strelkauskas 
et al.. 1975).
A large number of substances produced during pregnancy 
have been reported to have immunosuppressive properties and some or all 
of them could therefore play a part in bringing about abrogations of 
maternal thymo-lymphatic activity# They include the products of the 
placenta and the fetus as well as proteins of maternal origin. Placental 
products include hormones: HCG, HPL (see Section 3 of this chapter) and 
steroids (Barnes et al*. 1974), It is uncertain whether these placental 
hormones are inhibitory at serum concentrations, although HPL has been 
reported to be inhibitory by Petrucco et al.. 1976 and HCG has been 
reported to be inhibitory at those levels found in early pregnancy (8- 
11 weeks) by Jenkins et al.. 1972. Placental hormones could, however, 
exert their effects during the circulation of maternal lymphocytes past 
the placenta where they are present in high concentrations (Amoroso and 
Perry, 1975), Other placental products include SP1 (see Section 3 of this 
chapter) and three unidentified proteins: a protein precipitating with 
heparin (Lozovoy et al#, 1975), an alpha-2-mobility glycoprotein (Riggio 
et al#, 1971) and a protein of molecular weight less than 150,000 
daltons (Hanrahan et al#. 1975). The fetal-specific protein, AFP, is 
also known to have immunosuppressive properties (Lau and Linkins, 1976). 
Maternally-derived proteins with immunosuppressive properties include 
serum sialomucins, which are usually elevated in the first and second 
pregnancy and could represent an acute phase response (Good et al..
1974; Good , 1974), prolactin (Skutsch, 1974; Skutsch, 1975), cortisol 
(Lewis et al.. 1966; Petrucco et al#, 1976) and 5P2 (see Section 3 of
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this chapter). It has been claimed by Beckman and his colleagues 
(Beckman et al.. 1974b) that genetic incompatability may stimulate the 
production of another immunosuppressive protein, PZP. However, out of 
four genetic systems studied by these workers only two showed this 
relationship.
(iii) The production of specific blocking factors to 
balance the developing cell-mediated immunity; It is evident that other 
factors are present in pregnancy sera which specifically block maternal 
lymphocyte reactivity to fetal and trophoblast antigens* Autologous 
maternal serum was shown to inhibit specific responses of maternal 
lymphocytes stimulated by fetal lymphocytes (Robert et al.. 1973), 
paternal cells (Rocklin et al*. 1976) and placental antigens (Stimson 
et al.. 1979). Presence of autologous maternal serum in tissue culture 
was found to inhibit trophoblast lysis by sensitized maternal lympho­
cytes (Taylor et al.. 1975).
The possibility that cell-mediated immunity in tumour 
progression, allotransplantation and pregnancy to antigens which are 
either weak or are supplied in large or continued doses may be balanced 
by production of enhancing antibodies or antibody-antigen complexes 
(blocking factors) has been discussed in a review by Halliday (1972), 
who argued that in pregnancy the initial requirement for immunosuppression 
to allow blocking factors to form could be fulfilled by some of the 
non-specific immunosuppressive factors, notably placental hormones.
It has been observed that lymphocyte reactivity to trophoblast antigens 
is not detectable during the first trimester of pregnancy (Taylor et al.,
1975). Antibody-antigen complexes formed in antigenic excess are known 
to be profoundly tolerogenic at very low concentrations. This observation 
is reflected in the Effector Cell Blocade theory which postulates a
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State of activated B and T-lymphocytes held in blocked state by antibody- 
antigen complexes in tumour progression (Nossal, 1974; Schrader and Nossal,
1974) and could equally well apply to the pregnancy situation. It has 
also been postulated that cell-mediated immunity originally developed 
to destroy malignant cells, then with the advent of placentation humoral 
immunity was developed to provide specific blocking factors to block 
cell-mediated immunity (Coggin and Anderson, 1974).
In pregnancy the blocking activity has been found to 
increase with parity and has been assigned to gel-filtration fractions 
of maternal sera containing IgG antibodies by a number of workers 
(Buckley, 1972; Robert et al., 1973; Gatti et al., 1975; Pence et al*.
1975; Rocklin et al., 1976). Although the specificity of these anti­
bodies has not been determined recent studies on primiparous women 
have established that in such women they are not directed at HL-A anti­
gens (including products of HL-A A,B and C loci) but appear instead
r X a  - ,(i ke.)
to be directed at HL-ABR'^alloantigens or placental-specific antigens 
(Stimson et al., 1979)
Studies of placental eluates also point to the presence 
of enhancing maternal IgG antibodies, although their nature is in*» 
completely understood. Revillard et al. (1976) reported the presence 
of two antibody populations in human placental eluates. One of these 
antibody populations was shown to have anti-HL-A specificities and 
the antibodies exhibited lymphocytotoxicity in the presence of comple­
ment, However, evidence has been put forward for complement inactivator 
production by the human placenta (Strachan, 1976). Antibodies directed 
at HL-A antigens were also detected in placental eluates by Doughty 
and Gelsthorpe (1976). The other antibody population detected in 
placental eluates by Revillard et al. (1976) was shown to have anti-
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la-like specificities and the antibodies were noncytotoxic* Using immuno­
fluorescence techniques McCormick et al, (1971) and Faulk and Johnson 
(1977) have detected maternal IgG antibodies on the human trophoblastic 
basement membrane which, when eluted, were shown to inhibit most mixed 
lymphocyte reactions. The inhibition was independent of anti-HL-A activity 
(Faulk et al,, 1974) and was postulated to be due to antibodies directed 
at la-like alloantigens (Johnson and Faulk, 1976), However, McCormick 
et al. (I97l) were unable to detect any anti-trophoblastic basement 
membrane antibodies in pregnancy or in post-partum sera, possibly due 
to a low titre present. Antibodies capable of inhibiting most mixed 
lymphocyte reactions and thought to be directed at la-like alloantigens 
were also detected in placental eluates by Jeannet et al. (1977), These 
findings are of interest as antisera directed at la-like antigens have 
been shown to depress mixed lymphocyte reactions and to impair in vitro 
antibody-dependent cellular cytotoxicity and immunoglobulin synthesis 
(Meo et al., 1975; Chess et al., 1976; Davies and Staines, 1976;
Hirschberg et al,. 1977).
It also appears that receptors for aggregated IgG are 
present on placental endothelial cells whose function may be to keep 
immune complexes from entering fetal circulation (Johnson et al., 1976), 
Finally, mention should be made of the specific immunosuppressive 
mechanism which results in a degree of selective unresponsiveness 
between maternal and fetal lymphocytes and which has been postulated 
to involve specific surface repellent molecules on fetal lymphocytes 
(Finn, 1975). Such molecules are thought to cross the placenta and 
coat maternal lymphocytes thus preventing them from attacking fetal 
cells. This mechanism would explain the generally observed lack of 
graft-versus-host reactions, despite frequent migration of maternal
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lymphocytes across the placenta into the fetal circulation (Kadauaki _et
1965).
4.3b Abnormal States of Pregnancy with Suspected Immunological Aetiologies
It is well known that both passive and active immunization 
of pregnant and non-pregnant animals with fetal and placental proteins 
is capable of inducing abortions and abrogations of reproductive 
performance (see review by Stevens, 1974). Abortions have been induced 
by passive immunization of animals possessing cross-reacting antigens 
with anti-AFP, anti-HCG, anti-SPI or anti-HPL antisera. Although the 
possibility that the abortifacient effects were simply a consequence 
of the damage caused by the deposition of antibody-antigen complexes 
in the placenta or in fetal tissues cannot be excluded, these findings 
can equally well be interpreted as indicating that all the antigens 
involved are essential for pregnancy. It is interesting to note that 
AFP, HCG, SP1 and HPL are all believed to have immunosuppressive 
properties* Active immunization of animals possessing cross-reactive 
antigens with HPL or HCG results in reduction in reproductive function. 
Immunization of baboons with the beta-subunit of HCG has lasting anti­
fertility effects (Stevens, 1979).
Immunological response against the placenta is suspected 
in pre-eclampsia, which is a disease of primigravidas with many of 
the hallmarks of immune-complex disease (Kitzmiller and Bernirschke,
1973; Petrucco et al., 1974; Yang et al., 1975; Scott and Beer, 1976). 
Injection of pregnant rats with heterologous anti-placenta serum can 
lead to a pre-eclampsia like syndrome characterised by hypertension 
associated with placental and kidney damage (Lanford et al*. 1967;
Smith e t à l . , 1967). The nephrotoxicity of anti-placenta serum suggests
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the involvement of antigens common to both placenta and kidney. Studies 
by Keren and his associates (Koren et al,, 1970) have indicated that 
some, though not all, of the renal damage caused by anti-placenta sera 
is attributable to the deposition of antibody-antigen complexes in 
glomerular capillary walls. Unlike normal pregnancy, cell-mediated 
immunity is not reduced in the second and third trimesters of severe 
pre-eclamptic pregnancy (Petrucco et al.. 1976). Furthermore, the 
levels of maternal serum sialomucins are frequently raised (Good e_t 
^ , ,  1974).
Complications of pregnancy due to maternal sensitization 
to fetal alloantigens are well documented. These include erythroblastosis 
fetalis, anaemia, leucopenia (Jensen, 1966), thrombocytopenia (Sitarz et 
al.« 1976), haemolytic disease of the newborn (Faulk et al,, 1968) and 
congenital nephrosis (Fudenberg and Fudenberg, 1964). Rocklin and his 
colleagues (Rocklin et al». 1976, Rocklin et al.. 1979) reported that 
blocking IgG antibodies (thought to be directed at la-like alloantigens) 
present in the sera of pregnant women were absent from the sera of 
chronic aborters but appeared in their serum during subsequent success­
ful pregnancies. Also, Stimson et al. reported that blocking IgG anti­
bodies (thought to be directed either at la-like alloantigens or at 
placental-specific antigens) present in the sera of primigravida were 
absent from the sera of a group of abortion-prone women studied. Several 
other conditions of pregnancy, such as unexplained intrauterine death 
and intrauterine growth retardation may well have immunological factors 
in their aetiologies. However, the evidence is in most cases fragmentary 





5. USE OF AFFINITY CHROMATOGRAPHY IN THE SEARCH
FOR. AND PURIFICATION OF. NEW PROTEINS
Serological and electrophoretic methods are very useful in 
the study of new proteins of unknown function: they suffer, however, from 
the disadvantage that their ability to distinguish relatively rare tissue 
specific proteins amonst the wide array of proteins found in all tissues 
is very limited. It is therefore very useful if contaminating proteins 
can be removed from the crude tissue extract used for immunisation so as 
to evoke the maximum immune response. Protein fractionation can be 
achieved by means of conventional physico-chemical methods or, 
alternatively, immunochemical methods such as antibody affinity chromato­
graphy (Parikh and Cuatrecasas, 1977), which consists in principle of 
the selective adsorption of a specific antigen to a solid support on 
which the corresponding antibody has been covalently attached. One 
particularly useful variant of the latter method involves the removal of 
the contaminating proteins from the crude material by affinity columns 
of sepharose coupled with the antibodies against the contaminating 
proteins and has been referred to as negative antibody affinity chromato­
graphy (NAAC) (Sutcliffe, 1976), An enriched single fraction of a 
specific protein for immunisation can be collected after it passes 
unretarded through the NAAC column. This is not possible with the use of 
conventional protein separation techniques, where several fractions 
usually result which have each to be analysed by raising a corresponding 
antiserum and the average degree of purification of a specific protein 
is proportional to the total number of protein fractions obtained.
Once an antiserum to the specific protein obtained by the 
use of the NAAC purification procedure is available, positive affinity
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chromatography may be a suitable method for subsequent rapid and 
efficient purification of the specific protein from crude extracts: it 
is particularly useful for those proteins which are at a low 
concentration in the initial extract or where there is a contaminant 
with similar physico-chemical characteristics to the antigen to be 
purified*
The efficiency with which an antigen is obtained from 
positive antibody affinity chromatography is mainly affected by the 
dissociation constant of the antibody and by the stability of the 
antigen under the elution conditions. It is suspected that in some cases 
the covalent linkage of antibodies to a solid matrix may result in an 
apparent increase in the affinity for antigens so that relatively more 
severe conditions may be required to dissociate the immobilised
antibody-antigen complex compared to the effort required when they are
formed in solution (Palmer, 1972), Occasionally other problems may also 
arise in individual systems such as non-specific adsorption and the co­
elution of contaminating proteins, especially when crude preparations of 
antibodies or antigens are used as the immobilised affinity ligand. Non­
specific binding may be due to a number of factors, such as hydrophobic 
interactions with matrix-bound ligands (Yon, 1972; Shaltiel and Er-el, 
1973; 0 'Carra et al., 1974), ion-exchange binding (Dean and Lowe, 1972; 
Hixon and Nishikawa, 1973; Parikh et al,. 1974) to non-specific or
conformational occlusion (O'Carra et al*. 1974), Another problem which
may arise is elution buffer-induced solubilisation of the matrix bound 
antibody (Parikh et al,. 1974), Also, too low a dissociation constant 
may effectively result in the irreversible binding of antigen and 
antibody: this can, however, be countered by preparing the antibody from 
sera taken from animals soon after the onset of the humoral response to
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the antigen in question, since there is a higher proportion of low 
affinity antibodies early in the immune response (Hunter, 1976)* All 
these problems have to be taken into consideration when contemplating 
the purification of a protein by antibody affinity chromatography or 
interpreting the results of such a purification.
Although antibodies are relatively stable in the wide 
variety of strong reagents which are used to dissociate antibody-antigen 
complexes in affinity chromatography, such as chaotropic thiocyanate and 
iodide ions at 1*5M to 3M concentration (Avrameas and Temynck, 1969; 
Dandliker et al,, 1967; Dandliker et al,, 1968; de Saussure and Dandliker, 
1969), 5M guanidine-HCl (Dandliker et al,. 1968), 8M urea (Slobin and 
Sela, 1965), glycine-HCl buffer, pH2*8 (Avrameas and Ternynck, 1969), 
glycine-NaOH buffer, pHI1 (Omenn et al,. 1970) and 3M Magnesium Chloride 
(de Souza et al,. 1976), many antigens may be more sensitive to at least 
some of these dissociating agents. The sensitivities of many pregnancy- 
associated proteins are unknown and each should therefore be carefully 
tested before proceeding with antibody affinity chromatography: many are 
large, probably complex proteins - for example, PAPP-A, PAPP-B, PZP, and 
PP6 - and may therefore be particularly susceptible to dénaturation,
NAAC has been applied before to the fractionation of 
placental extracts (Anderson et al,, 1974), as well as to soluble tumour 
antigens (De Carvalho et al,) amniotic fluid and fetal serum (Sutcliffe, 
1976), Although affinity chromatography has been employed in the 
purification of a great many proteins (Parikh and Cuatrecasas, 1977), 
including the pregnancy-associated proteins AUP (Sutcliffe et al.. 1978), 




Early Stage in Development of Chorionic Villi
(a) The trophoblast projection has occurred with the development 
of lacunae, and much intermingling with maternal tissue, which for clarity 
is not shown. No mesoblastic core has yet entered the villus,
(b) The mesoblastic core is now developing within the villus. 
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FIGURE 1.1b
Chorionic Villi at Different Ages
(a) 1 0 - 1 8  week embryo,
(b) 24 week embryo,
(c) Term placenta.
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FIGURE 1.2
The Term Placenta in situ and its Membranes 
Redrawn from Boyd and Hamilton (1970)
intervillous basal
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FIGURE 1.3
The Intervillous Space and the Placental Circulation 
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6, LINES OF FURTHER INVESTIGATION
The information presented in the preceding review of the 
literature has allowed me to formulate objectives for further experimental 
study which could initially be approached using immunochemical techniques. 
The first objective was to investigate the existence of naturally 
occuring maternal antibodies to placental-specific antigens. This 
investigation concentrated on three approaches - immunofluorescence, 
antibody affinity chromatography and dissociation of antibody-antigen 
complexes. Evidence from these approaches is presented in Chapter 2,
The second objective was to obtain further information on the specific 
protein products of the placenta and it gave rise to the experimental 
work described in Chapters 3 - 7 of this thesis. In Chapter 3 the use 
of negative antibody affinity chromatography in the search for specific 
placental proteins in placental soluble extract is presented. The 
purification and further study of one of the placental-specific proteins, 
PAPP-A, detected with the use of negative antibody affinity chromatography 
is described in Chapters 4,5,6 and 7, First, the sensitivity of PAPP-A 
and other pregnancy-associated and normal serum proteins to the dissociants 
of antibody-antigen complexes was examined: the results are presented in 
Chapter 4, These results were used to design a scheme for the purification 
of PAPP-A by antibody affinity chromatography. The purification and 
subsequent iodination of PAPP-A is described in Chapter 5. Preliminary 
studies of the subunit structure of PAPP-A form the subject of Chapter 6, 
Finally, studies on the concentration of PAPP-A in the blood during 
normal and complicated pregnancies are described in Chapter 7,
•49.




The existence of naturally-occurring maternal antibodies to 
placental antigens has been investigated using three experimental 
approaches:
(1) Immunofluorescence studies on placental sections.
(2) Adsorption of maternal serum on a placental protein 
affinity column.
and (3) Dissociation and separation of the antigen-antibody 
complexes present in maternal serum.
2. IMMUNOFLUORESCENCE STUDIES ON PLACENTAL SECTIONS
2.1 Introduction
This section deals with the first of the experimental 
approaches listed above: immunofluorescence studies on sections of 
placentas obtained from two normal and one agammaglobulinaemic women at 
delivery. The studies described here were aimed at detecting antibody 
specificities in maternal sera directed against placental-specific 
antigens and isoantigens rather than alloantigens. For this reason no 
attempt was made to test each maternal serum on sections of the placenta 
obtained from the same pregnancy nor to determine any maternal and fetal 
allotypes in such matched pairs. Instead, sections of two randomly chosen 
placentas were used. The immunofluorescence method employed maternal 
serum in the first layer and anti-human immunoglobulin fluorescent anti­
serum in the second layer. A preliminary step involving the use of 
antibodies to human immunoglobulin was introduced in order to block any 
endogenous immunoglobulins present in the placental sections. The effect
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of this blocking antiserum was compared with that of elution with 
buffers at different pH in order to determine whether the endogenous 
immunoglobulins were immunologically bound on the placenta* Sections of 
a placenta obtained from an agammaglobulinaemic patient and believed to 
contain little or no endogenous maternal immunoglobulin were used as a 
control in the study.
The maternal sera investigated in this study came from a 
range of pregnant subjects which included primi- and multi-parous women 
with and without a history of previous pathological abortions. The effect 
of absorption of these sera with placental soluble extract was 
investigated by substituting absorbed maternal sera for unabsorbed 
maternal sera in the experimental procedure outlined above. This was in 
order to determine whether soluble placental antigens were involved in 
the anti-placental activity (if any) of maternal sera. Sera from a male 
donor and from an agammaglobulinaemic pregnant woman were used as 
negative controls and a serum known to give a strong positive immuno- 
fluorescent reaction - rabbit antiserum to human placental chromatin - 
was used as a positive control.
2.2 Materials and Methods 
Tissues
Three placentas were obtained at the term delivery of 
normal infants: one of the placentas came from an agammaglobulinaemic 
patient. Placental tissues were first rinsed with cold PBS* Blocks of 
tissue were excised from from the midportion of placentas and snap- 
frozen in an acetone-solid CO^ mixture. Sections from each block were 
cut at a thickness of 8 micrometres with a cryostat, then air-dried on 
slides and stored under polyethylene glycol at -20° C until use. A fourth
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placenta obtained at the term delivery of a normal infant was rinsed 
with cold PBS, homogenised and the soluble extract was harvested#
Sera and Antisera
Serum was extracted from venous blood taken from eleven 
pregnant women in the third trimester of pregnancy; ten normal women 
which included two primipara and two multipara with no record of 
previous spontaneous or pathological abortions, two primipara and four 
multipara with records of previous spontaneous or pathological abortions 
(denoted "maternal sera i - x " in Table 2#l) and one agammaglobulinaemic 
pregnant woman (the donor of the agammaglobulinaemic placenta used in this 
present study)* A twelth sample of serum was obtained from a male donor* 
Serum samples were stored at -20° C until use. Aliquots of all maternal 
sera were absorbed with an equal volume of the placental soluble extract 
prior to use*
Rabbit anti-human placental chromatin antiserum was kindly 
provided by Dr# Ailsa Campbell (Department of Biochemistry, The 
University of Glasgow), It had been raised to chromatin extracted from 
fresh placental tissue using the method of Okita and Zordi (1974) and 
Zordi (1975). Sheep anti-human serum, sheep fluorescein isothiocyanate 
(FITC)-antibodies to human Ig and sheep FITC-antibodies to rabbit Ig 
were purchased from Wellcome,
Immunofluorescence Techniques
The techniques employed here were based on those originally 
described by Coons and Kaplan (1950), A preliminary step involving the 
use of sheep anti-whole human serum antiserum ("blocking antiserum") 
was introduced prior to treatment of the placental sections with the 
maternal serum to be tested which was followed by treatment with 
fluorescent antibodies to human Ig,
• 53.
Procedure
Slides containing fixed placental sections were immersed in 
a Coplin jar for one minute prior to use. The slides were then dried 
except for the area around and covering the placental section* All 
treatments were carried out in a moist chamber at room temperature, A 
single drop of the treatment solution was applied per section. Unless 
otherwise stated the duration of each treatment was 45 minutes. Sections 
were washed after each treatment in three changes of PBS, pH 7*5 for 30 
minutes. Unless otherwise stated each of the 32 tests listed in Table 2,1 
below was performed on three placental sections - one section from each 
of the two placentas obtained from normal women, and one section from 
the agammaglobulinaemic woman’s placenta.
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TEST TREATMENT (in order shown)
1* Sheep anti- 2, Other 3, Test serum
human serum dilution)
*20 - 29 YES NO One of placental soluble
extract-absorbed maternal 
sera i - x per test 
*30 YES NO Placental soluble extract-
absorbed agammaglobulin­
aemic maternal serum 
31 NO NO Rabbit anti-human
placental chromatin 
* tests 20 - 30 were not performed on sections from the 
agammaglobulinaemic woman’s placenta
As final treatment, the sections in tests 2 - 3 0  were 
exposed to sheep FITC-antibodies to human Ig (one-tenth dilution) for 
45 minutes and the sections in test 31 were exposed to sheep FITC- 
antibodies to rabbit Ig (one-tenth dilution) for 45 minutes* The sections 
in test 1 were hot treated with any FITC-antibodies, The sections were 
then mounted in 90^ glycerol buffered at pH 8*5 and examined with a 
Zeiss fluorescence microscope,
2,3 RESULTS
The untreated placental sections in test 1 (Table 2,1) 
showed no autofluorescence. Treatment with fluorescent antibodies to 
human Ig (test 2) did not give rise to any significant fluorescence of 
the agammaglobulinaemic woman’s placental section, but in the two normal 
placental sections weak and irregular fluorescence. This fluorescence 
was associated with the trophoblast basement membrane, the fetal blood 
vessels, the villous stroma and other structures thought to be deposits
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of fibrinoid material, but was not associated with the trophoblastic 
cytoplasm. Pre-treatment of the agammaglobulinaemic woman's placental 
section with sheep anti-human serum antiserum (test 3), pre-elution at 
pH2*a or pre-elution at pH 4»5 (tests 4 - 7 )  resulted in the sections 
displaying no significant fluorescence. Pre-treatment of the two normal 
placental sections with sheep anti-human serum antiserum (test 3) or 
pre-elution at pH 2*8 for 10 minutes or for 30 minutes (tests 4 and 5) 
resulted in sections displaying no significant fluorescence. However, 
limited granular fluorescent staining of the trophoblast basement 
membrane was observed in sections pre-eluted at pH 4«5 for 10 minutes or 
for 30 minutes (tests 6 and 7).
Treatment of the placental sections with each of the ten 
maternal sera (tests 8 - 17), with serum from the agammaglobulinaemic 
pregnant woman (test 18), with male serum (test 19) or with placental 
soluble extract-absorbed maternal sera (tests 20 - 30) did not give 
rise to any significant fluorescence of the placental sections. Only a 
very dull level of fluorescence was observed on all placental sections 
in tests 8 - 30 which bore no comparison to the strongly positive
reaction produced by rabbit anti-placental chromatin antiserum (test 31) 
in which very intense staining of the trophoblastic nuclei was observed 
in addition to some staining of the cytoplasm.
2.4 DISCUSSION
Immunofluorescence techniques involving the use of specific 
antibodies from animals immunised with purified placental proteins and 
fluorescein markers have been used to provide information on the local­
isation of these proteins in the placenta and have localised several
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placental-specific proteins in the trophoblastic cytoplasm (Beck et al,, 
1969; Fox and Kharkongor, 1970; Loke and Borland, 1970; Bohn and 
Rouneberger, 1973; Bohn, 1976; Lin and Halbert, 1976; Tatarinov et al,, 
1976; see also Chapter 1, Section 3,1), They have also been used 
previously in studies aimed at demonstrating the presence of naturally 
occurring antibodies to placental antigens. Immunofluorescence studies 
by McCormick and his colleagues (McCormick et al,, 1971) and by Faulk 
and Johnson (1977) of the distribution of immunoglobulin in the human 
placenta have demonstrated the presence of limited amounts of maternal 
IgG and traces of IgM on the trophoblastic basement membrane and deposits 
of fibrinoid material but not in the trophoblastic cytoplasm. In placentas 
which were not perfused considerable amounts of IgG were also detected 
by these workers in the villous stroma and around blood vessels: 
prolonged washing of the placental tissue resulted in diminished staining 
of these areas. The stromal IgG probably represents maternal immunoglobulin 
in transit: it is known that maternal IgG is selectively transferred 
across the placenta (Miller, 1966). Unlike the stromal IgG maternal IgG 
associated with the trophoblastic basement membrane could not be removed 
by washing but it could be eluted from the placental tissue with a low 
pH buffer (pH 2*3) suggesting immunological nature of its deposition 
there (McCormick et al., 1971; Faulk et al». 1974). IgG thus eluted has 
been shown to inhibit most mixed lymphocyte reactions and the inhibition 
was shown to be independent of anti-HL-A activity (Faulk et al,, 1974). 
Although the precise specificity of this IgG has not been established it 
is thought to be directed at la-like alloantigens expressed on human B- 
lymphocytes (Johnson and Faulk, 1976), McCormick and his colleagues 
(McCormick et al,, 1971) could not, however, detect these antibodies in 
pre-labour or in post-partum maternal sera: such sera caused no inhibition
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of labelled eluate activity on placental sections, IgG antibodies 
directed at la-like alloantigens were also dètedted in placental eluates 
by Revillard et al, (1976) and Jeannet et al, (1977). Other immunofluor­
escence studies aimed at the detection of maternal antibodies to anti­
gens expressed on placental tissue produced conflicting results, Hulka 
and his associates (Hulka et al,, 1961; Hulka et al,. 1963) claimed to 
detect anti-placental antibodies directed at trophoblastic cytoplasm in 
post-partum, but not in pre-labour maternal serum. However, other 
workers were unable to confirm Hulka*s findings (Curzen, 1970).
The placental tissue used in the present study had been 
subjected to only very limited washing with PBS and the fluorescence 
resulting the treatment of this tissue with fluorescent antibôdies to 
human IgG although much weaker than that reported by McCormick (McCormick 
et al,, 1971) formed a pattern similar to that reported by him for 
unperfused placentas. In both cases fluorescence was found to be 
associated with placental structures other than trophoblastic cytoplasm. 
In the present study the maternal origin of the immunoglobulins 
involved in the staining reactions is suggested by the finding of the 
lack of comparable staining of the placental sections obtained from the 
agammaglobulinaemic pregnant woman. Furthermore, the fluorescence- 
diminishing effect of the blocking antiserum was found to be mimicked by 
treatment with the pH 2*8 buffer while treatment with a higher pH buffer 
appeared only to diminish the staining of Ig in the villous stroma and 
had less effect on the staining of Ig in the trophoblastic basal 
membrane. The present findings are in agreement with the postulated 
immunological nature of the binding of this immunoglobulin on the 
trophoblastic basal membrane.
Treatment of the placental sections with sera from
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primiparous and multiparous pregnant women and with the negative 
control sera - male serum and the agammaglobulinaemic pregnant woman's 
serum - did not give rise to any significant fluorescence of the normal 
and agammaglobulinaemic woman's placental sections. Treatment of the 
placental sections with the positive control - rabbit anti-placental 
chromatin antiserum - on the other hand produced a strongly positive 
reaction: very intense staining of the trophoblastic nuclei was observed 
in addition to some staining of the cytoplasm,probably due to 
contamination of the original material used for immunisation. Thus, no 
evidence for the presence of antibodies to placental-specific proteins 
in maternal pre-labour sera was produced by the present study,
3. ADSORPTION OF MATERNAL SERUM ON A PLACENTAL PROTEIN AFFINITY COLUMN
3.1 Introduction
This section describes attempts to isolate and concentrate 
maternal serum antibodies directed against placental-specific proteins or 
placental isoantigens using a placental protein affinity column. Serum 
samples were obtained from a group of pregnant women and a control 
group of non-pregnant women. Within each group serum samples donated by 
women who had similar obstetric histories of previous successful or 
unsuccessful pregnancies were pooled together. Each serum pool was then 
adsorbed on a placental protein-affinity column and the adsorbed 
material eluted from the column with 2 M-KI, The eluates were initially 
assayed for total protein and Ig content and the percentage content 
of IgG and IgM determined. The eluates were then tested for anti- 
placental activity by:
(l) Immunofluorescence using placental sections according
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to the method described in Section 2 of this chapter
and (2) Double immunodiffusion against soluble placental 
antigens and, as control, soluble lung antigens,
3,2 Materials and Methods 
Tissues
Two placentas were obtained at the term delivery of normal
S ^ ction^
of normal infants and used to prepare 8 micrometre'^for fluorescence 
studies. The remaining tissue was homogenised and the soluble extract 
harvested. Adult lung tissue was also homogenised and the soluble 
extract harvested.
Sera and Antisera
Serum was extracted from venous blood taken from pregnant 
women in the third trimester of pregnancy, and from non-pregnant women. 
The serum samples were then pooled according to the scheme set out in 
Table 2,2, and stored at -20° C until use.
Table 2,2: Serum Pools
Serum Obstetric status Obstetric history of donors Number of Volume
pool of donors live births miscarriages donors (ml, )
1 NP(=non-pregnant) NO NO 3 23
2 NP YES NO 3 16
3 NP YES YES 2 8
4 P(=pregnant) NO NO 12 46
5 P YES NO 16 41
6 P YES YES 10 36
7 P NO YES 0 36
Standard human serum was purchased from Behringwerke, Sheep 
fluorescent FITC-antibodies to human Ig, sheep fluorescent FITC-anti-
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bodies to rabbit Ig, rabbit anti-human IgG (F^) and rabbit anti- 
human IgM (F^) antisera were purchased from Uellcome* Rabbit anti- 
human placental chromatin antiserum was the antiserum used in the 
experiments described in Section 2 of this chapter.
Preparation and Use of Placental Protein Affinity Column
Activation and substitution of Sepharose 48 were 
performed according to the method of Porath et al. (1967), 500 mg, 
of protein from the placental soluble extract was coupled to Sepharose 
4B and the placental protein-Sepharose packed into a 3 cm, diameter 
Uright scientific column, 2 M KI-PBS, pH 7»0 was passed through the 
column for 1 hour at a rate of 160 ml, per hr, following which the 
column was regenerated in PBS,
Each of the seven serum pools listed in Table 2,2 was 
fractionated over the placental protein affinity column. All 
fractionations were carried out at 4°C, In each fractionation the 
serum pool was passed through the column at a rate of 80 ml, per hr, 
and washed through with PBS until the eluate from the column gave 
a zero reading at 280 nm. The column was then desorbed with 2 M KI- 
PBS, pH 7*0 for 1 hour at a rate of 160 ml, per hr, and regenerated 
in PBS, The desorbed material was concentrated by ultrafiltration 
on an Amicon XM-100 A membrane (exclusion limit 100,000 daltons), 
separated from the KI by dialysis against 1:10 dilution of PBS, 
lyophilised and redissolved in 0*4 ml. of distilled water. The 
protein content of the desorbed material was subsequently determined 
using the folin phenol reagent (Lowry et al., 1951), The IgG and 
IgM contents were determined by radial immunodiffusion.
Immunochemical Methods
Radial immunodiffusion was performed according to Mancini
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et al, (1965). 2 microlitre aliquots of Behringwerke human serum at 1/5, 
1/10, 1/20, 1/40, I/8O and I/I6O dilutions and 2 microlitre aliquots of 
concentrated desorbed material from each of the seven fractionations 
over the placental protein affinity column were applied to two gels. One 
of these gels contained 1*8^ rabbit anti-human IgG (p^) antiserum and 
the other 1*8% rabbit anti-human IgM (P^) antiserum. The diameters of 
the precipitin rings formed after 48 hours were measured and used to 
construct standard reference curves of antigen concentration versus 
immunoprecipitate area.
Immunofluorescence studies were performed according to the 
scheme outlined in Section 2,2 of this chapter, A total of thirteen 
tests was carried out. Each test was performed on two placental sections, 
one from each of the two normal placentas (see under "Tissues"), Tests 
1 - 3  correspond to the tests 1 - 3 in Table 2,1, Tests 4 - 1 0  were 
carried out according to the procedure set out for tests 8 - 17 in Table 
2,1; however, in place of maternal sera (treatment 3), concentrated ® 
desorbed material from one of the seven fractionations over the placental 
protein affinity column was used per test. Tests 11 and 12 were carried 
out according to the procedure set out for tests 18 and 19 respectively 
in Table 2,1 using agammaglobulinaemic maternal serum and male serum.
Test 13 corresponds to test 31 in Table 2.1,
Double immunodiffusion was performed according to 
Ouchterlony (1968), Duplicate tests were set up: one with well to well 
distances of 6 mm. and a development time of 24 hours and one with well 
to well distances of 8 mm, and a development time of 48 hours, 2 micro- 
litre aliquots of concentrated desorbed material from each of the seven 
fractionations over the placental protein affinity column and 2 micro­
litre aliquots of rabbit anti-human placental chromatin antiserum were
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tested against 2 microlitre aliquots of lung and placental soluble 
extracts.
3,3 Results
The yields of total protein and IgG and IgM from the 
fractionation of the seven serum pools (Table 2*2) over the placental 
protein affinity column are shown in Table 2,3,
The untreated placental sections showed no autofluorescence 
(test 1), Placental sections treated with fluorescent antibodies to 
human IgG (test 2) showed weak and irregular fluorescence in structures 
other than the trophoblasic cytoplasm, Pre-treatment with anti-human 
serum antiserum (test 3) resulted in sections showing virtually no 
fluorescence. Treatment with the concentrated desorbed material from 
each of the seven fractionations over the placental protein affinity 
column resulted in all the sections exhibiting only very dull fluores­
cence and a similar effect was produced by treatment with serum obtained 
from the agammaglobulinaemic woman and with male serum (tests 4 - 12), 
Treatment with anti-placental chromatin antiserum (test 13) produced ir, ; 
intense staining of the trophoblastic nuclei and moderate staining of 
the trophoblastic cytoplasm.
No immunoprecipitin lines could be detected in double 
immunodiffusion experimentsnin the area of the gel between those wells 
containing concentrated desorbed material from each of the seven 
fractionations over the placental protein affinity column and wells 
containing placental soluble extract or adult lung soluble extract.
Faint immunoprecipitin lines were detected in the area of the gel 
between wells containing anti-human placental chromatin antiserum and 
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Inspection of the results in Table 2,3 reveals that in all 
fractionations over the placental protein affinity column protein 
desorbed from the column with 2 M KI represented a small percentage 
(between 0*1 and 1*3%) of the protein in the serum pool applied to the 
column. When the mean values for the IgG and IgM content of the material 
desorbed with 2 M KI after fractionation of the seum pools from the non­
pregnant group (13*8 - 5*4% IgG and 3*5 - 2*8% IgM) and the pregnant 
group (13*6 - 6*5% IgG and 5*1 - 1*5% IgM) are compared they are seen to 
be very similar. Furthermore these mean values are similar to normal 
serum values such as those for Behringwerke human serum which contains 
15*9% IgG and 1*2% IgM, These observations could suggest a low level of 
non-specific adsorption of serum proteins to the column in all 
fractionations over the column.
Even although the volume of the concentrated 2 M KI eluates 
(0*4 ml,) represented an average 100-fold volume concentration of sera 
pools within the pregnant group, as with the non-pregnant group, no 
evidence of positive immunofluorescent reactions with the placental 
sections could be obtained* The immunoglobulins in the concentrated 2 M 
KI eluates also failed to form immunoprecipitates with soluble proteins 
in the placental and adult lung extracts. These findings contrasted 
with the positive reactions obtained using rabbit anti-human placental 
chromatin antiserum in immunofluorescence tests and in double immuno­
diffusion.
The results reported here suggest that it may not be 
possible to use a placental protein affinity column to isolate and 
concentrate antibodies to placental specific proteins and placental 
isoantigens from third trimester maternal sera. However, these
•65.
conclusions are tentative as the methods of assaying the antibody 
presence were restricted to those which do not depend on the availability 
of highly purified placental proteins and to those which may not be 
able to detect very low levels of antibodies. Antibodies to two 
placental-specific proteins, HPL and HCG, have been detected in the 
sera of pregnant women as well as some non-pregnant individuals by means 
of highly sensitive techniques such as radioimmunoassay and 
haemagglutination (see Chapter 1, Section 4#3a). The use of such 
techniques was possible because both proteins are available in highly 
purified form. The presence of anti-HPL and anti-HCG antibodies could 
not be detected using gel precipitation techniques indicating that the 
concentration of these antibodies was extremely small. If antibodies to 
other placental proteins are also present in maternal serum at a very 
low concentration there might well be a state of antigen excess and a 
better approach would be to look for soluble antibody-antigen complexes 
in maternal serum. This approach is described in the following section.
4. DISSOCIATION AND SEPARATION OF THE ANTIBODY-ANTIGEN
COMPLEXES PRESENT IN MATERNAL SERUM
4.1 Introduction
This section describes an attempt to seek soluble antibody- 
antigen complexes in the sera of pregnant women, Multiparous pregnant 
women were chosen as the donors of the sera, since in such women 
stimulation by placental- and fetal-specific antigens may already have 
occurred during previous pregnancies. The procedure used involved 
dissociation of antibody-antigen complexes with 2 M KI, followed by the 
separation of antigens by elution under dissociating conditions through
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a filter membrane with an exclusion limit of 100,000 daltons. This 
approach naturally restricted the search to antigens of molecular weight 
below 100,000 daltons. This procedure was first tested by applying it to 
the separation of serum albumin from soluble sheep anti-human albumin - 
human albumin complexes prepared under conditions of antigenic excess in 
vitro. Antiserum to protein dissociated on XM100 A membrane in 2 M KI 
from pooled multiparous sera was raised in rabbits and analysed on two- 
dimensional antibody-antigen crossed electrophoresis,
4,2 Materials and Methods 
Tissues
The placenta, placental amnion, placental chorion and 
decidua were obtained at the time of term delivery of normal infants. 
These tissues and the following adult tissues - endometrium, myometrium, 
uterus, ovary, heart, liver, spleen, thyroid, lung kidney, adrenal and 
pancreas - were homogenised and the soluble extract in PBS harvested. 
Sera and Antisera
Samples of venous blood were obtained from fifteen pregnant 
multiparous women during the third trimester of pregnancy. The serum 
extracted from each blood sample was pooled. The volume of this serum 
pool was 120 ml, A sample of venous blood was obtained from an adult
male donor and the serum extracted.
Sheep anti-human serum antiserum and rabbit anti-PAPP-A 
antiserum were prepared in our laboratory (for details of the anti- 
PAPP-A antiserum preparation see Chapter 4, Section 2), Rabbit antisera
against human SP1, HPL and human albumin were purchased from




One- and two-dimensional AACE was carried out according to 
Laurell (1966; 1972) in 1% agarose gel. Double immunodiffusion was 
performed according to Ouchterlony (1968) and allowed to proceed for 
24 hours.
Preparation of Soluble Anti-human Serum - Human Serum Complexes
(1) The quantitative precipitation reaction between sheep 
anti-human serum antiserum and human serum.
To twelve 200 microlitre aliquots of anti-human serum 
antiserum in test tubes were added aliquots of human male serum 
beginning with 5 microlitres in the first tube, 10 microlitres in the 
second and thereafter increasing by 20 microlitres each time to 210 
microlitres in the final tube. The volume in each tube was made up to 
1 ml, with PBS, After 30 minutes incubation at room temperature and 
30 minutes at 4° C the solutions were centrifuged at 3,000 r,p,m, for 
10 minutes, the precipitates resuspended in PBS and centrifuged again.
The precipitates were then dissolved in 1 M NaOH and analysed for protein 
content by the method of Lowry et al,, 1951,
(2) The preparation of soluble complexes between anti-human 
serum and human serum albumin.
To 10 ml, of anti-human serum antiserum were added 17 ml, 
of human male serum (1:1*7 volume ratio of antiserum;antigen solution) 
with stirring and the solution left to stand for 30 minutes at room 
temperature and for 30 minutes at 4° C. The solution was then centrifuged 
at 3,000 r,p,m, for 10 minutes in order to remove any precipitate formed. 
Dissociation and Separation of Antigens from Antibody- Antigen Complexes
The dissociation and separation of antigens and antibodies 
Was attempted from:
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(l) soluble complexes between anti-human serum and human 
serum albumin
and (2) soluble antibody-antigen complexes in pooled multi­
parous sera.
In both cases the gamma fraction was initially precipitated from 
solution with 33% saturated (NH^)2SD^, pH 8*0 - 8*6, the precipitate 
removed by centrifugation at 9,000 r,p,m, for ten minutes and redissolved 
in a buffered solution. Precipitation with 33% saturated was
repeated twice. Finally the precipitate was dissolved in 50 ml, PBS and 
washed with PBS in a thin channel ultrafugation cell (TCF10 model) on an 
Amicon filter XM 1OOA (exclusion limit 100,000 daltons). The washing was 
continued until the filtrate gave a zero reading at 280 nm. The filtrate 
was concentrated to 10 ml, on an Amicon filter PM 10 (exclusion limit
10,000 daltons). The retentate was concentrated to 25 ml,, made up to 
2 M KI with 25 ml, 4 M KI, pH 7*0, washed with 2 M KI, pH 7*0, for 12 
hours and finally concentrated to 10 ml. Throughout the washing with 
PBS and 2 M KI the volume inside the ultrafiltration cell was maintained 
at 50 ml, and the gas pressure at 10 p,s,i, Thematerial eluted through^ 
the XM 100A membrane in 2 M KI was concentrated on an Amicon filter PM 
10 to 10 ml,, then dialysed against diluted PBS and the protein content 
determined by the method of Lowry et al, (1951).
The gamma fraction was precipitated from 10 ml, human male 
serum with 33% saturated (NH^)2S0^, the precipitation was repeated twice 
and the final precipitate was redissolved in 10 ml, PBS, The precipitate 
was then analysed for the presence of albumin on double immunodiffusion. 
The material obtained at different stages of the dissociation 
of anti-human serum albumin - human serum albumin complexes was tested 
for the presence of albumin on double immunodiffusion. Aliquots of the
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material obtained at the different stages of the dissociation of the 
antibody-antigen complexes from pooled multiparous sera were stored at 
-20 °C, They were analysed for the presence of SP1 on one-dimensional 
AACE at a later stage.
An aliquot of pooled multiparous sera was made up to 2 M KI 
with an equal volume of 4 M KI, pH 7*0, and left standing at 4 °C for 
12 hours. It was then dialysed against several changes of PBS and tested 
for the presence of human serum albumin on double immunodiffusion. The 
same procedure was repeated at a later stage in order to test for the 
presence of SP1 on double immunodiffusion.
Preparation of Antiserum to therProtein Dissociated on XM 10QA Membrane 
in 2 M KI from Pooled Multiparous Sera.
Two aliquots of the material dissociated on an XM 100A 
membrane in 2 M KI from pooled multiparous sera containing 8*6 mg, of 
protein each were lyophilised, resuspended in 1 ml, FCA and used to 
immunise two rabbits, 4*3 mg, of protein was used to boost each rabbit 
four weeks later, Antisera were obtained from the two rabbits on the 
seventh day following boosting. Absorption of 10 ml, aliquots of antisera 
was carried out by adding increasing amounts of adult male serum until 
5 ml, had been added and the formation of immunoprecipitate was no 
longer readily detectable, Antisera were then analysed on two-dimension­
al AACE and on double immunodiffusion using pooled multiparous sera, 
adult male serum and placental soluble extract as sources of antigens,
4,3 Results
Quantitative Precipitation Reaction between Sheep Anti-human Serum 
Antiserum and Human Serum
It was found that as increasing amounts of human serum were
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added to 200 microlitre aliquots of anti-human serum antiserum the 
quantity of the precipitate formed increased. The amount of precipitate 
formed was greatest when 50 microlitres of human serum were added. The 
addition of larger volumes of human serum resulted in decreased 
precipitation until a point was reached on the addition of 210 micro­
litres of human serum where no precipitate could be detected with the 
methods used (Figure 1).
The Dissociation and Separation of Antigens from Antibody-Antiqen 
Complexes
(1) Soluble complexes between anti-human serum and human 
serum albumin.
Albumin could not be detected by means of double immunodiffusion in the 
33% (NH^)2S0^-precipitated gamma-fraction of human male serum readjusted 
to the original serum volume. Albumin was not detected by double immuno­
diffusion in the filtrate collected when the 33% (NH^)2S0^-precipitated 
gamma-fraction of the 1:1*7 anti-human serum:human serum solution was 
washed on a XM 100A membrane in PBS but it was detectable in the filtrate 
collected when 2 M KI was used in place of PBS (Figure 2),
(2) Soluble antibody-antigen complexes in pooled multi­
parous sera*
When the material obtained at different stages of the dissociation of 
antibody-antigen complexes from pooled multiparous sera was analysed for 
the presence of SP1 on one-dimensional AACE the following results were 
obtained:
(1) SP1 was readily detectable in the 33% (l\IH^)2S0^- 
precipitated gamma-fraction of pooled multiparous sera
(2) No SP1 could be detected in the filtrate collected 
when the gamma-fraction of multiparous sera was washed on a XM 100A
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membrane with PBS,
(3) The presence of SP1 in the filtrate collected when the 
gamma-fraction of multiparous sera was washed on a XM 100A membrane with 
2 M KI could not be determined though it was suggested by the formation 
of a faint precipitin line immediately above the antigen well.
(4) SP1 was readily detectable in the material retained on 
the XM 100A membrane at the end of the dissociation procedure (Figure 3). 
i The material dissociated on the XM 100A membrane in 2 M KI 
from the gamma-fraction of pooled multiparous sera was found to contain 
30 mg, of protein.
Precipitin lines were formed on double immunodiffusion by 
SP1 in pooled multiparous sera treated with 2 M KI for 12 hours. These 
lines showed cross reactivity with those formed by human serum albumin 
and SP1 in untreated pooled multiparous sera.
Antisera to Protein Dissociated on a XM 10DA Membrane from the Gamma 
Fraction of Pooled -Multiparous Sera
Unadsorbed rabbit antisera to protein dissociated on a 
XM 100A membrane in 2 M KI from the gamma fraction of pooled multiparous 
sera formed three precipitin lines with human male serum on two-dimension­
al AACE. When these antisera were absorbed with human male serum to the 
point where precipitin formation was no longer readily detectable and 
analysed on AACE, one or too .■small precipitin arcs ^ were still detectable 
when concentrated human male serum was used as the source of antigens.
The antisera were therefore judged to be incompletely absorbed. One or 
possibly two small precipitin arcs and an additional large arc was 
detected when concentrated pooled multiparous sera was used as the 
source of antigens. A single large arc was detected when soluble 
placental extract was used as the source of antigens. The antigens in
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pooled multiparous sera and soluble placental extractwhich gave rise 
to the large precipitin arcs were shown to cross-react (Figure 4), Both 
rabbit antisera showed reactions of identity with commercial anti-SPI 
antiserum with respect to:
(i) the large precipitin arc formed on AACE (Figure 5) 
and (ii) the single precipitin line formed on double immuno­
diffusion when pooled multiparous sera was used as the source of antigens 
Using the incompletely adsorbed rabbit antisera to the 
protein dissociated on a XM 1OOA membrane in 2 M KI from multiparous 
sera or commercial anti-SP1 antiserum, SP1 was also detected on one- 
dimensional AACE in extracts of placental chorion and amnion. It was not 
detected in extracts of decidua, endometrium, myometrium, uterus, 
ovary and in extracts of the following adult tissues tested: heart, 
liver, spleen, thyroid, lung, kidney, adrenal and pancreas.
4,4 Discussion
Since the main precipitating activity of anti-human serum 
antiserum is due to anti-human serum albumin antibodies it is to be 
expected that the quantitative precipitation reaction between anti­
human serum antiserum and human serum is a reflection in the large 
measure of precipitate formation between anti-human serum albumin anti­
bodies and human serum albumin. From the findings that precipitate 
formation ceases at equal volume ratios of anti-human serum antiserum 
and human serum (Figure 1) it may be assumed that soluble complexes 
between anti-human serum and serum albumin were formed at 1:1*7 volume 
ratio of anti-human serum antiserum to human serum (see Section 4.1, 
"Materials and Methods"),
The results reported herein show that human serum albumin
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(molecular weight: 66,000 daltons), which is not precipitated from human 
serum with 33%-saturated (NH^)2S0^, can be dissociated from 33%- 
saturated (l\IH^ )2S0^-precipitated soluble complexes between anti-human 
serum and serum albumin by washing on an Amicon XM 1OOA membrane with 
a commonly used dissociating agent such as 2M KI, but not with PBS, The 
same procedure was therefore applied to 33%-saturated (NH2)^S0^- 
precipitated gamma fraction of pooled multiparous sera in order to 
test for the presence of naturally occuring soluble antibody-antigen 
complexes.
Immunization of rabbits with protein dissociated on an 
XM 100A membrane in 2M KI from the gamma fraction of pooled multiparous 
sera produced a strong response to a placental antigen in addition 
to limited anti-human serum response. The placental antigen was . 
subsequently identified as placental-specific protein, SP1 (see 
Chapter 1, Section 3.1), Several considerations argue against any 
conclusion that SP1 has been dissociated from soluble anti-SPI-SP1 
complexes in maternal sera. A follow-up study showed that SP1 is a 
protein which precipitates with 33%-saturated (^^2)4^0^ and , since 
it is unlikely that it was all coupled to antibodies in maternal sera 
its presence in the solution during dissociation with 2M KI would have 
depended very critically on the efficiency of the initial washing step. 
However, Spl is too big to be readily washed through an XM100A 
membrane; this is suggested by its molecular weight - 110,000 daltons 
according to Lin and Halbert et al. (1974) or 90,000 - 5,000 daltons 
according to Bohn (1974) - and was demonstrated by the failure to 
wash it through the XM 100A membrane in PBS. Little, if any SP1 could 
be detected on AACE in the filtrate collected when the gamma fraction 
of multiparous sera was washed on an XM 100A membrane with 2M KI and
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most SP1 was still present in the retentate at the end of the 
dissociation experiment. Some tunneling of SP1 molecules through 
the XM 100A membrane would not be surprising and 2 M KI may have 
aided the tunneling process by inducing reversible or irreversible 
conformational changes in SP1 molecules. It is unlikely that gross 
irreversible changes occured since cross-reactivity was observed 
on double immunodiffusion between SP1 in untreated multiparous sera 
and in sera exposed to 2 M KI for twelve hours.
Although a simple interpretation of the failure to find 
other anti-placental specificities in rabbit antisera is that no 
other placental-specific proteins or placental isoantigens of 
molecular weight between 10,000-100,000 daltons are involved in 
immune complex formation during pregnancy in multiparous women, a 
number of alternative explanations are equally viable. Some placental 
proteins may have been irreversibly denatured by exposure to 2 M KI 
for twelve hours (eg, PAPP-A; see Chapter 5, Section 2). Strongly 
bound antigens might not have been dissociated by 2 M KI, Some 
antigens may have been present in amounts insufficient to induce 
immune response in rabbits. Unresponsiveness in rabbits may also 
have been due to genetic factors. Weak responses would not have been 
detected with the methods used (AACE). Similarly small amounts of 
antigen might not have been detected on AACE. Furthermore, had any 
of the antigens bee monovalent they would not have been detected 
on AACE.
Few studies of immune complexes in maternal sera have 
been published. One such study by Masson and his colleagues (Masson 
et al., 1977) suggested the involvement of a placental antigen of
400,000 daltons in immune complex formation. Although the intriguing
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possibility that SP1 may be involved in immune complex formation was 
raised by the experimental findings described herein, the weight of the 
evidence produced was insufficient to determine whether or not it is 
involved. This possibility will need to be investigated more thoroughly. 
The present study produced no evidence of the involvement of any other 
placental-specific proteins in the molecular range 10,000 - 100,000 




Quantitative Precipitation Reaction Between Sheep Anti- 
Human Serum Antiserum and Human Serum
Increasing volumes of human serum were added to 200 micro- 
litre aliquots of anti-human serum antiserum and the quantity of 
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FIGURE 2.2
Double Immunodiffusion Test for the Presence of Human
Serum Albumin
The antiserum is anti-human serum albumin
The antigen uells were filled with 2 microlitre aliquots of;
(1) 1/20 dilution human serum
(2) 33^ ((\!H^ )2S0^-precipitated gamma-fraction of human serum 
adjusted to the the original serum volume
(3) Material eluted through a XM 1OOA membrane in PBS from the 
gamma-fraction of the 1:1*7 anti-human serum; human serum solution 
(adjusted to the original human serum volume)
(4) Material eluted through the XM 100A membrane in 2 M KI 
from the gamma-fraction of the 1:1*7 anti-human serum; human serum 
solution (adjusted to the original human serum volume).
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FIGURE 2.3
One-Dimensional AACE Patterns Formed by SP1 in 10 micro­
litre Aliquots of:
(l ) 33^ (l\IH^ )2S0^-precipitated gamma-fraction of pooled multi- 
parous sera (50 ml.)
(2) Material eluted through the XM 10OA membrane in PBS from
the gamma-fraction of pooled multiparous sera (10 ml.)
(3) Material eluted through the XM 100A membrane in 2 M KI
from the gamma-fraction of pooled multiparous sera (10 ml.)
(4) Material retained on the XM 100A membrane at the end of the 
dissociation procedure (50 ml*).
The antiserum is incompletely adsorbed rabbit antiserum to 
protein dissociated on the XM 100A membrane in 2 M KI from multiparous 
sera. The antiserum strength is 20%.
For demonstration of its cross-reactivity with commercial 
anti-SPI antiserum and reaction with pooled maternal sera see Figure 2.5.
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FIGURE 2.4
Two-Dimensional AACE Plate Showing Cross-Reactivity 
between Antigens in Soluble Placental Extract and Pooled Multiparous Sera. 
The antigens are:
(1)6 microlitre aliquot of soluble placental extract 
containing 600 microgram protein
(3) 4 microlitre aliquot of concentrated pooled multiparous sera 
containing 1,360 microgram protein
(2) Addition of (1) and (3).
Note that in (2) the main precipitin arc is larger than in (l) or (3).
(4) 4 microlitre aliquot of concentrated male serum containing 
1,360 microgram protein.
The antiserum is incompletely adsorbed rabbit antiserum to 
protein dissociated on a XM 100A membrane in 2 M KI from multiparous sera. 
The antiserum strength is 10%.
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FIGURE 2.5
Two-Dimensional AACE Plate Showing Cross-Reactivity 
Between Commercial Anti-SPI Antiserum and Rabbit Antiserum to Protein 
Dissociated on a XM 1QOA Membrane in 2 M KI from Multiparous Sera.
Antigen (l) is a 10 microlitre aliquot of pooled multi­
parous sera containing 680 microgram protein.
The antisera are;
(a) 5% commercial anti-SPI
(b) 15% incompletely adsorbed rabbit antiserum to protein 
dissociated on a XM 1OOA membrane in 2 M KI from multiparous sera
(c) Addition of (a) and (b).
Note that the larger precipitin arc in (c) is smaller than the single 
arc in (a) and the larger arc in (b). The smaller arc in (c), on the 








This chapter presents the use of negative antibody affinity 
chromatography (NAAC: see Chapter 1, Section 5) in the search for human 
placental-specific antigens in the soluble extract of the placenta. In 
the first experimental section attention is focussed on experiments 
aimed at the removal of adult and fetal-type protein from placental 
soluble extract by adsorption on columns of Sepharose coupled with anti­
adult and anti-fetal human protein antibodies. This is followed in the 
second experimental section by an analysis and comparison of the antisera 
raised in rabbits to unfractionated placental soluble extract and to 
NAAC products of placental soluble extract.
2. NAAC FRACTIONATIONS OF THE PLACENTAL SOLUBLE EXTRACT
2.1 Introduction
This section describes a series of NAAC fractionations of 
placental soluble extract using columns of Sepharose coupled with sheep 
anti-adult human serum protein antibodies alone or in conjunction with 
columns of Sepharose coupled with sheep anti-adult human tissue protein 
antibodies and columns of Sepharose coupled with rabbit anti-human 
amniotic fluid protein antibodies.
2.2 Materials and Methods 
Tissues
Thirty-six placentae were obtained at the time of term 
delivery of normal infants, rinsed with cold PBS, homogenised and the 
soluble extract harvested. A portion of adult human lung was also
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homogenised and the soluble extract in PBS harvested*
Sera and Antisera
Standard human serum was purchased from Behringwerke A, G*, 
West Germany, Adult human male serum serum was obtained from a volunteer.
Rabbit antisera against human serum albumin, human ferritin, 
human adult haemoglobin, HPL, and SP1 were purchased from Behringwerke 
A. G,, West Germany. Rabbit antiserum specific for PAPP-A was kindly 
donated by Drs. Lin and Halbert, Sheep antisera against adult male 
human serum (Sutcliffe, 1976) and adult human lung soluble extract were 
raised in our laboratory. Rabbit antiserum to NAAC - treated human amniotic 
fluid was raised in our laboratory by Sutcliffe et al. (1978). It had -_ 
been raised to the protein fraction of amniotic fluid (from normal 
second trimester pregnancies) which passed unretarded through a NAAC 
column of Sepharose coupled with sheep anti-adult male human serum 
protein antibodies.
Analysis of the Unfractionated and NAAC-fractionated Placental Soluble 
Extract
The placental soluble extracts and the various NAAC 
products of the placental soluble extract were analysed for total protein, 
serum albumin, haemoblobin and heat-stable alkaline phosphatase content.
The total protein content was determined by the method of Lowry et al. 
(1951), Serum albumin content was determined by measuring the area under 
the precipitin arc formed by albumin on one-dimensional AACE using anti­
human serum albumin antiserum. A standard curve for albumin was 
prepared using Behringwerke standard human serum (albumin content; 52*6 
mg, per ml.) and anti-human serum albumin antiserum. The haemoglobin 
content was assayed by Louise Nicholson using the cyanmethaemoglobin 
method of Drabkin and Austin (1932). The specific activity due to
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placental heat-stable alkaline phosphatase was determined by the method 
of Hunter (1969), In addition the NAAC products of the placental 
soluble extract were analysed for HPL and SP1 content by one­
dimensional AACE using anti-HPL and anti-SPI antiserum respectively. 
Prior to the analysis of the HPL and SP1 contents the protein 
concentrations of the NAAC products were adjusted to that of the 
placental soluble extract. Each millilitre of the placental soluble 
extract was arbitrarily designated as containing 100 U HPL and 100 U SP1 
and used to prepare standard curves for HPL and SP1. 
Immunoelectrophoretic Methods
One- and two- dimensional antibody-antigen crossed electro­
phoresis (AACE) according to Laurell (1966, 1972) and immunoelectro- 
phoresis according to Hirschfield (1959, 1960, 1962) were carried out in 
1% agarose gels. Double immunodiffusion was performed according to 
Ouchterlony (1968) and allowed to proceed for 24 hours,
5DS Slab Gel Electrophoresis
SDS slab gel electrophoresis was carried out by the method 
of Marsden et al. (1976), The spacer gel was 4*75% acrylamide and the 
running gel was a gradient of 7 - 15% acrylamide.
Preparation and Use of NAAC Columns
NAAC column 1 : Anti-adult human male serum protein column
20 g, of immunoglobulin purified by ammonium sulphate 
precipitation from sheep antisera against adult human male serum was 
conjugated to 1*9 kg. Sepharose 48 by the CNBr reaction (Porath et al», 
1976), The material was packed into a 15 cm, diameter Uright Scientific 
column (Sutcliffe, 1976),
NAAC column 2 : Anti-adult human lung tissue protein column
600 mg, of immunoglobulin purified ammonium sulphate
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precipitation from sheep antiserum against adult lung soluble extract 
was conjugated to 100 ml, Sepharose 48 by the CNBr reaction. The 
material was packed into a 3 cm, diameter Uright Scientific column,
NAAC column 3 ; Anti-human amniotic fluid protein column
300 mg, of immunoglobulin purified from rabbit antiserum to 
NAAC-treated human amniotic fluid was conjugated to 60 ml, Sepharose 40 
by the CNBr reaction. The material was packed into a 3 cm. diameter 
Uright Scientific column,
NAAC fractionation of the placental soluble extract was 
attempted using the protocol outlined in Figure 3,1, Placental soluble 
extract was passed through NAAC column 1 in PBS in aliquots of 546 mg,
(NAAC fractionation experiment 1 ) and 700 mg, (NAAC fractionation 
experiments 2,3,4) and at a rate of 400 ml, per hour,Material which 
failed to adsorb to the NAAC column (NAAC 1 product) was concentrated to 
ID ml, by ultrafiltration (Amicon PMIO) and analysed for total protein, 
serum albumin (experiments 1 - 4 ) ,  haemoglobin, HPL and SP1 (experiments
1 - 3)o The NAAC 1 products were also analysed on two-dimensional AACE 
using sheep anti-adult human male serum antiserum. In experiments 1 and
2 an aliquot of the NAAC 1 product was passed through the NAAC 2 column 
in PBS at a rate of 80 ml, per hour. In each experiment the material 
which failed to adsorb to this NAAC column was concentrated to 10 ml, by 
ultrafiltration, analysed for total protein and recycled over the regen­
erated column. The unadsorbed material which was the product of the re­
cycling (NAAC 2 product) was concentrated to 10 ml,, analysed for total 
protein, haemoglobin, HPL and SP1, 90% of the NAAC 2 product (experiments 
1 and 2 only) was next passed through NAAC column 3 at a rate of 80 ml, 
per hour. The remaining 10% was retained for assay. The material which was 
not adsorbed (NAAC 3 product) was concentrated to 10 ml, by ultrafiltration
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FIGURE 3.1
Protocol for NAAC Fractionations of Placental Soluble Extract
Placental Soluble Extract Experiment 1 : 546 mg.
Experiments 2,3,4: 700 mg.
Sheep Anti-Adult Human Male Serum Column: NAAC Column 1
i) Elute with PBS
NAAC 1 Product a) Concentrate
b) Retain aliquot for assay
Experiments 1 and 2 only
Sheep Anti-Adult Human Lung Column: NAAC Column 2 
i) Elute with PBS
ii) Concentrate eluate and recycle over regenerated 
NAAC 2 T^roduct a) Concentrate column
b) Retain aliquot for assay
Sheep Anti-NAAC-Treated Human Amniotic Fluid Column: NAAC Column 3 
i) Elute with PBS
NAAC 3 Product a) Concentrate
b) Retain aliquot for assay
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and analysed for total protein, haemoglobin, HPL, Sp1 and placental 
alkaline phosphatase.
Desorption of NAAC columns 1 - 3  was performed using 2 M 
KI, pH 7*0; the columns were then regenerated in PBS# The material 
desorbed from NAAC column 3 in 2 M KI was collected, concentrated by 
ultrafiltration (Amicon PMIO), separated from the KI by dialysis 
against PBS, lyophilised and redissolved in 1 ml. distilled water.
The concentrated material was then tested for cross-reactivity with 
antigens in humandecidual extract, placental soluble extract and lung 
soluble extraction two-dimensional AACE using antiserum to NAAC- 
treated human amniotic fluid.
The NAAC 1 products and the NAAC 3 products from experiments 
1 and 2 were analysed by SDS slab gel electrophoresis along with the 
soluble placental extract, adult human male serum, adult human haemo­
globin and the gamma fraction of sheep antiserum against adult human 
male serum purified by ammonium sulphate precipitation#
2,3 Results
The total protein concentration of the placental soluble 
extract was 20 mg. per ml, and it was found to be composed of 18% 
serum albumin, 43% haemoglobin and 39% other protein.
The results of the various steps of the NAAC fractionation 
experiments are summarised in Table 3,1, No precipitin arcs were formed 
by the NAAC 1 products of experiments 1 - 3 on two-dimensional AACE 
with sheep anti-adult human male serum antiserum.
Examination of the SDS slab gel (Figure 3,2) revealed 
that at least twelve of the fourteen visible bands formed by the NAAC 1 
product from experiment 1 corresponded in position to the bands formed
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by the NAAC 1 product from experiment 2, in which a total of nineteen 
bands was counted* Nine of these common bands were still present in 
the NAAC 3 products from experiments 1 and 2; the other three were 
missing from both. The NAAC 3 product from experiment 1 formed a total 
of ten bands, while the NAAC 3 product from experiment 2 formed a total 
of fifteen bands. Two of the bands formed on SDS gel by all the NAAC 
products examined corresponded in position to the two bands formed by 
adult haemoglobin. None of the bands formed by the NAAC products 
corresponded in position to the two main bands formed by the gamma 
fraction of rabbit antiserum. The patterns formed by all the NAAC 
products differed from that formed by adult male human serum.
Analysis of the material desorbed from NAAC column 3 in 2 M 
KI on two-dimensional AACE using antiserum to NAAC-treated human 
amniotic fluid revealed the presence of a single antigen of alpha- 
mobility which cross-reacted with an alpha-antigen found also in 
human decidua. The presence of this antigen in placental soluble 
extract or in lung soluble extract could not be demonstrated on two- 
dimensional AACE,
2,4 Discussion
Inspection of Table 3,1 reveals that there is considerable 
similarity between the different fractionations over each NAAC column 
with respect to the percentage recoveries of total protein and 
individual specific proteins.
Although extremely low recoveries of serum albumin (trace 
amount in experiment 2, undetectable by AACE in experiments 1, 2 and 3) 
and relatively;high recoveries of haemoglobin (68*0% - 83*7%) from 
NAAC column 1 were expected, the recoveries of placental proteins HPL
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and SP1 were unexpectedly low at 14% - 25% for HPL and 13% - 19% for 
SP1• However, relatively low recovery.values for HPL and SP1, 
ranging from 17% » 42% for HPL and from 20% - 38% for SP1 were also 
observed when aliquots of term maternal serum were fractionated over 
the same column,(Sutcliffe et al,. 1979), On that occasion high 
recoveries of AFP (89% - 116%) suggested little non-specific adsorption 
of protein to the NAAC column. Although occurence of non-specific 
adsorption of other proteins cannot be ruled out, more likely 
mechanisms responsible for low recoveries of individual proteins 
might be minor or cross-reacting antibody specificities on the column 
or specific interactions of proteins with the column not involving 
the binding by specific antibodies. Loss of some proteins could 
also be due to their instability.
In experiments 1 and 2 second adsorption over the NAAC 
column 2 was found to remove between ^ ^ as much protein as the
first adsorption over the column. Further adsorption over the 
column was not therefore judged to be worthwhile, especially as it 
would increase problems connected with storage of fractionated 
material and might have resulted in non-specific adsorption of 
placental-specific proteins on the column. Recoveries of haemoglobin 
from the NAAC column 2 were slightly lower at 58% - 62% than from 
the NAAC column 1 ; this may have been due to the presence of anti­
haemoglobin antibodies on the NAAC column 2, HPL recoveries from 
the NAAC column 2 on the other hand, were slightly higher at 38% - 
47% than from the NAAC column 1 ; this difference could have been 
due to a number of factors, including the presence of cross­
reacting antibodies on the NAAC column 1,
Although recoveries of haemoglobin from the NAAC column
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3 were high at 94% - 100%, neither HPL nor SP1 were present in sufficient 
quantities to allow their quantitation on AACE. However, the amount of 
both these proteins in the NAAC 2 products applied to the NAAC column 3 
were already small. The anti-NAAC-treated amniotic fluid antiserum 
used to make the NAAC column 3 has been shown by Sutcliffe et al, (1978) 
to have antibody specificities detectable on AACE directed at several 
ubiquitous adult tissue antigens, two fetal skin antigens and an 
alpha-mobility decidual antigen, AUP, Desorption of the NAAC column 3 
with 2 M KI was carried out after fractionation of the NAAC 2 products 
over the column and the concentrated desorbed material was analysed 
on AACE, An alpha-mobility antigen was detected in the desorbed 
material on two-dimensional AACE using antiserum to NAAC-treated 
amniotic fluid. This antigen cross-reacted with an alpha-mobility 
decidual antigen, AUP, No cross-reacting alpha-antigen could be 
detected on AACE in the lung soluble extract or in the placental 
soluble extract. It appears therefore that AUP, present in amounts 
undetectable by AACE in the placental soluble extract had been 
specifically concentrated on the column. Absence of the tissue 
antigens in the 2 M KI eluate suggests that they may have already 
been removed from the placental extract. The fetal skin antigens 
had not previously been detected in placenta. The presence of 
trace amounts of several placental-specific proteins in amniotic 
fluid has been reported ( see Chapter 1, Section 3,1) and some 
minor antibody specificities directed at placental-specific 
proteins may therefore have been present on the NAAC column 3, It 
was for this reason that adsorption over this column was limited 
to a single passage.
The findings from SDS gel electrophoresis of a large
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proportion of protein components in the NAAC 1 products from experiments 
1 and 2 common to both and the preservation of two-thirds of these 
common components during adsorption over the NAAC columns 2 and 3 
constitute further evidence of non-random removal of proteins from the 
placental soluble extract by the NAAC columns. The SDS gel electro­
phoresis results also provided no evidence of any significant 
contribution to the protein in the NAAC 1 products from the antibodies 
immobilised on the column.
In conclusion, the adsorption of aliquots of placental 
soluble extract over the NAAC column 1 removed virtually all of the 
quantitatively most important serum protein-and^albumin and presumably 
also the bulk of other serum proteins, since none could be detected in 
the NAAC 1 product on two-dimensional AACE using anti-adult human male 
serum. However, the adsorption over NAAC column 1 also removed a 
substantial proportion of HPL and SP1 from the placental soluble 
extract although relatively high recoveries of haemoglobin suggested 
that there was little non-specific adsorption of protein to the NAAC 
column. Subsequent adsorptions over NAAC columns 2 and 3 aimed at 
adsorption of ubiquitous tissue antigens and decidual antigens appear 
to have been effective in removing a number of proteins, many of them 
different to those removed by NAAC column 1, but also led to further 
removal of HPL and SP1 from the placental extract. The recovery of 
placental heat-stable alkaline phosphatase from the three column 
adsorption process was also low. However trace amounts of heat-stable 
placental alkaline phosphatase, HPL and SP1 have been found in amniotic 
fluid (see Chapter 1, Section 3,1; Sutcliffe, 1975) and it is therefore 
conceivable that antibodies to these proteins were present on the NAAC 
column 3, As has been previously stated, the recovery of individual
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proteins could be governed by a number of different factors and it is 
therefore not possible to determine with certainty the reasons for the 
relatively low recoveries of placental proteins observed or to predict 
the fate of other placental proteins during adsorption over the different 
NAAC columns.
3. RESPONSES TO IMMUNISATION WITH THE PLACENTAL SOLUBLE EXTRACT AND NAAC
PRODUCTS or PLACENTAL SOLUBLE EXTRACT
3.1 Introduction
This section presents the results obtained when the 
placental soluble extract and the NAAC products of placental soluble 
extract were injected into rabbits and the antisera analysed by AACE.
3.2 Materials and Methods 
Sera and Antisera
See Section 2,2 of this chapter.
Preparation of antisera to the soluble extract of placenta
Two aliquots of placental soluble extract^used in the 
experiments described in Section 2 of this chapter, containing 20 mg, 
of protein each, of which 18% was serum albumin and 43% was haemoglobin, 
were lyophilised, dispersed in 1 ml, of Freund's complete adjuvant each 
and used to immunise two New Zealand white rabbits (rabbits 1 and 2),
10 mg, of protein in Freund's complete adjuvant was used to 
boost each rabbit four weeks later.
Preparation of Antisera to the NAAC 1 Product of Placental Soluble 
Extract
Four aliquots of the NAAC 1 product from experiment 3
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(see Table 3.1) each containing 110 mg* of protein of which 50*9% was 
haemoglobin were lyophilised, dipersed in 1 ml* Freund's complete 
asjuvant each and used to immunise four New Zealand white rabbits 
(rabbits 3,4,5 and 6),
70 mg. of protein from the NAAC 1 product from experiment 4 
(Table 3,1) in Freund's complete adjuvant was used to boost each rabbit 
four weeks later.
Preparation of Antisera to the NAAC 3 Product of Placental Soluble 
Extract
Two aliquots of the NAAC 3 product from experiment 1 (Table 
3,1) containing 30 mg, of protein of which 72% was haemoglobin were 
lyophilised, dispersed in Freund's complete adjuvant and used to 
immunise two New Zealand white rabbits (rabbits 7 and 0),
30 mg, of protein from the NAAC 3 product from experiment 2 
(Table 3,1) of which 0*03% was albumin and 68% was haemoglobin was used 
to boost each rabbit four weeks later.
Antisera were obtained from rabbits on the seventh day 
following boosting. Aliquots of antisera were adsorbed in solution with 
pooled adult serum. Aliquots of antisera raised to the NAAC 1 product j 
were in addition adsorbed with protein from soluble extract of lung 
which had been polymerised with a final concentration of 0*4% 
glutaraldehyde and then dispersed into fine beads by homogenisation and 
washing in PBS (Avrameas and Ternynck, 1969),
Analysis of Antisera
Unadsorbed as well as adult serum-adsorbed antisera were 
tested on two-dimensional AACE with;
(1) Pooled adult serum,
(2) Pooled maternal serum.
■ 95.
(3) Placental soluble extract,
(4) Adult lung soluble extract.
Adult serum-adsorbed antisera were also tested on Immunoelectrophoresis 
with:
(1) Pooled maternal serum 
and (2) Placental soluble extract.
Adult lung-adsorbed antisera to the NAAC 1 product were tested on two- 
dimensional AACE with:
(1) Placental soluble extract 
and (2) Adult lung soluble extract.
Adult serum-adsorbed antisera were tested for cross-reactiv­
ity with;
(a) Anti-HPL, anti-SP1 and anti-PAPP-A antisera using 
pooled maternal serum as the source of antigens
and (b) Anti-human ferritin and anti-adult haemoglobin antisera 
using placental soluble extract as the source of antigens.
Antigens in pooled maternal serum and in placental soluble extract 
reacting with the antisera to placental soluble extract were also tested 
for cross-reactivity,
3,3 Results
Table 3,2 shows the number of AACE precipitation arcs 
formed by rabbit antisera against placental soluble extract with antigens 
from different sources. In a number of cases the AACE curves formed by ; 
the antisera were faint or overlapped with each other and the exact 
number present could not be determined with certainty. The minimum 
number of arcs counted is indicated in such cases.










































CC - X X
d © Q X
s 44 Ü
(0 L. ©
X © 0 w
c f— X(0 X X
ID u ©
44 3
o © X ©
OS « 0 X
w •H (4 X
44 X n 3



























































'  roj Xd CO X1 © d X
CO » • AQ CL d  c X  l4
Z d  X z  ©X  JZ X  X  44 X
X  X X—1 Z  Z  14 XX
X X  X  ©
z











f.- ■ CO C- CO r- CO N  CO
c c—J r - X
X X X  £3 X Q
d  X  in X  z X  z1 ^ 9 , • l4 • (4Q £3 X  d  d X M .X X I4 Xz  z X  1 ( z  ©  ©
d  X  X X © X  ©
X X  X -  (4 ». I4d  d X









p  UJ r—  CM CM A E E
'—4 - - 14 f4
' + 0 0
03 m
n
to -tS- X  VO 
*
to sr X  VO X  d  X  X
'->oc*or>rx-'




X X  ..
X Z  XQ X XZ X  « "  zDC X X









T~ CM CM X V-
(3
CN X  CM
X  x | x |
X  x | © © X © 44
© E X  X  u X  u44 c 3 C X  © CO X  ©
X  3 44 (4 © 3 t4 C 3 (4
0 X  X 3 X  44
X  X © 0 X X  0 X















































































































rabbits 4, 5 and 6 to the NAAC product of placental soluble extract with 
solid-phase lung protein frequently could not be accomplished in a single 
step and the antisera had to be readsorbed several times. This led to a 
dilution of the antibody titre and the resultant precipitin arcs 
produced on AACE were very faint. Fully adsorbed antisera formed a small 
number of precipitin arcs on AACE with placental soluble extract.
Antibodies to an antigen (antigen found in placental 
soluble extract but not in pooled maternal serum nor lung soluble 
extract which did not cross-react with HPL, SP1 or PAPP-A were 
produced by rabbits 7 and 8 immunised with the NAAC 3 product of 
placental soluble extract. The arc formed by the antigen on two- 
dimensional AACE was large and encircled the area in the antibody bed 
from behind the antigen well to just behind anodal end of the arc formed 
by ferritin (Figure 3,3), Its electrophoretic mobility was found to be 
between that of haemoglobin (Beta-1) and ferritin (alpha-2). Figure 3,3 
shows also the AACE arcs produced by rabbit 8 antiserum with lung soluble 
extract and with placental soluble extract and lung soluble extract 
applied to the same antigen well. The two antigens in common with the 
extracts of placenta and lung were found to cross-react with haemoglobin 
and ferritin on double immunodiffusion: the other antigen of alpha-2 
mobility found only in placental soluble extract was found to cross- 
react with HPL,
When antiserum to the NAAC 3 product of placental soluble 
extract produced by rabbit 7 was analysed on Immunoelectrophoresis the 
presence of an additional specificity against an antigen (antigen _b) in 
pooled maternal serum and in placental soluble extract was revealed 
(Figure 3*4), The antigen ^  system required at least 24 hours for 
development. The electrophoretic mobility of antigen _b was much lower
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than that of SP1 (Beta-1) analysed on the same immunoelectrophoretic 
plate. The only other arc formed on Immunoelectrophoresis by rabbit 7 
antiserum with both pooled maternal serum and placental soluble extract 
was formed by an antigen with electrophoretic mobility similar to 
that of HPL (alpha-2) tested in parallel. With placental soluble 
extract an arc corresponding in position to the precipitin arc formed 
by haemoglobin was also detectable. Anti-antigen Jb specificity was 
not detected on the same immunoelectrophoretic plate in the antiserum 
produced by rabbit 8, When rabbit 7 antiserum was tested on a separate 
immunoelectrophoretic plate with pooled adult serum and lung soluble 
extract no arcs were formed with the former and a single arc corres­
ponding in position to haemoglobin was formed with the latter.
Figure 3,5 shows the reaction of the following unadsorbed 
antisera with pooled adult serum:
(1) anti-placental soluble extract antiserum raised
in rabbit 1
and (2) anti-NAAC 3 product of placental soluble extract 
raised in rabbit 7,
Figure 3,6 shows the reaction of adult-serum adsorbed antisera to 
NAAC 1 product of placental soluble extract raised in rabbits 4, 5 
and 6 with placental soluble extract. Figure 3,7 shows cross- 
reactivity of antiserum to NAAC 1 product of placental soluble 
extract raised in rabbit 3 with rabbit antiserum to NAAC 1 product 
of term umbilical cord serum raised independently in our laboratory, 
which in turn shows reactions of identity with anti-PAPP-A antiserum 




The data summarised in Table 3,2 suggest consistent 
differences in the response of rabbits to adult serum protein, maternal 
serum protein, placental and ubiquitous tissue protein between groups 
immunised with different placental preparations and assayed by gel 
precipitation methods, despite some differences in the responses of 
individual rabbits.
The very limited response to adult serum proteins produced 
by those rabbits immunised with IMAAC 1 and the NAAC 3 products of 
placental soluble extract contrasts with the much stronger and more 
extensive anti-adult serum response produced by rabbits immunised with 
unfractionated placental extract. These findings suggest that the 
removal of adult serum protein by NAAC column 1 had been effective but 
not complete and subsequent adsorptions over NAAC columns 2 and 3 did 
not remove the remaining adult serum specificities. The incomplete AACE 
arc produced by the antisera to the NAAC 1 and the NAAC 3 products may 
indicate partial dénaturation of protein during the fractionation 
procedure.
Precipitating antibodies to the placental proteins found in 
maternal serum - HPL and SP1 - were produced by some of the rabbits 
within those groups immunised with unfractionated placental extract and 
NAAC 1 product. Antibodies to HPL but not SP1 were also produced by 
rabbits immunised with NAAC 3 product.
However the most significant difference in the response to 
proteins in maternal serum observed with different groups of rabbits was 
the production of anti-PAPP-A antibodies by all the rabbits immunised 
with the NAAC 1 product and one of the two rabbits immunised with the 
NAAC 3 product but not by the two rabbits immunised with unfractionated
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placental extract. Response to PAPP-A was induced Independently in our 
laboratory by the immunisation of rabbits with both term umbilical cord 
serum and term maternal serum fractionated over the NAAC column 1 
(Sutcliffe, 1979). The recoveries of PAPP-A in maternal serum fraction-, 
ated over the NAAC 1 column were found to be consistently higher than 
either that of HPL or SP1 (Sutcliffe et al*. 1979). Recoveries of both 
HPL and SP1 in placental soluble extract fractionated over the NAAC 
column 1 were also found to be low and further adsorption over the 
NAAC columns 2 and 3 resulted in still smaller recoveries of HPL and 
SP1• The low recovery of SP1 may partly account for the absence of anti- 
SP1 antibodies in rabbits immunised with the NAAC 3 product.
On the basis of the findings presented here as well as 
those reported by Sutcliffe et al. (1979) it may be concluded that 
adsorption of adult serum from PAPP-A -containing preparations on 
NAAC columns is effective in inducing anti-PAPP-A response in rabbits 
immunised with the NAAC product. Response to tissue antigens other than 
ferritin was only detected in antisera produced by three out of four 
rabbits immunised with NAAC 2 product; however many of the antigens were 
also detectable in adult lung soluble extract and only a few remained 
detectable in placental soluble extract after adsorption of antisera 
with solid-phase lung tissue protein. These results show that immunisation 
of rabbits with placental soluble extract from which contaminating 
adult serum protein had been adsorbed over a NAAC column induced only 
a limited response to antigens found in placental tissue but not in 
adult lung tissue.
Absence of any detectable response to ubiquitous tissue 
protein greatly simplified analysis of the two antisera raised to the 
NAAC 3 product and enabled detection on AACC of an antigen (antigen a;
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Figure 3.3) in placental soluble extract undetectable in maternal 
serum or in lung soluble extract. Another unidentified antigen (antigen 
Figure 3*4) was detected on immunoelectrophoresis in both placental 
soluble extract and maternal serum with one of the two anti-NAAC 3 
antisera. These findings suggest usefulness of NAAC fractionation 
methodology combining removal of adult serum protein with removal of 
tissue and decidual protein in the search for placental-specific 
antigens. However, this conclusion is tentative as further studies 
to determine the nature and specificity of the two antigens detected 
with antisera to the NAAC 3 product have not been possible due to 
lack of antisera.
Two factors preclude the drawing of generalised conclusions 
as to the usefulness of different forms of NAAC technology in producing 
immunogens capable of evoking specific immune response in rabbits ;
(l) observed variations in the response of individual rabbits to 
immunisation with the same immunogen and (2) the use of gel precipitation 
to assay the response. This method cannot detect antibodies against 
monovalent antigens and may also not detect antibodies against antigens 
present at a very low concentration in maternal serum or in tissue 
extracts. Nevertheless, the production of anti-PAPP-A specificities 
by all the rabbits immunised with the NAAC products of placental 
soluble extract provides a clear example of the value of NAAC 
technology. Preliminary studies carried out by Lin and his associates 
have indicated that this protein is specific for the placenta (see 
Chapter 1, Section 3.1), Specific antisera to PAPP-A were raised 
independently in our laboratory by immunising rabbits with NAAC 
products of term umbilical cord serum and maternal serum. Thus a 
pool of anti-PAPP-A antisera became available and enabled me to make
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PAPP-A a subject of further studies described in subsequent chapters.
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FIGURE 3.2
5DS Slab Gel Electrophoresis of;
(1) Placental soluble extract
(2) Adult male serum
(3) Gamma-fraction of rabbit antisera to adult male serum
(4) NAAC 1 product from Experiment 1
(5) NAAC 1 product from Experiment 2
(6) NAAC 3 product from Experiment 1
(7) NAAC 3 product from Experiment 2
(a) Adult haemoglobin.
m—1 04—
FIGURE 3.3 Two-Dimensional Antibodv-Antiqen Crossed Electrophoresis
Showing Antigen a .
Here, as in Figures 3.4, 3.6 and 3.7, the ovoid antigen 
wells are to the left of each run and the circular mark to the right of 
each antigen well represents the mobility of albumin in the first 
dimension electrophoresis.
The antiserum is adult serum-adsorbed anti-NAAC 3 product 
of placental soluble extract raised in rabbit J3. The concentration of 
antiserum is 20^.
The antigens are;
(1)6 microlitre placental soluble extract at protein 
concentration of 30 mg. per ml.
(2) Adult lung soluble extract at protein concentration of 
30 mg. per ml.
(3) Addition of (1) and (2).








I Immunoelectrophoresis Showing Antigen b.j
The circular mark above each marked antigen well represents 
the electrophoretic mobility of albumin.
The antisera are:
(a) Anti-HPL
(b) Adult serum adsorbed anti-NAAC 3 product of placental 
soluble extract raised in rabbit ^
(c) Adult serum adsorbed anti-NAAC 3 product of placental 




(1) 12 microlitre pooled maternal serum at protein concentration 
of 66 mg. per ml.
(2) 12 microlitre placental soluble extract at protein 
concentration of 35 mg. per ml.
Development time: 24 hours.
b = precipitin arcs formed by antigen ^  (see Table 3.2).
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One- and Two-Dimensional Antibody-Antigen Crossed Electro­
phoresis Showing Serum Antigens Detectable with Unadsorbed 
FIGURE 3.5 Rabbit Antisera to (i) Placental Soluble Extract and (ii) 
NAAC 3 Product of Placental Soluble Extract.
2  Shows the reaction of 10 microlitre pooled adult serum 
with unadsorbed antiserum against placental soluble extract raised in 
rabbit 1_ on:
(a) One-dimensional 
and (b) Two-dimenjional AACE.
II Shows the reaction of 10 microlitre pooled adult serum 
with unadsorbed antieerum against NAAC 3 product of placental soluble 
extract raised in rabbit 2»
The concentration of antisera in 2  and 2 1  20%.
The protein concentration of pooled adult serum is 69 mg.
per ml.
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Two-Dimensional Antibody-Antigen Crossed Electrophoresis
Showing Placental Antigens Detectable with Serum-Adsorbed 
FIGURE 3.6 Rabbit Antiserum to NAAC 3 Product of Placental Soluble
Extract.
(a), (b) and (c) show the reaction of 10 microlitre placental 
soluble extract with adult serum adsorbed antisera against NAAC 3 
product of placental soluble extract raised in rabbits 2# ^  and 6 
respectively.
The concentration of each antiserum is 20%.
The protein concentration of placental soluble extract is 
103 mg. per ml.
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Showing Cross-Rgactivltv Between Rabbit Ahtiaerum to 
WAAC 1 Product gf_ Placental Solubl# ptract and ftafabji 
An^iswum to NAAC 1 Product of* Teti»Atablllcal [Drd Serum 
(Sutcliff* Bt ai;:18?6).
1 i. C^ubl. IiBTWAQgiffU^ian ^K)wir>q CtOW-(^ajctivitt Q * W * n  
Rgt^U^ptijBTum'tQ I?AAC T ffoAy t  *pV T y m  '
Ci^rtS^tum (Sutcliff. et al. 1976> and Rabbit ftnU«PAPP-< 
FIGURE 3,7 ahtiaerum of Lin and Halbert.
2  Two-Dimensional Antibody-Antigen Crossed Electrophoresis,
The antisera are:
(a) Adult serum-adsorbed anti-NAAC 1 product of placental 
soluble extract raised in rabbit 2
(b) Adult serum-adsorbed anti-NAAC 1 product of term umbilical 
cord serum (Sutcliffe et a l ., 1976)
(c) Addition of (a) and (b).
The concentration of each antiserum is 10%.
Antigen (l) is 10 microlitre pooled maternal serum at 
protein concentration of 68 mg. per ml.
2 2  Double Immunodiffusion
Antisera are:
(a) Adult serum adsorbed anti-NAAC 1 product of term umbilical 
cord serum (Sutcliffe et al.. 1976)
(b) Anti-PAPP-A (Lin and Halbert).
Antigen (1) is 10 microlitre pooled maternal serum at a 
protein concentration 68 mg. per ml.
11
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CHAPTER 4 THE SENSITIVITY OF PREGNANCY-ASSOCIATED AND SERUM PROTEINS 
TO DISSOCIANTS OF ANTIBODY-ANTIGEN COMPLEXES
-110.
1. INTRODUCTION
The studies described in this chapter were designed to 
establish how the use of antibody affinity chromatography might be 
extended to high molecular weight serum proteins. Antibody affinity 
purification might in their case be difficult since it requires 
dissociation of the antigen-antibody complex without dénaturation of the 
antigen per se. which, being of a large molecular weight, is likely to 
be a complex structure of subunits and domains# Recently a number of 
high molecular weight protein antigens have been reported to occur in 
pregnancy sera - for example, PAPP-A, PAPP-B, PZP, PP6, SP1; see Chapter 
1, Section 3.1 - and there is a need to assess their sensitivity to 
dissociants of antigen-antibody complexes before attempting to purify 
them by affinity chromatography. Howver, since little is known about the 
quaternary structure and biological function of these pregnancy proteins 
the assessment of their sensitivity to dissociants of antigen-antibody 
complexes depends largely upon the gel precipitation assays which were 
originally used to define them (i.e. double immune diffusion and antibody* 
antigen crossed electrophoresis,).
An examination was made of the susceptibilities of a sample 
of large and average-sized serum proteins - including certain pregnancy 
proteins - to several dissociation agents commonly used in affinity 
chromatography to disrupt non-covalently bonded antibody-antigen 
complexes. The dissociation agents included in this study were: the 
chaotropic ions - thiocyanate and iodide, each at 3 M, 2*5 M, 2 M and 
1*5 M concentrations (Dandliker et al.. 1967; Dandliker et al.. 1960; 
de Saussure and Dandliker, 1969; Avrameas and Ternynck, 1969), 5 M 
guanidine-HCl (Dandliker et al.. 1968), 8 M urea (Slobin and Sela, 1965),
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pH 2*8 glycine-HCl buffer (Avrameas and Ternynck, pH 11 glycine-IMaOH 
buffer (modified from Omenn et al,, 1970, see also Hoag et al,, 1975), 
After treatment with a dissociating agent the extent of antigen 
dénaturation was assessed by changes in the antigen's precipitating 
behaviour on one-dimensional antibody-antigen crossed electrophoresis 
(AACE). The results of these studies were then applied to the partial 
purification of pregnancy associated plasma protein A (PAPP-A; molecular 
weight 750,000; Lin et al,. 1974b) by antibody affinity chromatography,
2. MATERIALS AND METHODS
Human Materials
Pools of serum collected from ten normal pregnant women at
38-42 weeks' gestation were used as sources of antigens for AACE and for
affinity chromatography. Uterine decidua from a termination of pregnancy 
of 11 weeks' gestation was homogenised in PBS to a final protein concen­
tration of 0*72 mg, per ml, and used as a source of alpha-uterine protein 
(AUP) (Sutcliffe et al.. 1978).
Antisera
Rabbit anti-PAPP-A, anti-steroid-binding globulin (SP2) 
(Bohn, 1974d) and anti-AUP antisera were prepared as previously described 
(Sutcliffe, 1976; Sutcliffe et al.. 1978). The anti-PAPP-A antiserum 
showed reactions of identity with that raised by Lin and Halbert 
(personal communication) (Fig. 4,1), Rabbit antisera against alpha-1- 
lipoprotein, alpha-2-macroglobulin, beta-1-lipoprotein, plasminogen, 
pregnancy-specific beta-1-glycoprotein (SPl), albumin and human placental 
lectogen (HPL) were purchased from Behringwerke AG, U. Germany, Rabbit 
antiserum specific for pregnancy zone protein (PZP) was kindly donated
- 1 1 2 -
by Drs, Lin and Halbert,
Preparation of Dissociation Agents
The final concentrations of the dissociation agents to 
which the human proteins were exposed were as follows:
(i) KSCN-PB3 and KI-PBS, each at 3 M, 2*5 M, 2 M and 1*5 M*
(ii) 5 M guanidine-HCl-PBS.
(iii) 8 M urea-PBS,
(iv) 0*2 M glycine-HCl pH 2*8,
(v) 0*2 M glycine-NaOH pH 11,
These solutions were prepared as 2-fold concentrates for subsequent 2- 
fold dilution in the experiments except in the case of guanidine-HCl 
which was prepared as a 7*5 M solution, urea which was 10*66 M and KI 
which was 5 M,
Except for the low and high pH buffers the pHs of all 
solutions were adjusted to neutrality. The pH of the pH 2*8 and pH 11 
buffers was altered to pH 2*5 and pH 11*4 respectively in order to 
produce the desired pH when added to the serum sample which acted as the 
source of the antigen to be tested#
Treatment of Proteins with Dissociation Agents
Into separate 1 volume aliquots of maternal serum were 
vigorously mixed equal volumes of the individual dissociation solutions 
except in the case of the control aliquot, into which was added 1 
volume of PBS, The exceptions in this procedure were the addition of 1*5 
volumes of 5 M KI (toyield 3 M Kl), the addition of 2 volumes of guanidine- 
HCl and 3 volumes of 10*66 M urea. All serum samples treated with KSCIM,
KI and 5 M guanidine-HCl were incubated for 1 hour at 18 deg. Centigrade 
to avoid crystallisation. Samples in pH 2*8 and pH 11 buffers were 
neutralised with pretitrated volumes of NaOH and HCl respectively after
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30 minutes' incubation at 4 deg. Centigrade. In addition, one sample in 
pH 2*8 buffer was neutralised after 15 minutes incubation at 4 deg. 
Centigrade. The volume of each sample was adjusted to four times the 
original serum volume with PBS at the end of the incubation period, 
dialysed for 18 hours against three changes of PBS and tested for the
presence of intact antigen on one-dimensional AACE.
Parallel studies on human AUP were carried out in the same
way using homogenised decidua as source material,
Immunoelectrophoretic Methods
Double immunodiffusion was performed according to Ouchter- 
lony (1968) and allowed to proceed for 24 hours. One-dimensional AACE 
(antibody-antigen crossed electrophoresis) according to Laurell (1966; 
1972) was carried out in 1% agarose gels. The treated samples , with 
controls on each plate, were subjected to electrophoresis for up to 15 
hours at 1*5 Volts per cm. After electrophoresis plates were washed, 
dried and stained with Coomassie Brilliant Blue,
Polyacrylamide Tube Gel Electrophoresis
Polyacrylamide tube gel electrophoresis was carried out in 
10% acrylamide using a tris-glycine tank buffer pH 8*9 (Maizel, 1971), 
Preparation and Use of Antibody Affinity Column for PAPP-A
Activation and substitution of Sepharose 48 were performed 
according to the method of Porath et al, (1976),
Rabbit anti-PAPP-A serum was first adsorbed by passage over 
a column of Sepharose coupled with human adult serum protein until no 
anti-adult serum antibodies were detectable by AACE. The immunoglobulin 
G (igG) fraction was prepared by DEAE ion exchange chromatography (Morris 
and Morris, 1976) and coupled to Sepharose 48, The IgG-Sepharose (5 ml, 
in PBS) was then packed into a 1*5 cm, diameter chromatography column,
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any residual protein-reactive groups were blocked with 0*1 M ethanolamine 
pH 8*0 and non-covalently bound protein was eluted as recommended by 
Pharmacia. This anti-PAPP-A column was then linked to a 1*5 cm. diameter 
column containing 25 ml. Sephadex G25 in PBS and the eluate from the G-25 
column was monitored with a Uvicord II.
Antibody affinity chromatography was performed at 4 deg* 
Centigrade using 10 ml. of pooled maternal serum as the source of PAPP-A. 
The serum was washed through the column with PBS (approx. 40 ml.) until 
the eluate from the G-25 column gave a zero reading at 280 nm. The 
column was then desorbed using 4 ml. of 2 M KI-PBS pH 7 as dissociating 
agentj* The desorbed material was rapidly separated from the KI by 
filtration in PBS on Sephadex G25 and the resultant fractions were 
assayed for PAPP-A by AACE.
Preparation of Antiserum to Affinity-Purified PAPP-A
PAPP-A prepared by affinity chromatography from 10 ml. of 
pooled maternal serum was subjected to polyacrylamide tube gel electro­
phoresis. Each tube gel was then sliced into 60 pieces, eluted with 100 
microlitres PBS and tesyed for the presence of PAPP-A by AACE. Fractions 
containing PAPP-A were pooled and lyophilised. One half of the lyophilised 
material was dissolved in 1 ml. Freund's complete adjuvant and used to 
immunise a rabbit. The other half in Freund's incomplete adjuvant was 
used as a booster 4 weeks later# Antiserum was obtained on the 7th day 
following boosting. Adsorption of antisera was carried out using normal 
adult human serum which had been polymerised with a final concentration 
of 0*4% glutaraldehyde (BDH) and then dispersed into fine beads by 




Effect of Dissociating Agents
The effects of dissociating agents on AACE precipitin arc 
formation by the proteins ranged from no apparent modifications of normal 
arc morphology through various degrees of alteration of normal up to a 
total loss of precipitation arcs. The various types of altered arcs fell 
into the following fairly discrete categories:
(a) Arcs split into a 'baseline' precipitate and a second 
blurred arc or trail.
(b) Arcs ending in a blurred trail.
(c) Flying arcs.
(d) Tall arcs, 
and (e) Blurred arcs.
These categories are represented in Table 4.1 by the letters a to e (for 
examples, see Fig. 4.2). Letters in parenthesis indicate that a less 
extreme alteration in arc morphology was observed but that the pattern 
could still be classified according to the above scheme. Where no 
alteration in the shape of the precipitin arc was detected (designated 
"+") the height of the arc was the same as that of the control sample 
run on the same AACE plate. From Table 4.1 it is evident that increases 
in the strength or the duration of the treatment result in larger 
alterations in precipitin arc morphology.
When the effect of dissociating agents on beta-1-lipoprotein 
and alpha-2-macroglobulin was in addition assessed by double immuno­
diffusion (Fig. 4.3), loss of the precipitating ability was observed 
where it had also been indicated by AACE. However, where a slight or 
gross alteration of precipitating behaviour had been detected by AACE,
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no such alterations could usually be detected by double immunodiffusion, 
which instead showed evidence of cross-reactivity between the treated 
and native antigens. One exception was found for alpha-2-macroglobulin. 
After treatment at pH 2*8 for 30 minutes, this protein formed two 
precipitin arcs both on AACE and on double immunodiffusion.
Preparation of PAPP-A by Antibody Chromatography
PAPP-A was susceptible to a greater range of dissociating 
agents than the other proteins in this study (Table 4,1 and Fig. 4.4).
It was, however, resistant to 1*5 M KSCiM and 1*5 M and 2 M KI. Antibody 
affinity chromatography followed by G-25 filtration of the 2 M KI-PBS 
desorbed material resulted in the recovery of desorbed protein which was 
free of KI. When the PAPP-A eluted from the column was tested by one- 
dimensional AACE, it gave a precipitin arc which was morphologically 
indistinguishable from that observed when testing unfractionated 
maternal serum. The eluted PAPP-A also gave reactions of identity with 
PAPP-A in unfractionated maternal serum (Fig. 4.1 and Fig. 4.5). Anti­
serum raised against this affinity product showed cross-reactivity with 
antiserum raised to maternal serum PAPP-A (Fig, 4.1).
When 3 M KSCIM was substituted for 2 M KI in the affinity 
chromatography procedure and the fractions containing the KSCIM-free 
eluate were tested for the prescence of PAPP-A on AACE, no precipitin 
arcs were detected.
4. DISCUSSION
The effectiveness of various dissociating agents has been 
evaluated by Johnson and Garvey (1977) for the purification of anti-BSA 
using BSA-Sepharose. They claimed that chaotropic ions at low pH
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dissociated maximum reactive antibody. Houver, these findings cannot be 
extended to the affinity purification of other antigens without first 
considering the stability of antigens in such dissociants* In the 
present study the susceptibility of proteins to dénaturation by 
dissociating agents was assessed by one-dimensional AACE which revealed 
a variety of minor changes in the morphology and the intensity of the 
precipitin arcs as well as showing when a total loss of precipitable 
antigen had occurred. Similar types of altered AACE peaks were observed 
by Bjerrum and Bog-Hansen (1975) for proteins subjected to controlled 
enzymatic degradation. The results with double immunodiffusion, although 
limited, suggest that this technique is a less sensitive means of 
comparing the antigenicities of native and purified proteins, since it 
did not reveal most of the minor changes detected by AACE.
As assayed by AACE, all proteins tested proved resistant to 
pH 11, 1«5 M KI, and in many cases 1*5 M KSCI\) and 2 M KI. In general the 
order of effectiveness of different agents in inducing alterations in the 
antigenicity of susceptible proteins reflected the order found for 
denaturing ability, that is, guanidine-HCl greater than urea and 
chaotropic ions (Habeeb, 1977). Also, the effectiveness of chaotropic 
ions in inducing loss of normal antigenicity increased in the order l” 
less than SCN"* which is the order found for the disruption of the 
tertiary structure of proteins (von Hippel and Uong, 1964), For many of 
the proteins (Table 4.1) increased concentrations of I and SCN" resulted 
in more extreme changes in precipitin arc morphology. An increase in the 
time of exposure to low pH from 15 to 30 minutes led to more extensive 
dénaturation of antigens. In one case (alpha-1-lipoprotein) dénaturation 
only became apparent after exposure to low pH for thirty minutes.
The sample size in Table 4,1 is too small to seek a general
.119-
relationship between molecular size and sensitivity to dénaturation. 
However, the data is compatible with the expectation that large size 
results in increased sensitivity. The results show that the very large 
glycoproteins - alpha-2-macroglobulin (composed of four dimeric subunits - 
Roberts and Hall, 1974; Frenoy et al., 1977), PZP (composed of two di­
sulphide bonded chains - Bohn and Winckler, 1976) and PAPP-A - were 
most susceptible to dénaturants. Some of the other proteins were found 
to be susceptible to lesser degrees, Alpha-1-lipoprotein and beta-1- 
lipiprotein both have complex structures involving several di-sulphide 
and non-covalently bonded, lipid-associated polypeptide chains (Scanu 
et al., 1975). However, alpha-1-lipoprotein did not appear to be 
susceptible to the action of chaotropic ions, which exert their effects 
mainly by destabilising hydrophobic bonds (Dandliker et al., 1967). This 
may be because the antigenicity of alpha-1-lipoprotein molecule has been 
found to be dependent on the presence of polar phospholipid head groups, 
which may not involve hydrophobic bonding (Chapman and Goldstein, 1976), 
Three relatively small proteins - albumin, alpha-uterine protein and 
HPL - were found to be completely resistant to the whole range of 
dénaturants investigated. Albumin is a monomer containing no bound 
carbohydrate and is exceptional in its conformational adaptability (Peters, 
1975). Similarly, HPL is a monomer containing no bound carbohydrate 
(Friesen, 1973). The structure of AUP is not established but it appears 
to be a dimer composed of two identical subunits (Sutcliffe et al.. 1980).
Considering the detailed alterations observed in morphologies 
of precipitin arcs, these tended to be typical of the antigen concerned 
rather than the dénaturant employed. The finding of multiple precipitin 
arcs (types a and b; see Table 4.1) suggest that dénaturation may involve 
the production of more than one class of altered antigen. Although these
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alterations could represent different ways in which the original 
antigen has unfolded (due perhaps to initial antigenic heterogeneity) 
it might instead reflect different patterns and extents of antigen 
dénaturation after removal of the denaturing conditions.
In all cases where no alteration in the shape of the 
precipitin arc was detected the height of the arc was the same as 
that of the control PBS-treated sample, indicating an antigen recovery 
of approaching 100% with each dissociant. However, the recovery of 
antigen from affinity chromatography will depend on a number of 
additional factors, the main one being the avidity of the immobilised 
antibody used and should therefore be determined with each particular 
antigen-antibody system for each of the dissociants found to give 
full antigen recoveries in the AACE test, Where antibodies of high 
avidity are to be used the highest concentration of a dissociating 
agent to which the antigen is resistant may well have to be employed.
The most susceptible of the proteins tested, PAPP-A, 
has previously only been partially purified by physico-chemical 
methods (Lin et al,, 1974a). Application of the present findings to 
its partial purification for the first time by affinity chromatography 
resulted in its recovery from the affinity column in an apparently 
normal state by elution with 2M KI, but not with 3M KSCN, supporting 
the findings in Table 4.1. Subsequent immunisation of a rabbit with 
this affinity product yielded antiserum which cross-reacted with an 
antiserum raised against PAPP-A which had not been exposed to dissociants.
These experiments provide evidence that the sensitivities 
to dénaturation summarised in Table 4,1 can be applied to affinity 
chromatography. Thus it may be that the purification of SP1 would be 
better achieved by dissociation with KI rather than by dissociation at
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low pH (as used by Bohn et al., 1976). Fitsche and Mach (1977) used 3M 
NaSCN as the dissociating agent in a study designed to compare the 
physico-chemical and immunological properties of carcinoembryonic 
antigens obtained from normal and malignant colon. They studied affinity- 
purified material by double immunodiffusion and radioimmunoassay. Although 
carcinoembryonic antigen is a monomer it could be that a milder dissociating 
agent would have revealed more subtle differences between the carcino­
embryonic antigens of normal and malignant tissue. Interestingly, two 
of the monomers reported in the present study were sensitive to 3 M KSCN 
(viz; plasminogen and SPl).
The present findings apply to the purification of proteins 
of unknown quaternary structure and biological function by antibody 
affinity chromatography for subsequent use in immunoassays or as immunogens 
for raising specific antisera. The search for new and probably weak 
antigens may require the use of affinity purification of antigens early 
in the studies in order to develop sufficient antisera to assay antigens 
during other, possibly more conventional purification techniques. Under 
such circumstances and especially if the initial antisera are of non- 
precipitating type, it may be advisable to choose T»5 M or 2 M KI-PB3 
as the dissociating agent.
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FIGURE 4.1
Double immunodiffusion plate showing cross-reactivities
between :
(i) Rabbit anti-PAPP-A antiserum of Sutcliffe et al. (1976) 
and rabbit anti-PAPP-A antiserum of Lin and Halbert.
(ii) Rabbit anti-PAPP-A antiserum of Sutcliffe et al. (1976) 
and rabbit anti-affinity purified PAPP-A antiserum.
and (iii) Maternai serum PAPP-A and affinity purified PAPP-A.
The antisera are:
(a) Anti-PAPP-A (Sutcliffe et al.. 1976)
(b) Anti-PAPP-A (Lin and Halbert)
(c) Rabbit anti-affinity purified PAPP-A.
Antigens are:
(1) Pooled maternal serum
(2) Affinity purified PAPP-A
(3) Pooled adult serum
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FIGURE 4.2
One-dimensional AACE patterns of native and 3 M KSCIM-treated
proteins.






(1) Native protein in serum
(2) 3 M KSCN-treated protein
Note the various types of aberrations produced, i.e.
(i) Arc split into 'base-line’ precipitate and a second blurred 
arc or trail (a2,b2)
(ii) Arc ending in a blurred trail (c2) 
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Native protein in serum 
- (13) Treated proteins. Treatments are:
3 M KSCN 
2.5 M KSCN
2 M KSCN 
1*5 M KSCN
3 M KI 
2-5 M KI 
2 M KI 
1*5 M KI
5 M guanidine-HCl 
8 pi urea, pH 8*8
0*1 M glycine-HCl, pH 2*8, for 15 minutes 
0*1 M glycine-HCl, pH 2*8, for 30 minutes.
1 2
FIGURE 4.4
One—dimensional AACE patterns of PAPP—A treated with
dissociation agents.
The antiserum is anti-PAPP-A (Sutcliffe et a l ., 1976). 
The antigens are:
(1) Native protein in serum
(2) - (15) Treated proteins. Treatments are:
(2) 3 M KSCN
(3) 2-5 PI KSCN
(4) 2 M KSCN
(5) 1-5 n KSCN
(6) 3 M KI
(7) 2*5 n KI
(8) 2 PI KI
(9) 1*5 PI KI
(10) 5 M  guanidine-HCl
(11) 8 M urea
(12) 0*14 M mercaptoethanol
(13) 0*1 n glycine-HCl, pH 2*8, for 15 minutes
(14) 0*1 PI glycine-HCl, pH 2*8, for 30 minutes
(15) 0*1 PI glycine-NaOH, pH 11.
1 2 3 4  5 6 7 8
9  1 0  11 12  13 l 4  15  16
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FIGURE 4.5
One-dimensional AACE patterns of native and affinity- 
purified PAPP-A . ■ DemonstratiQq_ o:^ cxQ^_s-reactivitv.
The antiserum is.anti-PAPP-A (Sutcliffe et al., 1976) 
Antigens are:
(1) Native protein in serum
(2) Affinity-purified protein
(3) Addition of (l) and (2),
Note that (3) is a single arc larger than either (I) or (2),
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CHAPTER 5 THE PARTIAL PURIFICATION OF PAPP-A BY ANTIBODY AFFINITY
CHROMATOGRAPHY
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1. THE EFFECT OF TIME OF EXPOSURE TO 1*5 M AND 2 M KI ON THE
IMMUNOCHEMICAL REACTIVITY OF PAPP-A
1.1 Introduction
In Chapter 4 the effects of dissociants of antibody-antigen 
complexes on the immunochemical reactivity of PAPP-A was assessed, PAPP-A 
was found to be resistant to 1*5 M and 2 M KI and 2 M KI was subsequently 
used with success in the partial purification of PAPP-A by small-scale 
affinity chromatography.
In order to assess the suitability of 1*5 M and 2 M KI for 
large as well as small-scale purification of PAPP-A by affinity 
chromatography the effect on PAPP-A of exposure to these dissociants for 
extended periods of time must be known. This is investigated in the 
present experimental section.
1.2 Materials and Methods
A full description of the experimental method is provided 
in Chapter 4, Section 2.2. The differences in the present set-up were as 
follows;
(1) Only two dissociating agents were used - 1*5 M and 2 M
KI.
(2) Eight serum samples were treated with individual 
dissociating agents. Seven of these were incubated for periods of 1 - 7 
hours: the remaining sample was incubated for 18 hours.
(3) Following dialysis, samples were only tested for the 




The effects of the dissociating agents on AACE precipitin 
arc formation by PAPP-A are shown in Table 5.1. Prolonged exposure to
1*5 M KI for periods up to 18 hours failed to produce any alterations in
the precipitating behaviour on AACE of PAPP-A. Prolonged exposure to 2 M 
KI produced alterations which first became apparent at 7 hours exposure.
1.4 Discussion
The extent of the 2 M Kl-induced irreversible dénaturation 
of PAPP-A was found to depend on how long it has been allowed to remain 
under denaturing conditions. This finding is in agreement with the 
general conclusion reached in Chapter 4 based on observations of the 
effect of the exposure of various antigens to low pH for periods of 15 
and 30 minutes. The similarity of the 2 M Kl-induced alterations in 
PAPP-A AACE arc morphologies with those induced by 1 hour exposure of 
PAPP-A to 2*5 M and 3 M KI (Chapter 4, Table 4.1) provides further 
support for the conclusion reached in Chapter 4 which was that such
alterations tend not to be random, but are typical of the antigen
concerned.
The immunochemical reactivity of PAPP-A (as assessed by 
AACE) was unaffected by exposure to 1*5 M KI for periods up to at least 
18 hours. This implies that 1*5 M rather than 2 M KI should be used 
whenever prolonged exposure of PAPP-A to a dissociating agent is 


























































































































































2a. PURIFICATION OF PAPP-A FROM TERM MATERNAL SERUM
2a.1 Introduction
Purification of PAPP-A from term maternal serum was under­
taken in two stages. Initially partially purified PAPP-A prepared by the 
small-scale antibody affinity chromatography (Chapter 4) was used to 
immunise sheep and the antisera thus obtained used to prepare an affinity 
column for the large-scale purification of PAPP-A,
The affinity column was then employed in the first stage of 
the purification procedure. Selection of further purification steps was 
guided by the knowledge of the biochemical characterisations of PAPP-A 
defined by the earlier work of Lin and his associates (Lin et al., 1974a; 
Lin et al., 1974b). According to these workers, PAPP-A has a pi of 
around 4*1, This enabled the selection of a suitable matrix for ion- 
exchange chromatography for use in the second step for purification: an 
anion exchanger, DEAE-cellulose, The molecular weight of PAPP-A as 
defined by Lin and his associates is 750,000 daltons: this enabled 
selection of a suitable matrix for gel filtration for use in the third 
and final purification step: Sepharose 6B which has an exclusion limit 
for proteins of 2 - 3 x 10^.
2a.2 Materials and Methods 
Materials
A pool of term maternal serum (300 ml.) was made from blood 
collected perrvaginam at normal deliveries. The protein concentration of 
the pooled serum was 32*4 mg, per ml.




Preparation of Sheep Antiserum to Affinity-Purified PAPP-A
Preparation of partially-purified PAPP-A by small-scale 
antibody affinity chromatography and preparation of rabbit antiserum 
to this affinity-purified PAPP-A were described in Chapter 4* Sheep 
antiserum to affinity-purified PAPP-A was prepared in a similar way, 
except that antibody affinity chromatography as described in Section 
2 of Chapter 4 was performed twice. The products from the two 
adsorptions over the affinity column were pooled prior to polyacrylamide 
tube gel electrophoresis. Antisera collected between the 7th and the 
21st day following boosting were pooled. Adsorption of pooled sheep 
antiserum to affinity-purified PAPP-A was carried out using adult 
human male serum which had been polymerised with a final concentration 
of 0*4% gluteraldehyde and then dispersed into fine beads by 
homogenisation and washing in PBS (Avrameas and Ternyck, 1969), The 
extent of adsorption was tested by two-dimensional AACE using adult 
human serum as the source of antigens. Adsorption was judged to be 
complete when no precipitin lines could be detected on AACE, The 
adult serum-adsorbed sheep anti-PAPP-A antiserum was checked for 
cross-reactivity with anti-PAPP-A antiserum kindly provided by Drs 
Lin and Halbert on double immunodiffusion.
Preparation and Use of Sheep Antibody Affinity Column for PAPP-A 
The immunoglobulin G (igG) fraction was precipitated 
from 550 ml, of adult serum-adsorbed sheep anti-PAPP-A antiserum 
with 33% (^8^)280  ^ by the method of Kekwick et al, (1942). 1*65 gm. 
of IgG thus purified was conjugated to 170 gtji, Sepharose 48 by the 
CI\!Br reaction (Porath et al., 1976), Before use the material was 
packed into a 3 cm. diameter Wright Scientific Column and washed
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with three volumes of 2 M KI in PBS at 4°C and then equilibriated with
PBS,
Antibody affinity chromatography was performed at
using 300 ml. of pooled maternal serum as the source of PAPP-A, The 
serum was washed through the column with PBS at a rate of 80 ml, per 
hour until the eluate from the affinity column gave a zero reading at 
280 nm. Material which failed to adsorb to the column was concentrated 
by ultrafiltration on a PM 10 membrane and analysed for PAPP-A content 
on one-dimensional AACE. The column was desorbed with 240 ml, 1*5 M KI- 
PBS, pH 7*0, as the dissociating agent at a flow rate of 100 ml. per 
hour. The eluate was diluted in PBS to below 0*8 M KI, as judged by 
conductance, concentrated to 90 ml, by ultrafiltration on a PM 10 
membrane and dialysed for 48 hours against three changes of a 20-fold 
excess of 10 mM KPO^, pH 7*5,
Preparation and Use of DEAE-cellulose Ion-exchange Chromatography Column 
DE-52 microgranular DEAE-cellulose (Whatman, New York) was 
packed into a 2*6 cm, diameter Pharmacia column to give a column volume 
of 100 ml. The column was equilibriated with 10 mM KPO^, pH 7*5 buffer 
(Buffer a) according to the instructions^of Whatman, The material from 
the affinity column in a total volume of 90 ml. Buffer A was applied to 
the column at 4°C and washed through the column with Buffer at a rate of 
48 ml, per hour. That material which failed to adsorb on the column was 
concentrated by ultrafiltration on a PM 10 membrane and analysed for 
PAPP-A content on one-dimensional AACE, Elution of the column was carried 
out with 500 ml.of a linear IMaCl gradient, starting with 10 mM KPO^, pH 
7*5 and ending with 10,hM KPO^, 0*5 M NaCl, pH 6*5, at a flow rate of 
48 ml, per hour. The column was finally flushed with 50 ml. of a limiting 
buffer, Eluates were collected at 3*7 ml, per tube. The eluate was
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monitored at 280 nm. with a Uvicord II analyser (LKB Instruments), The
linearity of the gradient was checked by measuring the specific
conductivity of the eluate. The presence of PAPP-A was assessed by 
testing each of the fractions by one-dimensional AACE, Those PAPP-A- 
containing fractions least contaminated with serum proteins were pooled, 
concentrated to 3 ml, by ultrafugation on a PM 10 membrane and used in 
the subsequent gel filtration purification step.
Preparation and Use of the Sepharose 6B Filtration Column
CL-Sepharose 68 (Pharmacia N. 3.) was prepared in PBS and
packed into a 1*5 cm, by 90 cm, Pharmacia column. The void volume was 
measured with dextran blue 2,000 (Pharmacia), Material recovered from 
the ion-exchange chromatography in a total volume of 3 ml, PBS was applied 
to the column, the column was washed in PBS at the rate of 20 ml, per 
hour and the eluates collected 3*3 ml, per tube at 4°C, The eluate from 
the column was monitored at 280 nm, with a Uvicord II, The presence of 
PAPP-A was assessed by testing each fraction by one-dimensional AACE,
In a separate experiment 3 ml, of pooled term maternal serum was 
fractionated over the same column following the experimental procedure 
outlined above.
The product of each purification stage was analysed for 
total protein content and for PAPP-A content. The total protein content 
was determined by the method of Lowry et al. (I95l), The PAPP-A content 
was determined by measuring the area of the arc formed by PAPP-A on one­
dimensional AACE using adult serum adsorbed sheep anti-PAPP-A, Each 
millilitre of the pooled term maternal serum was arbitrarily designated 




Sheep Anti-PAPP-A Column Chromatography
Sheep anti-affinity purified PAPP-A antiserum used to 
construct an antibody affinity column for PAPP-A showed cross-reactivity 
with anti-PAPP-A antiserum of Lin and Halbert on double immunodiffusion 
(Figure 5.1).
The material from term maternal serum which failed to adsorb 
to the affinity column was tested on one-dimensional AACE for the 
presence of PAPP-A, It was found to contain none. The concentration of 
protein and the amount of PAPP-A recovered in the material eluted from':, 
the column with 1*5 M KI-PB3 was determined and used to calculate the 
degree of purification of PAPP-A, The reults are shown in Table 5,2, 
Dialysis of the concentrated eluate from the affinity column resulted in 
the precipitation of protein which had to be removed by centrifugation, 
DEAE-Cellulose Ion Exchange Chromatography
The material which failed to adsorb to the affinity column 
was tested on one-dimensional AACE for the presence of PAPP-A, It was 
found to contain none. Those fractions eluted from the column with a 
salt gradient were analysed for protein and PAPP-A content. The results 
are shown in Figure 5*2. Three protein peaks were resolved. Elution of 
PAPP-A occurred over a wide NaCl concentration range (0*175 - 0*26 M 
NaCl) with a maximum at 2 M NaCl which corresponded to the middle 
portion of the descending limb of the second protein peak. It eluted in 
the same volume as two of the three protein peaks. The PAPP-A peak was 
asymmetric: it had an extended descending limb with a shoulder on it. 
Inspection of the distribution of the protein and PAPP-A peaks indicated 
that the least serum protein-contaminated fractions were likely to be 
those forming the descending limb of the PAPP-A peak and three of those
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fractions A,B and C were pooled and used in the subsequent purification 
step: see Figure 5,1 for the location of A,B and C, The concentration of 
protein and the amount of PAPP-A recovered in (i) pooled PAPP-A - 
containing fractions eluted from the column with a salt gradient and 
(ii) pooled fractions A,B,C were determined and used to calculate the 
degree of purification of PAPP-A in each. The results are shown in Table 
5,2.
CL-Sepharose 68 Gel Filtration
Fractions A,B,C resulting from the ion exchange chromatography 
were fractionated over the Sepharose 68 column. In a separate experiment 
pooled term maternal serum was fractionated over the same column. The 
fractions eluted from the column were analysed for protein and PAPP-A 
content. The results are shown in Figure 5,3 and Figure 5,4c, PAPP-A in 
fractions A,B,C eluted in 63*5 ml, elution volume; PAPP-A in term maternal 
serum eluted in 63*5 ml, elution volume. The concentration of protein 
and the amount of PAPP-A recovered in (i) pooled PAPP-A-containing 
eluate fractions and (ii) the eluate fraction containing the maximum 
amount of PAPP-A (Fraction 5, Figure 5,4c: designated 'PAPP-A purification 
product') were determined and used to calculate the degree of purification 
of PAPP-A in each. The results are shown in Table 5,2,
Morphology of AACE Arcs Formed by PAPP-A in Term Maternal Serum and in 
Partially-Purified Products
PAPP-A in purification products at different stages during 
the purification procedure formed two precipitin arcs, one within and 
parallel to the other one on AACE but not on double immunodiffusion. In 
the case of PAPP-A eluted from DEAE ion-exchange column the presence of 
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5.4). As can be seen from Figure 5,4 the proteins which formed these 
arcs eluted together or close together from the DEAE-Sephadex ion- 
exchange and Sepharose 68 gel filtration columns.
The double-arc phenomenon was also frequently observed 
with PAPP-A in term maternal serum before any purification although the 
area inside the large arc tended to stain darkly and the second arc 
within was usually less discernable.
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2b, PREPARATION AND ANALYSIS OF I-LABELLED PAPP-A PURIFICATION PRODUCT
2b.1 Introduction
The final product of the purification protocol described in
Section 2a - "PAPP-A purification product" - was iodinated and subjected
to further studies. In order to achieve iodination with least risk of
damage to the proteins being iodinated a gentle iodination method
employing lactoperoxidase was chosen (Bolton, 1977), The identification 
1 25
of the I-labelled species in the purification product was carried
out using AACE. Anti-PAPP-A antiserum was used to detect labelled PAPP-A
and anti-adult serum to detect any labelled serum proteins. The
1 25
biochemical characteristics of I-PAPP-A were then investigated by 
Sepharose CL 68 gel filtration and two-dimensional AACE, PAPP-A was 
identified in both systems by immune precipitation and its behaviour 
compared with that of PAPP-A from term maternal serum.
2b.2 Materials and Methods
Experimental Protocols for the Iodination of the PAPP-A Purification 
Product
(i) The enzymatic method using soluble lactoperoxidase (see 
Bolton, 1977), Iodination of 5 microgrammes of protein from the PAPP-A 
purification product (see Section 2a,3) was carried out using the 
soluble lactoperoxidase technique, 5 microgrammes of protein from 
pooled non-pregnant adult serum - the product of ten male and non- 
pregnant female sera - was also labelled by this method. In addition a 
blank iodination was performed in which no protein was added to the 
reaction mixture containing lactoperoxidase so that identification of 
the labelled species in the PAPP-A purification product due to labelled
—1
lactoperoxidase would be possible.




Na I: 100 mCi per ml*
0*5 M potassium phosphate buffer, pH 7*5,
1 mg, per ml, lactoperoxidase in 0*1 M potassium phosphate buffer, pH 7*5 
20 microgram, per ml, hydrogen peroxide diluted in 0*05 M potassium 
phosphate buffer, pH 7*5,
20 mg, per ml, tyrosine in 0*05 M potassium phosphate buffer, pH 7*5,
20 mg, per ml, KI solution in gelatin-phosphate buffer (0*05 M potassium 
phosphate buffer, pH 7*5, containing 0*2% gelatin).
Protein to be iodinated! 0*5 mg, per ml, in 0*05 M potassium phosphate 
buffer, pH 7*5,
12% horse serum-phosphate buffer (0*05 M potassium phosphate buffer, 
pH 7*5, containing 12% Wellcome type horse serum),
100 mg, per ml, solution of bovine serum albumin (Armour Pharmaceutical 
Company Limited),
Lactoperoxidase (B grade) was purchased from Calbiochem,
It was diluted from a 10 mg, per ml, stock solution (stored frozen) 
immediately before use.
The buffers contained no sodium azide as preservative,
Iodination
0*5 mCi, (5 microlitre) of Na^^^I was dispensed into a 
polystyrene tube and 20 microlitre of 0*5 M potassium phosphate buffer 
was added. The solution was continuously agitated and the other reagents 
were added in the following order:
(l) 10 microlitre (5 microgram,) of protein solution
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(2) 10 microlitre (10 microgram.) lactoperoxidase solution
(3) 10 microlitre (200 ng.) hydrogen peroxide solution.
The reaction mixture was incubated at room temperature for seven minutes 
and a further 10 microlitres of hydrogenperoxide solution was added.
After a further 7 minutes a third 10 microlitre aliquot of hydrogen 
peroxide was added, and then after a further 7 minutes' incubation, 50 
microlitres (img.) tyrosine was added to quench the reaction* After one 
minute, 50 microlitres of the carrier KI solution was added to the 
reaction mixture and the radioactivity in the iodination tube was counted 
in a LKB Ultragamma counter.
Separation of Labelled Protein from Unreacted Iodide
The Sephadex G-25 gel filtration medium was equilibriated 
in gelatin-phosphate buffer (0*05 M sodium phosphate buffer containing 
0*2% gelatin) and packed into a small column. The column was saturated 
with bovine serum albumin and all free albumin was washed off the 
column with gelatin-phosphate buffer. The iodination mixture was then 
transferred to the prepared column. The column was eluted with gelatin- 
phosphat buffer and 0*1 ml, fractions were collected into polystyrene 
tubes (of the same dimensions as the iodination reaction tube) 
containing 25 microlitres of 12% horse serum-phosphate buffer. The 
column was run until both the protein and small molecular weight peaks 
had been eluted and the radioactivity in all the fractions was 
measured. The tube with the protein peak was taken for use as a tracer,
(ii) The enzymatic method using solid-phase lactoperoxidase 
(David, 1972; David and Reisfeld, 1974). Iodination of 5 microgrammes of 
protein from the PAPP-A purification product was carried out at a later 
stage using lactoperoxidase covelently coupled to Sepharose 6B, 
Conjugation of lactoperoxidase to Sepharose 6B was carried out by the
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CNBr reaction Porath et al,, 1976) using 5 mg, lactoperoxidase per 1 ml, 
packed Sepharose, 20 microlitre of Sepharose slurry in 0*05 M potassium 
phosphate buffer, pH 7*5 was added to the iodination mixture instead of 
10 microlitre lactoperoxidase solution in the method described in (i) 
above. Addition of tyrosine to quench the iodination reaction reaction 
was not necessary.
Identification of Labelled Species in the Purification Product
(a) One-dimensional AACE using anti-PAPP-A antiserum
10 microlitre aliquots of PAPP-A purification product 
labelled by the soluble lactoperoxidase method (in 50 mM K^PO^, pH 7*5; 
35,000 c,p,s,) were added to wells 1 - 3 on an AACE plate. Term maternal 
serum (10 microlitres) was added as a source of carrier PAPP-A to well 
2, Pooled non-pregnant adult serum (l0 microlitres) was added to well 3, 
The antiserum used was 3% sheep anti-PAPP-A, A similar set of wells 
were used in a separate control plate which contained 3% non-immune 
serum. After electrophoresis and two days of washing to remove non­
precipitated counts, the gels were subjected to autoradiography with 
Kodirex (Kodak) X-ray film. The areas of intense radioactivity in the 
gel (and the corresponding areas in the control plate) were excised 
with a scalpel and counted in a LKB Ultragamma counter,
(b) Two-dimensional AACE using anti-adult serum antiserum 
A I D  microlitre aliquot of serum protein labelled by the
soluble lactoperoxidase method (38,000 c,p,s,) and a 10 microlitre 
aliquot of the PAPP-A purification product labelled by the soluble 
lactoperoxidase method (35,000 c,p,s.) (both in 50 mM K^PO^, pH 7*5) 
were added to wells 1 and 2 respectively. Well 1 was at the extreme 
left and well 2 in the middle of an AACE plate, 1*5 microlitres of 
pooled non-pregnant adult serum was also added to wells 1 and 2, The
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samples were subjected to electrophoresis in the first dimension over 
the same distance on the AACE plate. Second dimension electrophoresis 
was then carried out into gel containing 10% sheep anti-human male 
serum antiserum (Sutcliffe, 1976), After electrophoresis and two days 
of washing to remove non-precipitated counts the gels were subjected
to autoradiography with Kodirex X-ray film.
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Analysis of I-PAPP-A in the Purification Product
(a) Sepharose CL 6B gel filtration
The material resulting from iodination of the PAPP-A
purification product by the soluble lactoperoxidase method and that
resulting from blank iodination by the soluble lactoperoxidase method
was each subjected to gel filtration over a Sepharose 6B column. The
column used was the same as that used in the purification procedure:
see Section 2a.2. In each fractionation the material to be fractionated
was applied to the column, the column washed in PBS at the rate of
20 ml. per hour and the eluates collected at 2*55 ml. per tube. The
radioactivity in the fractions resulting from each fractionation was
counted in a LKB Ultragamma counter. The percentage of counts due to 
1 25
I-PAPP-A in the fractions resulting from the fractionation of the 
labelled purification product was determined by solid-phase immune 
precipitation: see below.
125
Solid-Phase Immune Precipitation of I-PAPP-A: 10 microlitre aliquots 
of Sepharose 68 fractions were added to tubes containing 50 microlitres 
of sheep anti-PAPP-A-Sepharose diluted 1:10 in 2% horse serum-phosphate 
buffer (0*05 M potassium phosphate buffer, pH 7*5, containing 2% horse 
serum). For details of the preparation of anti-PAPP-A-Sepharose see 
Section 2a,2. The radioactivity in each tube was measured in a LKB 
Ultragamma counter. The tubes were left on a gyratory shaker overnight
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at room temperature. The tube contents were then centrifuged and the 
Sepharose washed three times with 2% horse serum-phosphate buffer, 
pH 7*5: each time the supernatant was removed by centrifugation. Finally 
the radioactivity in each tube was measured,
(b) Two-dimensional AACE using anti-PAPP-A antiserum
To each of two wells, located one directly underneath the 
other in agarose gel on a 8 cm, by 8 cm, plate, were added 5 microlitre 
of purification product labelled by the solid lactoperoxidase method 
(10 microlitre in 50 mM K^PO^, pH 7*5; 5,600 c,p,s,) together with 
5 microlitres of term maternal serum containing Bromophenol Blue, The 
samples were subjected to electrophoresis along parallel tracks on the 
gel. When first dimension electrophoresis was completed the lower part 
of the gel containing one of the two electrophoresed samples was 
excised with a scalpel and cut into 30 pieces, each 0*25 cm, long. The 
radioactivity in each piece of gel was measured in a LKB Ultragamma 
counter. The other electrophoresed sample was subjected to electro­
phoresis in the second dimension into 20% sheep anti-PAPP-A antiserum- 
containing gel; for details of the antiserum preparation see Section 
2a,2, After electrophoresis and two days of washing the gel was 
subjected to autoradiography with Kodirex X-ray film and stained for 
protein with Coomassie Blue,
2b,3 Results
Identification of Labelled Species in the Purification Product
(a) One-dimensional AACE using anti-PAPP-A antigens
1 25Detection of immunoreactive I-PAPP-A in the labelled 
purification product was attempted on one-dimensional AACE plates 
containing anti-PAPP-A antiserum: see Figure 5,5, Immunoreactive
.145.
125 I-PAPP-A was detected as an intensely radioactive arc. The control
plate containing non-immune serum showed only faint activity around the
1 25margins of the antigen wells. The radioactivity in the I-PAPP-A
AACE arcs and the corresponding areas in the control plate were counted
and the results, expressed as a percentage of the counts applied, are
shown in Table 5,3#
(b) Two-dimensional AACE using anti-adult serum antiserum
1 25
The detection of immunoreactive I-serum proteins in the 
labelled pooled non-pregnant adult serum and in the labelled purification 
product was attempted on two-dimensional AACE plates containing anti­
adult serum 'antiserum: see Figure 5,6, The incorporation of a large 
number of immunoreactive serum proteins into the AACE arcs was 
observed when labelled when labelled non-pregnant adult serum was used 
as the antigen source. Incorporation of very few immunoreactive serum 
proteins into AACE arcs was observed when labelled PAPP-A purification 
product was used as the antigen source and the bulk of the radioactive 
material was found in the area close to the origin after electro­
phoresis ,
1 25
Analysis of I-PAPP-A in the Purification Product
(a) Sepharose CL 68 gel filtration
The material resulting from iodination of the purification 
product by the soluble lactoperoxidase method and that resulting from 
blank iodination by the soluble lactoperoxidase method was each 
fractionated over the Sepharose 68 column. Those fractions eluted from 
the column were counted in a gamma-counter and the results are shown in 
Figure 5,7,
Fractionation of the labelled purification product gave 
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to the three peaks which resulted from the fractionation of the 
product of blank iodination. The first of these three common peaks, 
fractions 14 - 22 in Figure 5.7, corresponds to the void volume of the 
column. The second peak, fractions 30 - 57, had a shoulder on the 
descending limb. The third peak, fractions 57 - 68, was the smallest of 
the three, A fourth peak, which was not observed in the eluate resulting 
from the fractionation of the product of the blank iodination, was 
detected in fractions 22 - 30,
125
The percentage of counts due to I-PAPP-A in those
fractions resulting from the fractionation of the labelled purification
product was determined by solid-phase immuno precipitation and the
1 25results are also shown in Figure 5,7, The elution volume of the I-
PAPP-A peak thus detected was 63*1 ml,
(b) Two-dimensional AACE using anti-PAPP-A antiserum
Two aliquots of material resulting from the iodination of
the purification product by the solid-phase lactoperoxidase method were
subjected to electrophoresis along parallel tracks on agarose gel. The
distribution of radioactivity over the gel was determined by counting
slices of the gel containing one of the electrophoresed samples in a
gamma-counter. The results are shown in Figure 5,8, Three radioactive
peaks were resolved. The first on corresponded to the position of the
antigen well. The second peak corresponded to the position of the 
1 25
I-PAPP-A precipitin arc detected by autoradiography: see the 
following paragraph. The third peak corresponded to the position of the 
Bromophenol Blue band.
The other electrophoresed sample was subjected to second 
dimension electrophoresis into anti-PAPP-A antiserum containing gel.
The presence of a single immunoreactive arc on the AACE plate was
■148.
revealed by autoradiography and protein staining; Figure 5,9, The AACE 
arc detected by protein staining corresponded in position to the most 
intensely radioactive part of the AACE arc detected by autoradiography; 




Prior to the present work being undertaken Lin et al>
(1974a) claimed to have acheived 115-fold purification of PAPP-A from 
third trimester maternal serum using a purification procedure which 
involved the combined use of DEAE ion-exchange chromatography and gel 
filtration. However they provided no physicochemical evidence of purity 
and their PAPP-A preparation contained easily detectable contaminating 
serum proteins. The goal of the purification procedure described in the 
present chapter was to obtain a highly purified preparation of PAPP-A 
suitable for the preliminary structural studies described in Chapter 6, 
The procedure incorporated an antibody affinity chromatography step 
followed by DEAE ion-exchange and gel filtration steps and has resulted 
in 448-fold purification of PAPP-A from term maternal serum.
Interpretation of yields and recovery data from the first 
two purification steps is difficult as precipitation is known to have 
occurred during dialysis of the concentrated eluate from the affinity 
column and the possibility that further precipitation may have occurred 
during application of the dialysed sample to the ion-exchange column 
cannot be excluded. Nevertheless, the anti-PAPP-A affinity chromatography 
step resulted in a considerable purification of PAPP-A (41-fold) with a 
yield of 20*8%. The second purification step, DEAE ion-exchange 
chromatography, resulted in a decreased (l4-fold) degree of purification 
of PAPP-A with a yield of 5%. However 130-fold purified PAPP-A was 
found in the ion exchange fractions selected for further purification.
The reason for the failure of this column to effect further 
purification of PAPP-A becomes apparent from inspection of Figure 5.2, 
PAPP-A was found to elute from the column over a relatively wide NaCl 
concentration range, namely 0*1 - 0*2 M, as a single peak with an
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extended descending limb containing a shoulder possibly due to a 
second peak. Since the linearity of the IMaCl gradient had been 
confirmed by measuring the specific conductivity of the eluate this 
pattern is unlikely to be due to discontinuities in the gradient but 
instead may suggest the presence of at least two species of PAPP-A in 
the material recovered from the affinity chromatography with different 
affinities for the ion-exchange column, the major species eluting as a 
peak with a maximum at 0*2 M NaCl, PAPP-A eluted in the same volume as 
two of the three protein peaks detected by adsorption at OC^gg whose 
maxima did not correspond to the maximum of the PAPP-A peak. Since the 
major objective was to obtain a highly purified and a most representative 
sample of the PAPP-A population with less regard being given to yield 
the highest purity fractions i,e, those corresponding in position to the 
lower half of the descendimg limb of the second protein peak were 
pooled for use in the next purification step. The elution profile of 
PAPP-A from the third and final purification column - Sepharose 68 gel 
filtration column - was more straightforward; PAPP-A eluted as a single 
peak which corresponded in position to one of the two protein peaks 
detected by absorption at other protein peak eluted in a
volume corresponding to the void volume of the column. The purified 
PAPP-A eluted in the same volume as the PAPP-A from term maternal 
serum fractionated previously over the same column: it can therefore be 
inferred that it did not suffer a gross alteration in molecular size 
during the process of purification. The Sepharose 6B column improved 
further the purity of the PAPP-A preparation: at the end of the 
purification procedure PAPP-A was found to have been purified 448-fold, 
The degree of purification was similar (427-fold) in the peak PAPP-A 
fraction used for iodination.
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The significance of the multiple AACE arcs formed by
partially-purified PAPP-A and by PAPP-A in term maternal serum before
any purification is unknown but suggests the existence of at least two 
overlapping immune reactions and therefore a degree of antigenic hetero­
geneity in the protein. The second arc within the main arc was easier to 
detect when partially purified preparations rather than term maternal 
serum were used as the source of PAPP-A; this appears to be due to a
lighter background within the arc formed by the partially-purified
PAPP-A due possibly to decreased contamination of the area within the 
arc by unrelated proteins. The antigenic variants which gave rise to , 
these arcs eluted together or close together from the chromatography 
columns and it may therefore be concluded that they are not separable 
by DEAE-cellulose ion-exchange or Sepharose 68 gel filtration.
An enzymatic method employing lactoperoxidase has been
chosen to radio-iodinate the purification product as it has been found
to minimise damage to labelled proteins, maintaining their structural
integrity (Miyachi and Chrambach, 1972) and resulting in preparations
with a high retention of immunological and other biological properties
• 1 25
(Miyachi et al., 1972; Krohn and Welch, 1974), Immunoreactive I- 
PAPP-A (identified as an AACE arc) accounted for almost 50% of the counts 
in the PAPP-A purification product labelled by the soluble lacto­
peroxidase method. Incorporation of very few immunoreactive serum proteins 
from this tracer into the AACE arcs was observed and the bulk of the 
contaminating material was of very slow electrophoretic mobility, A 
further iodination of the PAPP-A purification product was carried out 
by the soluble lactoperoxidase method. The elution pattern produced by 
this labelled purification product was very similar to that produced 
by the labelled lactoperoxidase, the product of the blank iodination, on
-1 52.
Sepharose 6B gel filtration except for one radioactive peak present in
the former eluate which was not detected in the latter. This peak was
identified as PAPP-A by solid-phase immune precipitation, Immunoreactive 
1 25I-PAPP-A eluted from the Sepharose 6B column in the same volume as 
PAPP-A from term maternal serum and it may therefore be concluded that 
it did not suffer any gross alteration in molecular size during 
iodination. The identity of the labelled species in the void in both 
fractionations has not been determined but it appears likely they are 
proteins damaged by the process of iodination, which have formed 
aggregates; several proteins are prone to this form of damage (see 
Bolton, 1977), In the case of the labelled purification product these 
aggregates may consist of lactoperoxidase, PAPP-A or contaminating 
serum proteins; which may be the same as the low electrophoretic 
mobility material detected on anti-serum AACE. The identity of the 
remaining peaks eluted from the Sepharose 68 column has not been 
established but as they are due to low molecular weight species it is 
most likely that they represent labelled lactoperoxidase ( molecular 
weight 77,500 daltons: Rombauts et al., 1967) and free ^^^lodine. In 
order to reduce contamination evidently resulting from the labelling of 
the lactoperoxidase molecules subsequent radio-iodinations employed 
lactoperoxidase covalently coupled to an insoluble matrix.
Analysis of the purification product labelled by the 
solid-phase lactoperoxidase method by electrophoresis on agarose gel 
revealed the presence of only three species. The species displaying the 
slowest mobility may have been detected previously in the purification 
product labelled by the soluble lactoperoxidase method as the slow 
electrophoretic mobility component on anti-serum protein AACE and the 
high molecular weight component (postulated to be due to aggregates) in
■153.
the void from Sepharose 68 gel filtration* The identity of the fastest
moving species associated with the Bromophenol Blue band has not been
125
established but a strong possibility is free Iodine non-covalently
bound to albumin in the carrier term maternal serum. The third species
of intermediate electrophoretic mobilityuere demonstrated to contain 
125
immunoreactive I-PAPP-A, The part of the arc formed by it on AACE
and detected autoradiographically which contained the maximum number of
counts and appeared most intense coincided with the arc detected by
protein staining: however the former arc extended slightly further
towards the cathodal end of the gel than the latter arc. This difference
is probably due to the greater sensitivity of autoradiography and its
125ability to detect the presence of a small number of I-PAPP-A
molecules. It may, however, indicate the presence of a small number of 
1 25
I-PAPP-A molecules of decreased electrophoretic mobility, too small 
to be detected by protein staining alone. Since only a single precipitin 
line was observed such molecules appear to be cross-reactive, Iodination 
damage resulting in decreased electrophoretic mobility of a proportion 
of molecules but an unaltered molecular size, as determined by 
Sepharose 68 gel filtration, and immunochemical reactivity, as 





The immunodiffusion plate shows cross-reactivities between: 
(a) Sheep anti-affinity purified PAPP-A antiserum 
and (b) Anti-PAPP-A antiserum of Lin and Halbert,
The antigens are;
(1) Pooled maternal serum
(2) Pooled adult serum
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FIGURE 5.2
Elution Profile of Protein and PAPP-A from DEAE-Cellulose
Column.
For details of column preparation and use see text.
The optical density due to the proteins was measured using 
a Uvicord II at 280 nm, and the trace is shown as a heavy fluctuating line. 
The specific conductivity of the eluate is indicated by a 
broken line: arrows indicate IMaCl concentrations.
The set of points joined by a line indicates the heights of 
the PAPP-A precipitin arcs produced on one-dimensional AACE by PAPP-A- 
containing eluate fractions.
The letters A,B,C indicate those fractions selected for 
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FIGURE 5,3
Elution Profile of Proteins and PAPP-A from the Sepharose
CL 68 Column.
For details of column preparation and use see text.
The optical density due proteins was measured using a 
Uvicord II at 280 nm. on eluate reulting from:
(l) The fractionation of term maternal serum 
and (2) Fractions A,B,C from ion-exchange chromatography: see 
Figure 5.2.
Their tracers are shown as:
(l) A heavy fluctuating line
and (2) A broken fluctuating line --------
respectively.
The first protein peak in each profile corresponds to the 
void volume of the column.
The position of PAPP-A-containing fractions in eluates
is also shown. The rocket height on the right abscissa refers to the 
heights of the rockets produced by PAPP-A in eluate fractions on one­
dimensional AACE. In all cases 20 microlitre aliquots of eluate 
fractions were tested on AACE.
Curve (3) is the optical density tracer which resulted from 
fractionation of the product of a pilot PAPP-A purification 
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FIGURE 5.4
Morphology of AACE Arcs Formed by Partially-Purified 
PAPP-A and PAPP-A in Pooled Term Maternal Serum,
The antigens on Plate _a are :
(l)“(5) PAPP-A in eluates from consecutive slices of polyacrylamide 
tube gels obtained after electrophoresis of the small-scale purification 
product.
The antigens on Plate Jb are:
(m s ) PAPP-A in pooled term maternal serum
(l)-(9) PAPP-A in consecutive eluate fractions from DEAE-Sephadex
ion-exchange chromatography column; see Figure 5.2,
Fractions 6,7,8 correspond to fractions A,B,C in Table 5*2 
The antigens on Plate £  are:
(m s ) PAPP-A in pooled term maternal serum
(l)_(7) PAPP-A in consecutive PAPP-A-containing eluate fractions
from Sepharose CL-6B gel filtration column: see Figure 5,3,
Fraction 5 is the peak PAPP-A fraction in Table 5,2,
The antisera are:
Plate £  - 10% rabbit anti-PAPP-A 
Plates _b! & £  - 10^ sheep anti-PAPP-A.
A A *
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FIGURE 5.5
1 25Autoradiograph of One-Dimensional AACE Arcs Formed by I-
PAPP-A in the Purification Product Labelled by the Soluble LPO Method.
The antiserum is 3% sheep anti-PAPP-A.
The antigens are;
125
(1) 10 microlitre I-labelled purification product
(2) 10 microlitre ^^^I-labelled purification product added to
10 microlitre pooled term maternal serum
125
(3) 10 microlitre I-labelled purification product added to 
10 microlitre pooled non-pregnant adult serum.





Autoradiograph of Two-Dimensional AACE Pattern Formed by
125I -serum Proteins in Non-Pregnant Adult Serum and in the Purification
Product Labelled by the Soluble LPD Method.
The antigen wells are marked ^  and The circular mark to
the right of each antigen well represents the mobility of albumin in the
first dimension electrophoresis.
The antigens are:
1 25(a) 10 microlitre I-labelled pooled non-pregnant adult
serum added to 1*5 microlitre pooled non-pregnant adult serum
125
(b) 10 microlitre I-labelled purification product added to 
1*5 microlitre pooled non-pregnant adult serum.
The antiserum is 10^ sheep anti-human serum.
The autoradiograph was developed for 3 hours.
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FIGURE 5.7
Sepharose CL 68 Gel Filtration of the Purification Product 
Labelled by the Soluble LPO Method and Material Resulting from Blank 
Xddination by the Soluble LPO Method.
For details of column use see text.
Legend:
cps in fractions resulting from fractionation of the 
labelled purification product.
0 - 0  cps in fractions resulting from fractionation of the 
product of blank iodination*
% cps bound to anti-PAPP-A Sepharose in solid phase immune 
precipitation.











Electrophoretic Separation of the Material Resulting from 
Iddination of the Purification Product by the Solid-Phase LPO Method.
For experimental details see text.
The first radioactive peak (gel slice 7) corresponds to the 
position of the antigen well.
125
1_ indicates the position of the I-PAPP-A precipitin arc 
detected by autoradiography (see Figure 5.9),
2 indicates the position of the Bromophenol Blue band.
Correction : Gel slice 7 contained 1*42 x lo"^  c.p.100s. not 4*2 x 10"^  c. 
p,1DDs, as indicated on the graph.
cpIOOl
1 X 1  O '
1X10^
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Autoradiograph of the Two-Dimensional AACE Pattern Formed
1 25
by I-PAPP-A in the Purification Product Labelled by the Solid-Phase 
LPO Method
The antiserum is 20^ sheep anti-PAPP-A,
The antigen is 5 microlitre PAPP-A purification product 
labelled by the solid-phase LPO method added to 5 microlitre pooled 
term maternal serum.
The tracing of the precipitin arc detected on the AACE 
plate stained for protein has been superimposed over the autoradiograph, 
O  =  albumin




The purification and iodination of PAPP-A from term 
maternal serum was described in Chapter 5, The molecular weight of 
PAPP-A has been estimated as 750,000 daltons by Lin et al. (1974) but 
no information relating to its subunit structure was available prior 
to the present study being undertaken. Studies were therefore carried 
out on labelled PAPP-A in the purification product whose production 
was described in Chapter 5 in order to gain an insight into its 
subunit structure.
Labelled PAPP-A in the purification product was analysed 
by SDS polyacrylamide gel electrophoresis. Initially analyses were 
performed on immune precipitated PAPP-A from the PAPP-A purification 
product labelled by the soluble lactoperoxidase method. These 
experiments employed 10^ SDS polyacrylamide tube gels and a 1% SDS 
polyacrylamide slab gel. The information gained from these analyses 
was used to select more suitable concentrations of polyacrylamide 
for the analysis of PAPP-A from the purification product labelled 
by the solid phase lactoperoxidase method.
1.2 Materials and Methods
1 25
A. Analysis of I-PAPP-A from the Purification Product Labelled by
the Soluble Lactoperoxidase Method
10^ SDS Polyacrylamide Tube Gel Electrophoresis 
125
I-PAPP-A from the labelled purification product was
immuno-precipitated on an AACE plate containing sheep anti-PAPP-A
antiserum! see Chapter 5, Section 2b.2. The areas of the gel from the
125
AACE plate containing precipitin arcs formed by I-PAPP-A in the 
purification product which had been applied to the AACE plate alone
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(arc Figure 5*5) or together with either pooled maternal serum
(arc 2, Figure 5.5) or pooled non-pregnant adult serum (arc 3, Figure
5.5) were excised with a scalpel. The radioactivity in each precipitin-
containing piece of gel was measured in an LKB Ultragamma counter and
the gel was boiled for 5 minutes in 50 microlitres of ^ dilution of the
standard SDS extraction buffer (Maizel, 1971; Marsden et al.. 1976).
The molten agarose-SDS-tracer mixture was pipetted onto tube gels where
it cooled and set before the upper reservoir buffer was added. 5 micro-
litres of the same labelled purification product (17,900 c.p.s.) was
added to 25 microlitres of tank buffer and 15 microlitres of the
standard SDS extraction buffer and boiled for 5 minutes. All four
samples were subjected to SDS polyacrylamide gel electrophoresis
(method according to Maizel, 1971) in 10^ polyacrylamide gels. After
electrophoresis gels were snap-frozen in liquid nitrogen and sliced
into 65 fractions using a Mickle gel slicer (Gomshall, Surrey), The
radioactivity in each fraction was measured in a LKB Ultragamma counter,
7% SDS Polyacrylamide Slab Gel Electrophoresis 
1 25
I-PAPP-A was extracted from the labelled purification 
product by solid phase immuno-precipitation. 10 microlitres of the 
purification product (35,800 c.p.s.) was added to a tube containing 
100 microlitres of 10^ slurry of anti-PAPP-A-Sepharose in 2% horse 
serum-phosphate buffer (50 mM KgPO^ buffer, pH 7*5, containing 2% 
Wellcome Type 5 horse serum). For details of the anti-PAPP-A-Sepharose 
preparation see Chapter 5, Section 2a,2. The tube was incubated over­
night on a gyratory shaker at 4°C. After centrifugation to remove the 
supernatant the Sepharose was washed four times with 2% horse serum- 
phosphate buffer, the supernatant being removed each time by centri­
fugation. At the end of the washing cycle the supernatant was removed
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replaced with 40 microlitres of 2% horse serum-phosphate buffer. 25 
microlitres of the standard SDS extraction buffer was then added to 
the Sepharose and the resultant slurry boiled for 5 minutes. The 
slurry was then centrifuged and the supernatant analysed by SDS poly­
acrylamide slab gel electrophoresis. A set of five calibrated viral 
polypeptides was applied to a separate track on the same SDS poly­
acrylamide slab gel. The SDS polyacrylamide slab gel was run according 
to the method of Marsden et al. (1976) but using a uniform 1% 
concentration of acrylamide in the resolving gel. Following electro­
phoresis the slab gel was dried and subjected to autoradiography
using Kodirex (Kodak) X-ray film.
1 25
B. Analysis of I-PAPP-A from the Purification Product Labelled by
the Solid-Phase Lactoperoxidase Method
S% and 3% SDS Polyacrylamide Tube Gel Electrophoresis 
1 25
I-PAPP-A was extracted from the labelled purification 
product by solid-phase immunoprécipitation, 50 microlitre aliquots of 
the labelled purification product were added to each of the following 
four tubes: two tubes containing 25 microlitres of 50^ slurry of anti- 
PAPP-A-Sepharose in 2% horse serum-phosphate buffer each and two 
control tubes containing 25 microlitres of 50^ slurry of horse serum- 
Sepharose in 2% horse serum-phosphate buffer each. For details of the 
anti-PAPP-A-Sepharose preparation see Chapter 5, Section 2a.2. Horse 
serum had been conjugated to Sepharose 48 by the CNBr reaction (Porath 
et al., 1976). A control set of four tubes containing 50 microlitre 
aliquots of the product of "blank” iodination by the soluble lacto­
peroxidase method instead of the labelled PAPP-A purification product 
was also set up. The tubes were incubated overnight on a gyratory 
shaker. The radioactivity in each tube was measured in an LKB Ultra-
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gamma counter. After centrifugation to remove the supernatant the 
Sepharose in each tube was washed four times with 2% horse serum- 
phosphate buffer, the supernatant being removed each time by 
centrifugation. At the end of the washing cycle the supernatant 
was removed and the radioactivity in each tube measured in a LKB 
Ultragamma counter.
Cross-linked bovine serum albumin (BSA) and cross- 
linked aldolase for use as molecular weight standards were kindly 
provided by Dr Bohn R, Coggins (Department of Biochemistry,
University of Glasgow). Cross-linked BSA contained the following 
molecular weight species; 68,GOO; 136,000; 204,000; 272,000; 340,000;
408,000 daltons. Cross-linked aldolase contained the following 
molecular weight species: 40,000; 80,000; 120,000; 160,000 daltons.
Boiling mix for use in this experiment was made up of 
20 mM dithiothreitol (DTT) and 2% SDS in lOmM Na^PO^, pH 7*5. 200 
microlitres of this boiling mix was added to anti-PAPP-A-Sepharose 
which had been incubated with the labelled PAPP-A purification 
product (combined contents of tubes 1 and 2; Table 6.1), The resultant 
slurry was incubated overnight on a gyratory shaker at room temperature, 
following which the sample was boiled for 5 minutes. The slurry was 
centrifuged and a 5 microlitre aliquot of the supernatant counted 
in a LKB Ultragamma counter. 85 microlitre aliquots of the supernatant 
were applied to 5% and 3% SDS polyacrylamide tube gels together with 
10 microlitres of 0*1% bromophenol blue and 10 microlitres of glycerol. 
100 microlitre aliquots of cross-linked BSA and cross-linked aldolase 
solutions were each added to 50 microlitres of boiling mix and boiled 
for 5 minutes. 20 microlitres of the aldolase-boiling mix solution was 
then applied to a 5^ polyacrylamide tube gel and 40 microlitres of the
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BSA-boiling mix solution was applied to a 3% polyacrylamide tube gel.
In addition, 10 microlitres of 0*1% bromophenol blue and 10 microlitres
of glycerol were also added to each gel. SDS polyacrylamide tube gel
electrophoresis was carried out as described by Maizel (1971).
After electrophoresis the tube gels containing molecular
weight markers were stained with 0*2% Coomassie blue and scanned at
600 nm. in a Gilford spectrophotometer fitted with a Model 252 gel
scanner. The mobility of any bands present was determined as:
distance of band from origin________ _
^f~ distance of bromophenol blue band from origin 
Using the densitometer traces plots were made of vs. logarithm
of molecular weight for each series of cross-linked markers. The
tube gels containing radioactive samples were snap-frozen in liquid
nitrogen and sliced into approximately 20 fractions each using a
Mickle gel slicer. The radioactivity in each fraction was measured




A. Analysis of I-PAPP-A from the Purification Product Labelled by
the Soluble Lactoperoxidase Method
10^ SDS Polyacrylamide Tube Gel Electrophoresis
The material extracted from each of the three AACE 
1 25precipitin arcs formed by I-PAPP-A in the purification product 
resolved into a single radioactive band on 10^ SDS polyacrylamide 
gel electrophoresis. This band was situated near the top of each gel. 
The level of radioactivity in the area of the gel containing the 




I-PAPP-A from the same labelled purification product
which had not been precipitated on AACE resolved into two radioactive
bands on 10^ SDS polyacrylamide tube gel electrophoresis; a major band
at the top of the gel and a minor band in the upper quarter of the gel*
As in all the other gels, the level of radioactivity in the area of
the gel containing the bromophenol blue marker was slightly raised
above the baseline. The results are shown in Figure 6.1,
1% SDS Polyacrylamide Slab Gel Electrophoresis
The material immuno precipitated from the labelled PAPP-A
purification product on anti-PAPP-A-Sepharose and subjected to SDS
polyacrylamide slab gel electrophoresis formed an area of intense
radioactivity at the junction of the loading and the running gels.
The largest of the viral polypeptides examined - 156,000 daltons
molecular weight - was found in the running gel; see Figure 6,2,
In the experiments just described penetration of the
1 25
major radioactive component in the immune precipitated I-PAPP-A
into 10% SDS polyacrylamide tube gels and a 1% SDS polyacrylamide
slab gel was insufficient to allow molecular weight determination.
Polyacrylamide gels with a smaller degree of cross-linking - 3% and
3% - were therefore chosen for the purpose of determining the molecular
weight of PAPP-A subunits,
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B, Analysis of I-PAPP-A from the Purification Product Labelled by
the Solid Phase Lactoperoxidase Method
5% and 3% SDS Polyacrylamide Tube Gel Electrophoresis
Aliquots of the labelled PAPP-A purification product 
and the product of "blank" iodination by the soluble lactoperoxidase 
method were incubated with anti-PAPP-A-Sepharose and horse serum- 
Sepharose and the percentage of counts immobilized on Sepharose
.170.
determined. The results are shown in Table 6.1.
The plots of mobility (R^) vs, logarithm of molecular
weight for cross-linked aldolase and BSA markers were linear over the
molecular weight range 40,000 - 160,000 for aldolase and 68,000 -
408,000 for BSA; see Figure 6,3, The distribution of counts in the
3% and 3% SDS polyacrylamide gels containing immune precipitated 
125
I-PAPP-A is shown in Figure 6.4, Both gels contained two radio­
active peaks; in each the second peak was detected as a shoulder on 
the descending limb of the major peak. The molecular weight of the 
radioactive components detected on 5% and 3% gels was estimated from 
plots a and b (Figure 6.3) respectively* The molecular weight of the 
major protein component detected in the 5% gel (peak 1 ; Figure 6.4a) 
was estimated by extrapolation of plot a (Figure 6,3) to be around 
180,000. The molecular weight of the minor protein component detected 
in the 5% gel (peak 2; Figure 6,4a) was estimated directly from plot a 
(Figure 6,3) as 74,000. The molecular weight of the major protein 
component detected in the 3% gel (peak 1; Figure 6.4b) was estimated 
directly from plot b (Figure 6.3) as 180,000, The molecular weight 
of the minor protein component detected in the 3% gel (peak 2; Figure 
6.4b) was estimated directly from plot b (Figure 6.3) as 93,000, These 
findings are summarised in Table 6,2.
1,4 Discussion
1 25
10^ SDS polyacrylamide tube gels of total I-labelled
PAPP-A purification product labelled by the soluble lactoperoxidase 
1 25method and I-PAPP-A extracted from AACE precipitin arcs all 
contained a radioactive band located very near the top of each gel.
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origin of the radioactivity associated with the bromophenol blue
1 25band in each gel is unknown but it may represent free Iodine
(as in Figure 5.7). The identity of the minor radioactive band
1 25detected only on the SDS polyacrylamide gel of total I-labelled 
PAPP-A purification product is unknown but a strong possibility 
must be lactoperoxidase protein, since Sepharose 68 gel filtration 
has already indicated this protein as the main contaminant of the 
PAPP-A purification product labelled by the soluble lactoperoxidase 
method.(see Figure 5,7), 1% SDS polyacrylamide slab gel electrophoresis 
of solid phase immune precipitated PAPP-A labelled by the soluble 
lactoperoxidase method revealed that the main component was a species 
of slow mobility and molecular weight greater than about 150,000 
daltons. It was therefore concluded that the molecular weight of 
PAPP-A subunits was greater than 150,000 daltons.
Incubation of duplicate samples of : (l) PAPP-A 
purification product labelled by the solid phase lactoperoxidase 
method and (2) product of "blank" iodination by the soluble lacto­
peroxidase method (ie, labelled lactoperoxidase) on anti-PAPP-A- 
Sepharose and on horse serum-Sepharose produced remarkably consistent 
results (Table 6.1), The extent of non-specific retention of counts 
from labelled lactoperoxidase was fairly high and constant (8*2%'—
8*3%) on both anti-PAPP-A-Sepharose and horse serum-Sepharose, The 
extent of non-specific retention of counts from labelled PAPP-A 
purification product on horse serum-Sepharose was much smaller (3*8%) 
and a significant difference was observed in the amount of counts 
retained from PAPP-A purification product on anti-PAPP-A-Sepharose 
(29%), This finding suggests that the bulk of material retained from 
PAPP-A purification product labelled by the solid phase lactoperoxidase
.174.
method on anti-PAPP-A-Sepharose was adsorbed by a specific immuno­
logical reaction,
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Analysis of solid phase immune precipitated I-PAPP-A 
from the purification product labelled by the solid phase lacto­
peroxidase method on 5% and 3% SDS polyacrylamide tube gels revealed 
the presence of two components of different molecular weight on each 
(Figure 5.4), As predicted-, penetration of these components into the 
gels was sufficient to allow molecular weight determination. The 
molecular weight of the major component was determined as approximately
180,000 daltons (Table 6.2). The molecular weight of the minor . 
component was estimated as 74,000 daltons on the 5% gel and 93,000 
daltons on the 3% gel. The different values obtained for the molecular 
weight of the minor component may be due to different standards used 
to calibrate the gels or alternatively it may indicate the presence 
of two or more closely migrating minor components. The nature of the 
minor component (or components) is unknown, but one possibility is 
that it represents a product of poteolysis. One way of testing this 
possibility would be to examine the degradation products produced by 
treatment of PAPP-A with trypsin. At present, however, it is not 
possible to decide on the basis of the available evidence whether 
the 74,000 - 93,000 component(s) is a subunit of PAPP-A, a degradation 
product of a subunit of PAPP-A or a contaminating protein polypeptide 
(for example lactoperoxidase).
On the evidence of the findings described here it may 
be concluded that PAPP-A, whose molecular weight has been estimated 
as 750,000 daltons (Lin et al., 1974) contains polypeptide subunits 
of approximately 180,000 daltons and may therefore be composed of 
up to four such subunits. In addition it may also contain subunits
.175.
of molecular weight between 74,000 - 93,000 daltons. Confirmation 
of the findings described here and further investigations, such as 
treatment with urea under reducing and non-reducing conditions (to 
establish the number of disulphide-linked subunits present) will have 
to await purification of a sufficiently large quantity of PAPP-A to 
allow analysis to be carried out directly on the unlabelled protein. 
Since PAPP-A is a glycoprotein (Lin et al.. 1974), final interpretation 
of the results of SDS polyacrylamide gel electrophoresis will also 
have to await determination of its carbohydrate content. This is 
especially so since it is known that glycoproteins containing more 
than 10% carbohydrate behave anomalously during SDS polyacrylamide 
gel electrophoresis when compared to standard proteins (Bretscher,
1971; Segrest et al., 1971); they show decreased mobility and a 
higher apparent molecular weight. Different approaches may therefore 
be necessary for the estimation of their actual molecular weight 
(Segrest and Backson, 1972),
•1 76.
FIGURE 6.1
Analysis of the PAPP-A Purification Product and of Immune-
125
Precipitated I-PAPP-A by 10% SDS Polyacrylamide Tube Gel Electrophoresis
The PAPP-A purification product had been labelled by the 
soluble lactoperoxidase method.
Polyacrylamide gels were sliced following electrophoresis 
and the radioactivity in each slice measured.
The gels are;
(l) Labelled purification product (17,908 c.p.s, applied)
*#-#- (2) Material extracted from the AACE precipitin arc formed
125 ,
by I-PAPP-A in the labelled purification product (16,057 c.p.s,
r \ .
applied)
— (3) Material (2) above together with pooled term maternal 
serum which had been added to the AACE plate (17,601 c.p.s, applied)
(4) Material (2) above which had been added to the AACE 
plate together with pooled non-pregnant adult serum^(16,459 c.p.s, 
applied).
The smallest radioactive peak near the bottom of each of 






Analysis of Immune Precipitated i-PAPP-A by 1% SDS
Polyacrylamide Slab Gel Electrophoresis
Track (a) shows the mobility of a set of five calibrated 
viral polypeptides which are marked by black dots to the left of the 
track. Their molecular weights are 156,000, 136,000, 120,000, 66,000, 
and 42,000 daltons.
The PAPP-A purification product had been labelled by the 
soluble lactoperoxidase method.
In track (b) is ^^^I-labelled PAPP-A which had been 
dissociated from anti-PAPP-A-Sepharose,
The origin and cathode are at the top of the gel. Part of
the loading gel has been excluded from the plate. The horizontal line
marked by a star to the right of the gel - shows the interface between
the loading and the running gels.
-178-
FIGURE 6,3
Plot of Mobility (Rp) vs. Logarithm of Molecular Weight
(a) Cross-linked aldolase subjected to electrophoresis in 5^ 
SDS polyacrylamide tube gel.
(b) Cross-linked BSA subjected to electrophoresis in 3^ SDS 
polyacrylamide tube gel.
Molecular weight of the species in cross-linked aldolase; 
40,000; 80,000; 120,000; 160,000.
Molecular weight of the species in cross-linked BSA:
68,000; 136,000; 204,000; 272,000; 340,000; 408,000.
 ^ Distance of band from origin
f ca cu a e as. Distance of Bromophenol Blue band from origin
M.W.
1X10
03 04 0 5 06 07 08 0-9
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FIGURE 6.4
Radioactivity in Slices of (a) 5% and (b) Z% SDS-
Polyacrylafnide Tube Gels Following Electrophoresis of Immune-Precipitated
125
' I-PAPP-A
The PAPP-A purification product had been labelled by the
125
solid-phase lactoperoxidase method, I-PAPP-A was dissociated from 
anti-PAPP“A“Sepharose and 4,220 c,p,s, applied to each gel.
The peaks are numbered (1 ) and (2), The arrow indicates the 
position of the bromophenol blue band.
%■180.




The possibility that placental-specific proteins might 
be of use in the diagnosis of certain complications of pregnancy has 
been examined in Chapter 1 section 4,1. Prior to the present work 
being undertaken the only published work on the application of PAPP-A 
to obstetric diagnosis has been a study by Lin and his colleagues (1977), 
Their findings indicated that PAPP-A concentration may be increased by 
toxemia, but is not affected in pregnancies complicated with insulin- 
dependent diabetes. In the present study the concentration of PAPP-A 
in the blood during normal pregnancies and pregnancies complicated by 
intrauterine growth retardation, diabetes or a variety of other conditions 
was assayed by antibody-antigen crossed electrophoresis (AACE), The 
assay employed the monospecific sheep anti-PAPP-A antiserum which I 
prepared previously (see Chapter 5 section 2,a,2),
2. MATERIALS AND METHODS
The concentration of PAPP-A in the serum of 53 patients 
attending the University Hospital in Aberdeen was assayed by the
author. Samples of blood collected from these patients were kindly
provided by Dr C.U, Horne (Department of Pathology, Department of 
Medicine, Aberdeen), The composition of this group of patients was 
as follows: - normal pregnancies (34 patients); pregnancies complicated 
by intrauterine growth retardation (19 patients). As my research was 
drawing to a close, a further 294 patients were made available by 
our clinical colleagues. Dr C.U. Horne (Aberdeen) and Dr A.B, MacLean 
(formely of Department of Midwifery, Queen Mother Hospital, Glasgow;
■1 82.
currently of Department of Obstetrics and Gynaecology, University of 
Christchurch, New Zealand). Of these 294 patients, 249 were attending 
Queen Mother’s Hospital, Glasgow; the remaining 45 patients were attending 
the University Hospital in Aberdeen. The composition of the two groups 
of patients is summarised in Table 7.1. Noteworthy in particular are 
the 45 diabetic patients from Aberdeen. Using my antiserum, my supervisor 
carried out the necessary AACE assays with the technical assistance of 
S. Gibb.
The clinical status of all of the patients was assessed 
without knowledge of the concentration of PAPP-A in their blood. 
Biochemical and immunochemical methods
In most cases blood was collected, allowed to clot and 
the serum was kept for PAPP-A analyses. In some cases plasma was 
obtained from blood treated with lithium-heparin. Data has been 
presented by Sutcliffe et al. (1981) which shows that the level of 
PAPP-A measured in blood is not affected by this anti-coagulent. After 
centrifugation, serum and plasma samples were divided into aliquots 
and stored at -20^ C.
The concentration of PAPP-A was assayed by the one­
dimensional antibody-antigen crossed electrophoresis method of Laurell 
(1966) with the modification that 100 mM-tris was present in the gel 
and tank buffers, A further modification was that the direction of 
current flow in the electrophoresis tank was reversed after 3 hours 
(the orientation of the AACE plates was also reversed). The latter 
method was adopted by Lin et al. (l974b), since the buffer capacity 
of the system is too small to support electrophoresis in one direction 
for 17 hours without changes in the pH occuring. During electrophoresis, 
Sutcliffe and Gibb found that pH differences of as little as 0*2 pH
-183.
TABLE 7.1
Details of the patients included in the study
Glasgow Series Aberdeen Series
A,Normal Pregnancies 107 34
B,Pregnancies with Complications;
Intrauterine growth retardation 18 19
Diabetes
i. Insulin-treated 15
ii. Gestational - 30
Oedema of the leg/ankle 7
Elevated blood pressure
i. During pregnancy only 10
ii. Outwith pregnancy also 4
Large infant, weight over 4 kg. 5
Abnormal maternal weight gain 9 -
Twins 4
Spontaneous abortion 4
Threatened abortion 8 -
Premature labour 12





ii. Fetal distress 3






units were accompanied by blurring and elongation of the precipitin 
arcs. The antiserum used for AACE was monospecific sheep anti-PAPP-A 
(for details of preparation see Chapter 5 section 2,a,2) at a final 
concentration 1*2% (v/v). Between 2 and 20 microlitre of patient serum 
(or plasma) was added to the sample wells. All samples were assayed in 
duplicate, each duplicate being carried out on two separate occasions.
The mean concentration of PAPP-A is expressed in microgram, per ml., 
based on a primary standard of purified PAPP-A (Sutcliffe et al,, 1980), 
For reliable quantitation, the present assay has a sensitivity of 9*5 
micogram* PAPP-A per ml, (13 pmole per ml.).
The determination of PAPP-A concentrations was carried 
out on coded samples.
Statistical methods
Statistical analysis was performed by A.U, Bowman (Department 
of Statistics, University of Glasgow) and my supervisor.
Preliminary plotting and data sorting was carried out 
using the statistical computing package, MINITAB (Ryan et al,. 1976), 
Statistical analyses were carried out on observations made after the 
twenty-eighths week of gestation only since there was little information 
on complicated pregnancies before this period. The square root trans­
formation was applied to the data to remove skewedness. Analyses of 
variance (Scheffe, 1959) were used in three different situations, as 
follows ;
(a) An examination for the control data of the effect of
the baby's sex and place of birth (Aberdeen or Glasgow),
(b) For the Aberdeen series, the effect on PAPP-A levels
of both the sex of the baby and the presence of maternal complications,
(c) As for (b) but including the Glasgow data as well. In
•185.
each case models were fitted using the statistical computing package: 
GLIM (Baker and Nelder, 1978),
In a considerable number of patients repeated blood samples 
were obtained at different stages of gestation. This was especially in 
the case of the Aberdeen series. As this might induce correlations the 
statistical analyses were repeated after all but one (randomly chosen) 
sample had been omitted from each of these patients. The conclusions 
obtained were similar to those resulting from the full data set. After 
the analyses of variance had shown that there was a significant effect 
due to complications of pregnancy, the technique of multiple comparisons 
(Scheffe, 1959) was used to identify which of the complications were 
associated with significant differences in PAPP-A levels (Wallenstein 
at al. (1980) have provided a critic of this type of analysis,),These 
analyses were carried out on data after 28 weeks of pregnancy: when 
the concentration of PAPP-A was rising. It was therefore a possibility 
that any apparent difference in mean PAPP-A values between two groups 
of patients might be due to differences in the distribution of samples 
during pregnancy, rather than to a real difference in PAPP-A levels 
at comparable stages of gestation. This possibility was excluded by 
testing subsets of the results,
3. RESULTS
PAPP-A in the peripheral blood during normal pregnancy
PAPP-A was first detected by AACE from 14 weeks of 
pregnancy in normal patients. As normal pregnancy proceeded, levels 
rose (Figure 1) and individual values became scattered with a skewed 
distribution (Figure 2), This skewedness also occured in some of the
-186.
groups of complicated pregnancies (Figure 2), To reduce this skewedness 
and to permit parametric statistical analyses, the data were transformed 
by expressing values as the square root of the PAPP-A concentration. For 
this reason, the results in Figure 1 have been plotted on a square root, 
not a linear scale.
An analysis of variance revealed no significant difference 
between the controls for the Aberdeen and Glasgow series. For the 
Aberdeen series, there was no detectable effect of the babies' sex on 
PAPP-A values. However, from about 28 weeks of pregnancy until term it 
seemed that normal pregnancies in the Glasgow series had somewhat greater 
PAPP-A values if the baby was a male rather than a female. This was 
confirmed by an analysis of variance,
Sutcliffe and Bowman investigated the possibility of 
relationships between the weight of the baby at delivery and the 
concentration of PAPP-A in maternal serum, Male and female babies were 
distinguished and divided into four groups according to the following 
periods of pregnancy: 14-20 weeks, 21-30 weeks, 30-36 weeks, 37-42 weeks 
and 38-41 weeks. In no case did any correlation or even the suggestion 
of a trend appear. Similarly, no effect of parity was detected,
PAPP-A in peripheral blood of complicated pregnancies 
Growth retardation
No significant differences were detected when patients with 
intrauterine fetal growth retardation were compared with controls (Figure 
2), In this group the weight of the baby at delivery ranged from 0*94 to 
2-50 Kg,
Diabetes
When insulin-treated diabetics were compared with gestational 
diabetics and controls (Figures 2, 3 and 4), analysis of variance and
•187.
multiple comparisons showed that insulin-treated diabetics had 
significantly lower levels of PAPP-A in their blood than had controls 
or gestational diabetics. No significant differences could be 
detected between gestational diabetics and controls, although the 
former had a very wide range of values including some of the highest 
in the study. No effect of the sex of the baby was noted on PAPP-A 
values,
Other complications
PAPP-A values for all the other complication (see Table 
7.1) were plotted out against gestation. No significant differences 
from control values were observed,
4, DISCUSSION
The concentration of PAPP-A in the blood of patients at 
term ranged from 0*03 to 0*31 mg, per ml. This compares well with the 
results of Hughes et al, (1980) who based their data on a standard of 
pure PAPP-A which was purified in a different manner (Bischof, 1979) to 
the protein standard used in the present work: see Sutcliffe et al,, 
1980, In the control data of the Glasgow series, fetal sex was found 
to significantly effect PAPP-A values with males' levels being 
somewhat higher than females' levels from 30 weeks of gestation onwards, 
In the last 10 weeks of gestation in the Glasgow series the mean PAPP-A 
value for females was 68^ of that in males, A similar effect of fetal 
sex on PAPP-A values was observed by Lin et al, (1974b), In their study 
during the last month of gestation the mean PAPP-A value for female 
fetuses was approximately 66^ of the value in male fetuses. However in 
the present work a significant sex difference was not observed in the
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other classes of patients and in particular in the Aberdeen controls. 
This discrepancy between the Aberdeen and Glasgow series is difficult 
to account for. Both sets of control patients were selected on a 
random basis from the out-patient clinic. The only difference apart 
from geographical location seems to be that the Aberdeen controls 
included many more repeat samples than the Glasgow controls: the 
relatively fewer individual pregnancies screened may have resulted in 
poor sampling. One can only conclude that a sex difference may contrit 
bute to the variance in PAPP-A values in the latter part of the 
pregnancy.
Prior to the present study being undertaken there had 
been no reports in the literature on studies on the effect of 
intrauterine growth retardation on levels of PAPP-A in maternal blood. 
Intrauterine growth retardation is a diagnosis made at birth when the 
baby’s weight is in or below the tenth percentile of the mean weight 
for gestation. These small-for-weight babies are subject to a higher 
neonatal mortality and morbidity. Since the probable cause of intra­
uterine growth retardation is fetal malnutrition (Naeye, 1965) 
attention has in recent years been focussed on the in utero diagnosis 
of this condition. The most common test hitherto employed combines 
serial ultrasonic cephalometry with serial estriol excretion 
measurements. This combination of tests has stood favourable 
comparison with other methods including the measurement of HPL 
concentration in maternal blood (Robinson et al,, 1973, 1974), However 
as has been previously observed (Chapter 1, Section 4,1) the estrogen 
excretion test is not completely reliable. The measurement of creatine 
in amniotic fluid has been found to be useful in assessing fetal 
maturity (Begneand et al,, 1969) but is less convenient to perform
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than the measurement of substances in maternal blood or urine, A rapid 
method for assessing intrauterine growth retardation by radioactive amino 
acid uptake by the placenta has been described by Garrow and Douglas 
(1968), This method however suffers from several drawbacks such as low 
uptake ratios and the need to introduce radioactive substances into the 
body.
The full potential of assays of placental-specific proteins 
in maternal blood will not be understood until the physiological 
function of these proteins and the relationship between their production 
and other aspects of placental function, such as transport, is known. 
Nevertheless studies are currently in progress aimed at establishing 
which, if any, of the placental-specific proteins may be of practical 
value in the prediction of intrauterine growth retardation: see Chapter 
1, Section 4.1, The application of the HPL test to intrauterine growth 
retardation diagnosis has been the subject of more studies than any 
other placental-specific protein* These studies have yielded contradictory 
results (see Chapter 1, Section 4.1; Spellacy et al., 1966; Sciarra ejk 
al., 1968; Saxena et al., 1969; England et al., 1974; Lindberg and 
Nilson, 1974; Kelly et al., 1975) and the test has no established 
clinical use, Spellacy et al, (1974) in a large series found that the 
women most likely to have abnormally low HPL concentrations in the third 
trimester of pregnancy are those in which intrauterine growth retardation 
arises secondary to other diseases such as pre-eclampsia or chronic 
renal disease. Low levels of another placental-specific protein, SP1, 
in the third trimester of pregnancy have been reported to be associated 
with intrauterine growth retardation (Tatra 1977) and the SP1 test has 
been claimed to be of greater value than HPL in predicting intrauterine 
growth retardation (Gordon et al., 1977; Towler et al,, 1977; Horne et
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al,, 1979), All the other placental-specific proteins investigated have 
proved disappointing in clinical practice. In the present study no 
significant differences in the levels of PAPP-A in third trimester 
maternal blood were detected when patients with intrauterine growth 
retardation were compared with normal pregnant women. An independent 
study by Hughes et al, (1980) has yielded similar results. These 
findings indicate that PAPP-A concentration in maternal blood may not 
be used as an index of placental efficiency and fetal nutrition.
This is one of the first reports on the concentration of 
PAPP-A in gestational as well as insulin-dependent diabetic pregnancies. 
Previously Lin et al, (1977) had found no significant difference 
between 26 insulin-dependent diabetes and controls during the last 
month of pregnancy. They did not study gestational diabetes. Pregnancy 
is a diabetogenic experience which increases insulin needs in the 
established diabetic. Advancing pregnancy imposes a progressive stress 
on the pancreatic beta cell reserve and, where the effective insulinogenic 
reserve is inadequate, abnormal carbohydrate metabolism ensues and 
gestational diabetes. Diagnosis of diabetes in pregnancy may be 
accomplished by means of several tests of insulinogenic reserve in 
addition to the standard glucose tolerance tests (Kaplan, 1961; Kyle 
et al,, 1964; Mestman et al,, 197l), There appears to be a stage of 
diabetes which is incapable of identification biochemically at present 
(Camerini-Davalos et al., 1970), During this unpredictable stage women 
who will later develop diabetes deliver an unusually high proportion 
of overweight babies and in the 2 - 3  years immediately preceding overt 
diabetes there is a raised perinatal mortality rate (Metz, 1975), A test 
is yet to be described which will directly or indirectly detect the 
metabolic abnormalities which accompany diabetes and which could be used
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in the diagnosis of pre-diabetes.
The well supervised diabetic now has a good chance of a 
successful pregnancy. The higher perinatal mortality rate associated 
with diabetic pregnancies (15 - 20%) may be significantly reduced by 
good maternal metabolic supervision and the proper timing of delivery 
(Kyle, 1975), It is known that in the diabetic pregnancy the risk of 
fetal loss in utero increases as term approaches. At the same time the 
risk of neonatal death is increased when pregnancy is terminated before 
the 37th week of pregnancy (Hagbard, 1951), Early termination is 
therefore justified only if there is no corresponding increase in fetal 
loss. This consideration has led to the search for some physiologic 
measurement which could serve as a means of detecting early fetal 
stress. Despite its limitations, discussed in Section 4,1 of Chapter 1, 
the most widespread test hitherto used has been an estimation of estriol 
or total estrogens in a 24 hour specimen of urine. The fetal death rate 
associated with diabetic pregnancies has been reduced to 1% by Gabbe _et 
al. (1977) who used daily 24 hour estrogen determinations in 
combination with weekly contraction tests to time the delivery of the 
baby, Gabbe et al,, 1977b also reported improved control of the 
perinatal death rate with the use of plasma estriol assays. However, as 
has been discussed in Chapter 1, Section 4,1, other workers have not 
been able to demonstrate the superiority of assays of plasma estriol 
and estradiol-17 to that of urinary estrogens. In addition, ultrasono­
graphy has been used in determining the date of delivery since the size 
of the fetus is known to affect its chance of survival (Gellis and 
Hsia, 1959), Of all the placental-specific proteins HPL has been most 
extensively investigated for its possible value as a marker of fetal 
welfare. Studies of HPL levels in pregnancy have failed so far to
-1 92.
establish its clinical value. Investigations of other placental-specific 
proteins such as HCG, heat-stable alkaline phosphatase or histaminase 
have not so far produced any clinically useful markers of fetal welfare. 
The clinical value of the other placental-specific proteins such as SP1 
has not yet been properly assessed. However, plasma levels of SP1 in 
pregnancy have been reported to be related to the maternal blood sugar 
level and carbohydrate metabolism (Tatra et al,, 1976a,b; Singh et al,, 
1979) and there is some evidence to suggest that plasma levels of several 
other placental-specific proteins - HPL, HCG and PAPP-B - may be altered 
in pregnancies complicated by insulin-dependent diabetes (see Chapter 1 
Section 4,1),
In the present study no significant increase in the mean 
value could be detected in the concentration of PAPP-A in patients with 
gestational diabetes compared with controls, although some very high 
values were found in that type of diabetic. It is not known whether 
those high values relate to the extent to which the patients' diabetes 
was controlled. In the group of insulin-controlled diabetics the mean 
concentration of PAPP-A was reduced to 55% of the mean for gestational 
diabetics and to 65% of that in the controls. Both of these differences 
were significant at p=0*05. It is not known why these findings differ 
from those of Lin et al, (1977) though differences in patient type and 
management leave open many possibilities. The present results on insulin- 
dependent diabetics suggest that plasma levels of PAPP-A may be influenced 
by maternal carbohydrate metabolism. The significance of these results 
for placental physiology will require further investigation.
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FIGURE 7.1
The Concentration of PAPP-A in Normal Control Patients (N) 
From the Glasgow (G1) Series Plotted Against Gestation Time (weeks)
□  Male fetus 
#  Female fetus
The linear axis of PAPP-A concentration is in square root units and the 



























Summary of the PAPP-A Concentration in Maternal Serum from 
26 Weeks of Pregnancy to Term
The data groups above the dotted line are from the Glasgow 
series and those below the line are from the Aberdeen series.
Each data group is divided into:
Male fetus 
Female fetus 
N - Normal control patients 
R ~ Intrauterine growth retardation 
G - Gestational diabetes 
I - Insulin-treated diabetic
The figures at the right hand side represent the number of 
patients in each data'group (under the heading Pt) and the number of 
individual blood samples which were assayed in the data group (under the 
heading S).
As outlined in Section 4, Materials and Methods, most of 
the Aberdeen patients had more than one blood sample analysed during the 
course of their pregnancy.
The data bars were drawn as follows (see the bottom data 
bar in the Figure):
The mode (A) and 25 percentiles ( TT ) were calculated from 
the data in mg, PAPP-A per ml.
The mean (I) and - 2 standard deviations (2<r) were 
calculated from the square root transformed data (mg, PAPP-A per ml,) 
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FIGURE 7.3
The Concentration of PAPP-A in Mothers Affected with 
Gestational Diabetes (A) or Insulin-Treated Diabetes (A)
To avoid confusion, repeat samples have been joined up for 

















The Concentration of PAPP-A (mg. per ml.) in Cases of 
Insulin-Treated Diabetes
Males (a ) and females (#) are distinguished.






CHAPTER 8 CONCLUSIONS AND PROSPECTS
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The purpose of this chapter is to review the main 
conclusions drawn in the preceding chapters, discuss how the aims of 
this thesis, set out in Chapter 1, Section 6, have been achieved and to 
suggest directions for further experimental work.
The studies described in Chapter 2 were aimed at detecting 
antibodies in maternal sera directed against placental-specific 
antigens. Maternal sensitisation to fetal alloantigens has been well 
documented but sensitisation to specific products of the placenta has 
not been uneqivocally demonstrated. It has been suggested that anti­
bodies or soluble antibody-antigen complexes act as specific blocking 
factors to cellular immunity in pregnancy: see Chapter 1, Section 4.3a. 
Antibodies to placental-specific proteins were not detected in the 
present study using techniques which do not depend on the availability 
of pure antigens i.e. immunofluorescence and gel precipitation. A 
method has been devised for the dissociation of antigens of molecular 
weight 10, - 100,000 daltons from soluble antibody-antigen complexes 
which was successfully applied to the dissociation of albumin from 
albumin-anti-albumin complexes formed in antigen excess,Application 
of this method to multiparous sera produced no firm proof for the 
involvement of any placental antigens of molecular weight 10, - 100,000 
daltons in immune complex formation during pregnancy. Although 3P1 was 
present in trace amounts in the dissociated material, its molecular 
weight (100,000) and the fact that the bulk of it was detectable in 
the retentate at the end of dissociation argued against a conclusion 
that it had been dissociated from immune complexes. The involvement 
of SP1 in immune complex formation during pregnancy nevertheless 
remains a possibility which will need to be investigated further. The 
best approach in future studies might be to investigate the presence
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of maternal antibodies to individual placental-specific proteins when 
purified preparations of these proteins become available. Much effort 
is at present directed at the purification of such proteins. The 
development of sensitive antigen-specific methods of immune complex 
detection is also an area of current scientific endeavour.
The main experimental effort described in this thesis has 
been directed at increasing the state of knowledge of placental-specific 
proteins. In Chapter 3 the use of negative antibody affinity 
chromatography (IMAAC; the technique which has been described in Chapter 
1, Section 5) in the search for specific placental proteins was 
presented. This approach has revealed several placental proteins, in 
addition to HPL and SP1, at least three of which appeared to be 
placental-specific: PAPP-A (see Chapter 1, Section 3.1) and two other 
antigens whose identity has not been established. These results, which 
are subject to variations in rabbit responsiveness and the limitations 
inherent in the gel precipitation methods used to assay the response, 
nevertheless provide an indication of the value of NAAC technology in 
the search for new tissue-specific proteins.
Before the purification of PAPP-A for the first time by 
antibody affinity chromatography was undertaken it was necessary to 
assess the extent to which a protein was irreversibly denatured by a 
variety of commonly used dissociants. This was assessed by one­
dimensional AACE. Application of this test to a sample of serum proteins 
showed that exposure to several dissociants frequently resulted in 
irreversible dénaturation of the proteins. This finding draws attention 
to a relatively neglected aspect in purification protocols; in several 
published studies no attempt has been made to assess the effect of the 
dissociants used on the immunoprecipitating behaviour of antigens prior
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to purification and the purified antigens were assayed by double immuno­
diffusion or immunoelectrophoresis rather than AACE (see for example 
Kostner, 1972; Hoag et al., 1975; Houwen et al., 1975; Bohn et al., 1976; 
Eitsche and Mach, 1977; Johnson and Garvey, 1977). In the present study 
AACE was found to be superior to double immunodiffusion for examining 
the dénaturation of antigens. The test allowed the selection of a suitable 
dissociating agent for use in the purification of PAPP-A by antibody 
affinity chromatography.
The purification and study of PAPP-A from term maternal 
serum has been described in Chapters 5 and 6. The purification product, 
which was shown to contain 427-fold purified PAPP-A when assessed by 
AACE was iodinated and analysed by AACE, Sepharose 6B gel filtration 
and SDS polyacrylamide gel electrophoresis. The purification product 
labelled by soluble lactoperoxidase was found to contain two bands on 
10% SDS polyacrylamide gel electrophoresis: (l) a major band which was
located very near the top of the gel as was the single band formed by
1 25
immune-precipitated I-PAPP-A; this band was therefore attributed to
PAP:P-A polypeptide and (2) a minor band not detected in immune-precipi- 
1 25
tated I-PAPP-A and therefore attributed to lactoperoxidase. The
purified PAPP-A had a molecular weight and electrophoretic mobility
1 25similar to native PAPP-A in maternal serum, Immune-precipitated I- 
PAPP-A was found to contain a major component of approx. 180,000 daltons 
and a minor component of between 74, - 93,000 daltons. It was concluded 
that PAPP-A whose molecular weight has been estimated as 750,000 daltons 
(Lin et al,, 1974b) may contain up to four 180,000 daltons polypeptide 
subunits. The nature of the minor component will need to be investigated 
further. Final interpretation of these results will also have to await 
purification of a sufficient quantity of PAPP-A to allow further analysis
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such as the determination of carbohydrate content and SDS polyacrylamide 
gel electrophoresis in the presence and absence of reduction to be 
carried out directly on the unlabelled protein. In most cases in which 
a specific placental protein has been thoroughly characterised it has
been found to be very similar in physicochemical and sometimes also
immunological properties to a protein present in the normal non-pregnant
(see Chapter 1, Section 3,1) and the hypothesis has been put forward
that all placental proteins are analogues of proteins present in the 
normal adult (Gordon and Chard, 1979), Proteins showing physicochemical 
homologies with PAPP-A should therefore be sought. The known molecular 
weight and electrophoretic mobility of PAPP-A and the finding reported 
here that it may be composed of subunits of approx, 190,000 daltons and 
in addition contain subunits, or subunit fragments of 74, - 93,000 
daltons suggest that it may be structurally related to alpha^-macro- 
globulin. The molecular weight of alpha^-macroglobulin has been reported 
as between 620, - 820,000 daltons (see Hall and Roberts, 1978) and it 
is known to be a homotetramer (see Swenson and Howard, 1979) consisting 
of two 370,000 daltons protomers each of which contains two disulphide- 
linked polypeptides of 185,000 daltons (Frenoy and Bourrillon, 1974),
The polypeptides of alphag-macroglobulin can be cleaved to two 85,000 
daltons fragments by a variety of endopeptidases (Harpel, 1973; Swenson 
and Howard, 1979), The demonstration of physicochemical homology between 
PAPP-A and alpha^-macroglobulin would give direction to future investi­
gations into the function of PAPP-A, since one function of alpha^-macro- 
gldbulin as an inhibitor of active endopeptidases is already known (see 
Barrett and Starkey, 1973), The possibility that PAPP-A shows physico­
chemical homology with alpha^-macroglobulin is currently being investi­
gated in my supervisor's laboratory.
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A comparison of the levels of PAPP-A in third trimester 
pregnancy blood of normal women and those affected with insulin-dependent 
diabetes, gestational diabetes, fetal intrauterine growth retardation and 
a variety of other disorders was reported in Chapter 7. It revealed one 
group of women with a significantly reduced mean PAPP-A concentration.
This group was the insulin-dependent diabetics, Lin et al, (1977; see 
Chapter 1, Section 4,1) have previously reported no significant difference 
between PAPP-A levels of insulin-dependent diabetics and controls during 
the last month of pregnancy. It is not known why the present findings 
differ from those of Lin et al, (1977) but the difference may be due to 
a variety of factors connected with the type and management of the patients 
included in both studies. The present findings suggest that the levels 
of PAPP-A in maternal circulation may be influenced by some aspects of 
maternal carbohydrate metabolism. Unfortunately, detailed obstetric data 
were not available on the donors of the blood samples used in the present 
study. Further investigations to establish the factor, or factors, 
associated with some insulin-dependent diabetic pregnancies which can 
effect the levels of pAPP-A would be desirable. These may well uncover 
a specific area where PAPP-A measurements will be of diagnostic value.
The present study was the first study of the plasma levels PAPP-A in 
gestational diabetics. Although the mean concentration for this group 
was not found to be significantly different from that of the control 
normal women, a few very high values were observed. Further investigations 
to establish the factors responsible for these occasional high values 
may also be of value.
.203.
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